Pateint Impact Stories In the News NOVEMBER 2022 Digital Biomarkers Could Reshape CNS Diagnosis, Treatment The life sciences industry continues to embrace artificial intelligence (AI), algorithms, and machine-based learning in its pursuits to collect and analyze important pharmaceutical and healthcare data. READ MORE NOVEMBER 2022 Digital Biomarkers Could Reshape CNS Diagnosis, Treatment The life sciences industry continues to embrace artificial intelligence (AI), algorithms, and machine-based learning in its pursuits to collect and analyze important pharmaceutical and healthcare data. READ MORE NOVEMBER 2022 Digital Biomarkers Could Reshape CNS Diagnosis, Treatment The life sciences industry continues to embrace artificial intelligence (AI), algorithms, and machine-based learning in its pursuits to collect and analyze important pharmaceutical and healthcare data. READ MORE NOVEMBER 2022 Woman's Husband's Health Journey Inspires EverythingALS. NBC10’s Erin Coleman speaks to Everything ALS founder Indu Navar about her husband’s own ALS diagnosis and how the group is working to better ALS research. READ MORE NOVEMBER 2022 Walk to Defeat ALS happening in North Las Vegas. Indu Navar, founder of EverythingALS, joined us to talk about how your participation helps raise funds and awareness. READ MORE NOVEMBER 2022 Non-profit conducts study to diagnose ALS quicker. In the 150 years since ALS was discovered there is still no cure or single test to diagnose the disease. READ MORE NOVEMBER 2022 New technology helping ALS patients in Louisiana. ALS, often called Lou Gehrig’s disease, is a progressive motor neuron disease that gradually robs people of their ability to walk, talk, swallow, and eventually breathe. READ MORE SEPTEMBER 2022 Q&A With Indu Navar, founder of Everything ALS. Indu Navar, founder of Everything ALS, speaks with Pharm Exec about how she lost her husband to the disease and how she's trying to improve the way its diagnosed. READ MORE SEPTEMBER 2022 EverythingALS Joins Forces with Aural Analytics, FeetMe, ZEPHYRx and Others for a First-Of-Its-Kind ALS Research Study. Patients can now apply to participate in citizen-led multi-modal digital biomarkers study for prognosis and diagnosis of ALS. READ MORE AUGUST 2022 Groundbreaking research involving artificial intelligence could diagnose ALS patients sooner Five thousand people in the U.S. are diagnosed with a neurological disease called ALS every year. Medical experts say it typically takes an average of two years to diagnose, but new research will likely make that timetable a lot shorter. READ MORE AUGUST 2022 NeuroSense Joins EverythingALS Open Innovation Consortium; Set to Enroll US and EU Patients in Phase IIb Study EverythingALS , a patient-focused non-profit that brings together patients, caregivers, physicians, researchers, and pharmaceutical companies using technological innovations and READ MORE AUGUST 2022 ‘Death by 1,000 cuts:’ How emerging tech could change the journey for ALS patients In 2016, Indu Navar’s husband, Peter Cohen, experienced the first symptom of what turned out to be amyotrophic lateral sclerosis (ALS), a progressive degenerative disease commonly known as Lou Gehrig’s disease. READ MORE JULY 2022 Healthbeat: New ALS research driven by patient-focused non-profit SCRANTON, LACKAWANNA COUNTY— New research is underway to better understand and treat ALS, a difficult disease to diagnose with no known cure. ALS patient Paul Miller of Scranton is one of the participants. READ MORE JULY 2022 Bentonville man works to help diagnose ALS sooner BENTONVILLE, Ark. (KNWA/FOX24) — A Bentonville man is dedicating his life to advocating for people with ALS and trying to help diagnose the disease sooner. READ MORE JULY 2022 These 2 Surprising Traits May Predict ALS, New Research Says Amyotrophic lateral sclerosis (sometimes called Lou Gherig’s disease, or ALS ) affects around 15,000 Americans, with about 5,000 receiving a new diagnosis each year, according to the Centers for Disease Control and Prevention READ MORE JUNE 2022 Continue that momentum from the ALS Ice Bucket Challenge by getting involved in a unique study - New Day NW Researchers want every American to start recording their voice daily. They believe this data could be used to eventually develop cures for Alzheim READ MORE MAY 2022 Patients giving voice to ALS research Back in 2014, millions of people poured icy water over their heads to spread ALS awareness and support research for the devastating neurodegenerative disease. Now tech developers want to hear your voices. READ MORE MAY 2022 Live At 9: Researchers Collecting Audio and Video to Help ALS Detection Remember the summer Americans took time to dump buckets of ice water on their heads to help fight the deadly disease ALS? This summer, there’s a more comfortable way to help researchers learn about ALS and other neurological disorders. READ MORE MAY 2022 A Connecticut man is battling a fatal disease with ‘enormous courage’. Love and his work with an ALS group give him ‘purpose’ Three years ago Austen Eadie-Friedmann, 38, had a dynamic career in the pharmaceutical/biotech field working for a Fortune 500 company and living in exciting places such as New York City, Boston and Europe, with his husband, William DeGregorio. READ MORE FEBRUARY 2022 San Francisco based nonprofit launches new ALS research A San Francisco-based nonprofit is recruiting average people to take part in ALS research KCBS Radio’s Keith Menconi explains. READ MORE FEBRUARY 2022 Mitsubishi Tanabe Pharma joins EVERYTHINGALS consortium to help accelerate biomarker discovery for Neurological diseases February 28, 2022 (San Francisco, CA) -- Today, EverythingALS.org (EALS), a patient-centric, citizen-based California nonprofit accelerating the discovery of digital biomarkers for neurological diseases such as amyotrophic lateral sclerosis (ALS), announced that Mitsubishi Tanabe Pharma Holdings America, Inc. READ MORE DECEMBER 2021 ALS, Lou Gehrig’s Disease, takes many lives, Everything ALS is doing Deb Fabricatore lost her younger brother to ALS in 2014, and became involved in ALS advocacy. Indu Navar lost her husband in 2019 and immediately stepped up into action by building a nonprofit devoted to honoring her husband. READ MORE NOVEMBER 2021 Open-Data Platforms for Direct Engagement with Patients, Researchers, and Pharma Indu Navar, CEO and Founder of EverythingALS, explores the roles of Artificial Intelligence, Machine Learning, and Brain Computer Interface in the search for a cure for ALS. She will also share innovative research studies on ALS detection, how Pharma can work with and support ALS patient advocates, and her key leadership lessons for digital health entrepreneurs and innovators. READ MORE NOVEMBER 2021 Bay Area Nonprofit Seeks 300 Volunteers in ALS Speech Study SAN FRANCISCO (CBS SF) -- A Bay Area nonprofit dedicated to advancing research on an incurable -- and fatal -- disease of the nervous system is looking for 300 more people by the end of this month to participate in the largest-ever research project on the illness. READ MORE OCTOBER 2021 EverythingALS Launches “Stories and Innovation in ALS” Podcast October 21, 2021 (Silicon Valley, CA) – For an inside look at how ALS impacts patients and their caregivers as well as the innovations that researchers and clinicians are coming up with to find biomarkers, treatments, and cures for this life-threatening disease, start listening to the EverythingALS podcast , READ MORE JULY 2021 Episode 30: Machine Learning for a Cause Canada has been an early leader in the AI space and there is no shortage of activity flourishing across the country. Today, we welcome Fanny Sie from Roche Canada and Indu Navar of Everything ALS to talk about machine learning and the End ALS Kaggle Challenge . READ MORE JULY 2021 New project to better identify and treat ALS uses AI and data sharing I n health, science begins with the patient. Roche believes that the only way to improve the way Canadians access care is by working with all stakeholders, including public and private organizations, patient communities and citizens. READ MORE APRIL 2021 Richard Sperry, Head of Research Partnerships and Collaborations at EverythingALS Richard Sperry, Head of Research Partnerships and Collaborations at EverythingALS, speaks about the use of biomarkers to better understand the progression of ALS. With the help of artificial intelligence, EverythingALS and their partners, Modality.ai, are tracking speech patterns to add to an expanding collection of ALS research. READ MORE APRIL 2021 EverythingALS Selected to Present at the American Academy of Neurology Annual Meeting, April 17-22 April 16, 2021 (Los Altos, CA) – EverythingALS, a California nonprofit dedicated to bringing technological innovations and data science to support people with ALS, has been selected to present its scientific research at the American Academy of Neurology (AAN) READ MORE APRIL 2021 Accelerating Rare Disease Research | Indu Navar | TEDxSantaCatalinaSchool n this moving, personal talk, Indu Navar tells how she lost her husband, Peter Cohen, to ALS and what she is doing to bring together patients, families, researchers and people everywhere to change the way that rare diseases are looked at. READ MORE MARCH 2021 The Story of Modality.AI: HealthTech Award Winner HealthTech Networking Club member and winner of the HealthTech Startup Award in January David Suendermann-Oeft, CEO and Founder of Modality.AI , spoke with the bene : studio team about what inspired him to start the company, their biggest achievements so far, and advice for startup leaders in the digital health space. READ MORE MARCH 2021 ‘End ALS Challenge’ Invites AI Community to Tackle 3 Key Questions Roche Canada’s Artificial Intelligence Centre of Excellence (AI CoE), in collaboration with Answer ALS and EverythingALS , opened a challenge that asks the global artificial intelligence (AI) community to model solutions for key questions in amyotrophic lateral sclerosis (ALS). READ MORE MARCH 2021 Roche Canada AI Centre to tackle ALS MISSISSAUGA, Ont. – The Roche Canada Artificial Intelligence Centre of Excellence (AI CoE) is excited to collaborate with Answer ALS and EverythingALS to launch an initiative called the End ALS Challenge, with the support of ALS Society of Canada, Ontario Brain Institute (OBI) and NetraMark Corp. READ MORE MARCH 2021 Roche Canada Artificial Intelligence Centre of Excellence opens digital competition to tackle ALS MISSISSAUGA, ON, March 18, 2021 /CNW/ - The Roche Canada Artificial Intelligence Centre of Excellence (AI CoE) is excited to collaborate with Answer ALS and EverythingALS to launch an initiative called the End ALS Challenge , with the support of ALS Society of Canada , Ontario Brain Institute (OBI) and NetraMark Corp READ MORE MARCH 2021

EverythingALS in the News Click here to VIEW our publications Publications SEPTEMBER 2026 Better Call Saul star Russell Andrews, 64, reveals the common symptoms he experienced before shock ALS diagnosis... as he opens up about Eric Dane connection In the months since announcing his diagnosis with amyotrophic lateral sclerosis (ALS), actor Russell Andrews has turned a debilitating health battle into a mission of advocacy. The progressive neurodegenerative disorder has claimed the lives of numerpis stars, including Grey's Anatomy actor Eric Dane , who was just 53 years old when he passed earlier this year. Read more SEPTEMBER 2026 Russell Andrews Says He’s ‘On The Clock’ In Emotional Confession About Fiancée Amid ALS Battle Russell Andrews knows that an ALS diagnosis changes the conversation around the future. But rather than retreat from public life, the actor has chosen a different path, one built around advocacy, visibility, and gratitude for the people standing beside him. In a deeply personal new interview, Andrews reflected on the uncertainty of living with the progressive disease, the fear he felt for his children, and the emotional reality of watching his fiancée remain committed through a battle neither of them expected. Read more SEPTEMBER 2026 EverythingALS and Vision 2030 Announce Expanded International Scientific Advisory Board to Support ALS Research Collaboration International advisory board brings together leading ALS researchers, clinicians, and nonprofit leaders to help guide ALS research through the Allen Institute’s Brain Health Accelerator. SEATTLE--(BUSINESS WIRE )--EverythingALS and Vision 2030 have announced the expansion of the Vision 2030 Scientific Advisory Board, bringing together a distinguished international group of ALS researchers, clinicians, and nonprofit leaders to help guide and support an ALS focused research collaboration with the Allen Institute’s Brain Health Accelerator. Read more SEPTEMBER 2026 New Alzheimer’s blood tests could help patients get answers earlier MADISON, Wis. (WMTV) - Getting answers about Alzheimer’s disease can be a long and complicated process, but new blood tests are giving doctors a simpler way to look for biological signs of the disease. Dr. Nathaniel Chin, a UW Health Alzheimer’s specialist, said the tests can detect proteins associated with Alzheimer’s and give doctors more certainty about what may be causing a patient’s memory symptoms. Read more SEPTEMBER 2026 New App Provides Resources To Caregivers of Neurodegenerative Patients on the Central Coast A new app is getting the attention of local caregivers for patients of neurodegenerative diseases, which can help lead “from care to cure.” The Peter Cohen Foundation introduced an app recently called EverythingALS . “Named after Peter, my husband,” says Indu Navar, EverythingALS founder and app developer. “We have over 24 pharma companies who have partnered with us, about 15 clinics and institutions have partnered with us, and I work with about 7000 ALS families from 60 countries.” Read more AUGUST 2026 Russell Andrews ‘Went Numb’ After ALS Diagnosis, but Says ‘Lending My Voice Is the Least I Can Do’ (Exclusive) For Russell Andrews, being diagnosed with amyotrophic lateral sclerosis (ALS) was something he never saw coming. So, when the 64-year-old actor — best known for his roles in Straight Outta Compton and Better Call Saul — started experiencing symptoms, he didn’t think much of it. “I would feel twitches in my arms. I would feel like I was having pinched nerves consistently in my neck,” he tells PEOPLE. “But my walking was fine, my balance was fine.” Read more AUGUST 2026 Researchers turn to AI to decipher a devastating neurological condition For individuals with amyotrophic lateral sclerosis (ALS), the diagnostic journey is typically a harrowing and expensive year-plus ordeal involving at least three healthcare professionals. ALS, a fatal condition with few options for treatment, slowly robs patients of their ability to move and communicate. Diagnosing the condition can be extremely difficult, according to the ALS Association, a nonprofit group that supports ALS research. Read more JULY 2026 Chris Johnson’s ALS diagnosis sparks Ice Bucket Challenge revival, but expert says awareness alone won’t move the needle Chris Johnson’s ALS diagnosis sent shockwaves through the NFL and the Nashville community, and the outpouring of support has reintroduced the Ice Bucket Challenge to a new generation. But 12 years after the original viral sensation raised millions for medical advancement, the question remains: why is ALS research still so far behind? Read more JULY 2026 Everything ALS founder provides insight on Chris Johnson diagnosis At the end of June, former Tennessee Titans running back Chris Johnson revealed that he has been diagnosed with Amyotrophic Lateral Sclerosis (ALS) at the age of 40. ALS is a neurodegenerative disease with no cure. ALS impacts the nerves in the brain and spinal cord that affect motor skills. The nerves that give signals to the muscles to contract and move become diseased and die off, resulting in an inability to use those muscles. This affects physical movement in the arms and legs, the ability to speak, and even the ability to breathe. Eventually, the disease is fatal. Read more JUNE 2026 Anthropic Launches Claude Science, Illumina's Spatial Insights Tool, Wellcome Sanger Institute, Google DeepMind AI Consortium Hartwig Medical Foundation and Ultima Genomics expand their strategic collaboration; Thermo Fisher launches its Invitrogen E-Gel Power Snap Lite Electrophoresis System; the Pistoia Alliance announces the next phase of its Identification of Medicinal Products Ontology; and more. Read more JUNE 2026 Why Trust Is Clinical Trials' Next Big Breakthrough Clinical trials face major delays, costing sponsors $800,000 per day in lost sales, as 80% fail to meet enrollment targets. Experts link this to a lack of trust rooted in past unethical practices and concerns about data extraction. EverythingALS and Citizen Health pioneer patient-centric models to rebuild trust. EverythingALS, a nonprofit founded by Indu Navar, empowers ALS patients as collaborators via AI trial-matching and biomarker development. Citizen Health, venture-backed and co-founded by Nasha Fitter, focuses on rare diseases and achieves high data-sharing consent by treating patients as partners. Both show trust boosts engagement, improves quality, accelerates research, saves millions in drug development and positions trust as infrastructure. Read more JUNE 2026 Advanced care planning push, skipped checkups and a new Alzheimer's resource A federal proposal on end-of-life planning, why young adults are skipping checkups, a new Alzheimer's tool and heat safety — today's health headlines. CLEVELAND — The Trump administration is pressing hospitals and Medicare patients to make health care decisions before they become incapacitated. A new proposal would require hospitals to report end-of-life decisions starting in 2028, or risk losing payments by 2030. Read more JUNE 2026 New tool helps Alzheimer's families find clinical trials RICHMOND, Va. — A new tool aims to help families caring for a loved one with Alzheimer's disease by making it easier to find treatments and programs. The Alzheimer's Disease Registry Initiative, known as ADRI, is a virtual research platform that connects people with Alzheimer's or dementia and their caregivers to researchers. The goal is to match patients with clinical trials to accelerate breakthroughs in Alzheimer's treatment. Read more JUNE 2026 Seattle's Allen Institute drives $400M push for breakthroughs in neurological disease treatments: HealthLink SEATTLE — A multi-million dollar initiative led by the Allen Institute in Seattle aims to propel new treatments and therapies for some today's most confounding neurological diseases. Neurodegenerative diseases affect an estimated 57 million people worldwide, according to estimates from the Allen Institute. Read more JUNE 2026 New funding towards ALS research; fishermen and oil companies continue battle over rights to drowned land Earlier this month, the organizations EverythingALS and Vision 2030 announced a partnership with the Allen Institute to accelerate research into the progression of amyotrophic lateral sclerosis, also known as Lou Gehrig’s disease or ALS. The disease is a progressive neurodegenerative condition where patients lose the ability to walk, use their hands, talk and eventually breathe. But the new investment will be geared towards finding using AI-powered technology to look for a cure at the cellular level. Read more JUNE 2026 EverythingALS and Vision 2030 Invest in Allen Institute Initiative to Accelerate ALS Research SAN FRANCISCO--(BUSINESS WIRE )--Lou Gehrig Day — EverythingALS, a nonprofit dedicated to accelerating research, technology, and patient access for amyotrophic lateral sclerosis (ALS), and Vision 2030 are partnering with the Allen Institute to accelerate research into ALS disease progression and to identify new targets that could form the basis for novel medicines to treat the disease. This ALS-focused research will be supported by EverythingALS and Vision 2030’s $1M initial investment in the newly launched Allen Institute’s Brain Health Accelerator. The Allen Institute has committed $200M to the Brain Health Accelerator, a research initiative to study neurodegenerative diseases. Read more MAY 2026 Husband's ALS battle inspires new app During ALS Awareness Month, EverythingALS founder Indu Navar is turning personal loss into a mission to transform the way ALS is understood, managed, and treated. After losing her husband Peter to ALS, Indu used her background in technology to create EverythingALS, a platform using artificial intelligence and data to support patients and caregivers, connect people to clinical trials, and help track changes in speech, breathing, and movement. By bringing together patients, researchers, clinicians, and technology, EverythingALS is working to accelerate research, provide better answers, and ultimately help change the future of ALS care. Read more MAY 2026 Using AI to Transform ALS Research and Patient Care Indu Navar, founder and CEO of EverythingALS, discusses how artificial intelligence and remote digital tools are changing the way ALS is studied and monitored. Drawing from her personal experience losing her husband, Peter Cohen, to ALS, she explains how EverythingALS enables people to participate in research from home while helping researchers better understand disease progression. The interview highlights the potential of speech, movement, and other digital data to accelerate clinical trials and the development of new treatments for ALS. MAY 2026 How One Caregiver Is Rethinking ALS, Alzheimer's & Healthcare with Indu Navar This week on Mind What Matters, Elizabeth Humphreys and Nikki DeLoach sit down with entrepreneur, technologist, and healthcare innovator Indu Navar for one of the most eye-opening conversations the podcast has had to date. After losing her husband Peter to ALS, Indu found herself confronting a healthcare system that felt outdated, disconnected, and devastatingly slow. Instead of walking away from that experience, she decided to challenge the system itself. Read more MAY 2026 New AI matchmaker pairs ALS patients with clinical trials in seconds EverythingALS has launched a new online tool called SAVA AI that uses artificial intelligence to instantly match people with amyotrophic lateral sclerosis (ALS) to clinical trials. The platform is available for free through the EverythingALS website or as a mobile app, providing patients with a secure way to find research opportunities they may be eligible for in real time. Read more MAY 2026 HHS Proposes to Restructure Biomedical Research With AI Research breakthroughs tackling complex diseases and chronic illnesses can take years. The U.S. Department of Health and Human Services is hoping to speed that up ten-fold with artificial intelligence-enabled ecosystem of shared research and experimental procedures. The Advanced Research Projects Agency for Health, a unit of HHS, is spearheading a five-year Intelligent Generator of Research grant program with the stated intent of disrupting a centuries-old status quo of research spearheaded by individual labs. Read more APRIL 2026 EverythingALS Launches AI called SAVA AI to Match Patients with Clinical Trials SEATTLE--(BUSINESS WIRE )--EverythingALS, the patient-focused nonprofit leveraging technology and data science to accelerate care and research for ALS, today announced the launch of SAVA, an AI-powered clinical trial matching tool that connects ALS patients with clinical trials they may qualify for. Read more APRIL 2026 Denham Springs man uses his ALS journey to help others navigate the disease BATON ROUGE, La. (WAFB) - This week is Patient Access Week, a time to recognize the people who make sure patients get the help they need when they need it. Joe Redmond has been living with ALS for more than a decade, far outlasting the average survival window of two to four years after a diagnosis. Now, he is using his own experience to light the path for others. Read more MARCH 2026 Congress Approves Record $315 Million for ALS Research Amid New Treatment Efforts Indu Navar is quoted on EverythingALS's open-data platform, its nearly two dozen pharma consortium partners, and the importance of patient-industry collaboration in removing barriers to clinical trial participation. The article also highlights EverythingALS's expert-led discussions and efforts to establish speech metrics as FDA-approved clinical endpoints. Read more FEBRUARY 2026 Why Every Caregiver Needs a One-Page Emergency Plan Part of being a caregiver is to expect the unexpected and to create calm in moments of chaos. That pressure can be immense, so finding ways to lessen it can go a long way. In honor of National Caregivers Day, we asked experts about the best ways to do this. One way is to create a one-page emergency plan, a cheat sheet of all the details, routines and practices necessary to -prevent delay and indecision during emergencies. Read more FEBRUARY 2026 From Tragedy to Innovation: Patient-Led Data Systems and ALS w/ Indu Navar A conversation with Indu Navar We have to care to cure! Indu Navar is the founder of EverythingALS and a leading voice in patient-driven ALS research. After losing her husband to ALS following a long and exhausting diagnostic process, Indu turned her background in technology and data systems toward fixing what she saw as a broken approach to ALS care and research. Read more FEBRUARY 2026 Should You Share Your Health Info With an AI Chatbot? Indu Navar, founder of EverythingALS, weighs in on the risks and benefits of sharing personal health data with AI tools. She argues that patient data is the highest currency available for fighting rare diseases like ALS, and that the potential to accelerate a cure should outweigh privacy concerns — while still recommending basic safety precautions. Read more FEBRUARY 2026 ALS Advances Unite Patients and Pharma on Novel Targets, Biomarker Breakthroughs Indu Navar, CEO and founder of EverythingALS, joins BioSpace's Denatured podcast alongside the Chief Medical Officer of VectorY Therapeutics. The episode covers how patient-pharma collaborations are accelerating clinical trials, the latest advances in ALS biology, and the development of biomarker-driven endpoints. Read more FEBRUARY 2026 Historic ALS Investment Signals New Treatment Momentum Coverage of Congress approving a record $315 million in federal ALS research funding for 2026. Indu Navar is quoted on EverythingALS's pharma consortia, the organization's push for FDA approval of speech metrics as clinical trial outcomes, and its expansion of the expert talks series. Read more FEBRUARY 2026 EverythingALS Advances a New Clinical Research Model for ALS Trials A deep dive into how EverythingALS is modernizing ALS clinical trials with a speech-based digital biomarker awaiting FDA review. The machine learning algorithm, trained on data from over 1,200 participants including the HEALEY ALS Platform Trial at Mass General, matched speech pathologist assessments 96% of the time — and requires only one minute of recorded audio, no clinic visit needed. Read more FEBRUARY 2026 Rare Disease Day Read more Wisconsin Live Desk talks with the founder of EverythingALS ahead of rare disease day. JANUARY 2026 EverythingALS Taps 'Power in the Crowd' to Revamp Research Norms After less than three years of collecting voice samples, the Peter Cohen Foundation / EverythingALS awaits FDA approval of its AI algorithm as a secondary biomarker for tracking ALS progression. Indu Navar discusses how the listener-effort prediction model — the first-ever objective, scalable digital biomarker for any neurological disease — will be deployed in clinical trials as early as Q1 2026, across its consortium of 22 pharma partners. Read more JANUARY 2026 EverythingALS Taps 'Power in the Crowd' to Revamp Research Norms After less than three years of collecting voice samples, the Peter Cohen Foundation / EverythingALS awaits FDA approval of its AI algorithm as a secondary biomarker for tracking ALS progression. Indu Navar discusses how the listener-effort prediction model — the first-ever objective, scalable digital biomarker for any neurological disease — will be deployed in clinical trials as early as Q1 2026, across its consortium of 22 pharma partners. Read more NOVEMBER 2025 Q&A: Caregivers 'the Invisible Backbone' of the Neurodegenerative Disease Journey In recognition of National Family Caregivers Month, Healio interviews Indu Navar about her personal caregiving experience with her husband Peter, the founding of EverythingALS, and how the organization supports caregivers through community groups, education, and participation in remote digital research studies — turning lived experience into contributions to ALS biomarker development. Read more OCTOBER/NOVEMBER 2025 AI Offers New Hope for ALS Patients Seeking Clinical Trial Matches Indu Navar, CEO and founder of EverythingALS, discusses how AI and machine learning are being used to match ALS patients with clinical trials. The piece highlights EverythingALS's role in connecting patients to research opportunities and the potential of technology to accelerate treatment development for those living with the disease. Read more OCTOBER 2025 SAVA AI: Transforming How Patients Find Clinical Trials SAVA AI is an intelligent trial-matching platform that connects patients to the right clinical trials in seconds rather than weeks. Built by EverythingALS, the system combines human insight with advanced large-language-model (LLM) technology developed in partnership with Amazon Web Services. It interprets a person’s natural questions such as “Are there any ALS trials recruiting in Texas?” and delivers personalized, plain-language results drawn from verified, real-time sources like ClinicalTrials.gov . Read more SEPTEMBER 2025 Air Pollution’s Link To Amyotrophic Lateral Sclerosis (ALS) Air pollution from fossil fuels is the main contributor to climate change. The damage caused by air pollution doesn’t stop there; it also contributes to human diseases, suffering, and premature deaths. Indu Navar, an expert researcher, caregiver, and nonprofit founder , answered some questions for us about air pollution exposure and amyotrophic lateral sclerosis (ALS) . She is one of the founders of Everything ALS . Read more SEPTEMBER 2025 3 American Business Women Who Are Making A Difference In The World September 22 is American Business Women’s Day when we celebrate the achievements of the many successful women entrepreneurs and business leaders who are thriving amid the challenges of our ever-changing political and economic environment. Read more SEPTEMBER 2025 Invisible battles: The fights we don’t see until it’s too late High blood pressure, often referred to as the “silent killer,” is one of the most common yet ignored threats to health, affecting nearly 50% of adults in the U.S. Lacking symptoms, it can escalate into a hypertensive crisis triggering stroke, heart attack and kidney damage. The leading expert and chair of the latest American Heart Association guidelines breaks down what the numbers mean, why so many people remain undiagnosed and how small changes in lifestyle can save lives. Read more AUGUST 2025 Confidence Through Health Indu Navar, CEO of EverythingALS.org, provides us insight into the challenges and benefits of merging technology advancements with the healthcare system. In just a few short years, Indu has brought together multiple players in the neurological care area to improve the speed and capacity for patient care. Read more JULY 2025 Research Moves Slowly. Rare Diseases Don’t—So Patients Aren’t Waiting When Casey McPherson became a father, his purpose became clear. He needed to raise his daughter, Rose, to be loving, courageous, healthy and strong. He needed to protect her. Read more JULY 2025 It was already difficult enough for patients and caregivers dealing with severe illness. Indu Navar set up Everything ALS to help people with that process. Now things are about to get more difficult. Indu gives advice on this MM as to her organization and how it can help navigate the ever changing healthcare landscape. Read more MAY 2025 10 Things You Should Never Say to a Caregiver Avoid these platitudes, and learn what to say instead. Read more MAY 2025 KBOO's Lexus Ponce interviews nurse practitioner Martha Beach about how people with serious medical conditions can prepare in the face of more frequent emergencies like wildfires. Read more APRIL 2025 Bay Area app uses AI to help people with early detection of ALS symptoms A former tech executive who lost her husband to amyotrophic lateral sclerosis, ALS, hopes her app will help people with the early detection of ALS symptoms. Read more APRIL 2025 The Ice Bucket Challenge Is Back: Why Some Are Criticizing the 'Rebranding' of the Viral Trend 11 Years Later Students from the University of South Carolina started a recent campaign using the ice bucket challenge to raise mental health awareness Read more APRIL 2025 Everything ALS AI app helps connect thousands to clinical trials Read more MARCH 2025 I started a nonprofit to fight ALS after my husband's death. Here's how tech and AI can help us find a cure. Indu Navar has spent her career in tech, building and investing in organizations in Silicon Valley. She founded the Peter Cohen Foundation and EverythingALS after her husband died of ALS. Cohen had a long tech career, too. He built Amazon Mechanical Turk and AWS at Amazon. Read more MARCH 2025 App connects people with ALS, caregivers to supportive tools, guidance EverythingALS Pathfinders program offers one-on-one support with people diagnosed with ALS MELBOURNE, Fla. – Every 90 minutes, someone gets diagnosed with ALS. And every 90 minutes, someone dies from the disease. There’s no cure and the statistics are discouraging, but there’s a mobile app that’s creating hope for people living with ALS and their caregivers. Read more FEBRUARY 2025 Denham Springs man diagnosed with ALS helping to connect community DENHAM SPRINGS, La. (Louisiana First ) — Joe Redmond had a successful career as a radio and music executive in Louisiana and Tennessee for 40 years. Over time, he started having trouble with his voice and speaking. “I was slurring and often asked to repeat things so I knew something was wrong,” he said. Redmond saw many doctors over five years. Finally, he was diagnosed with Amyotrophic lateral sclerosis (ALS), or Lou Gehrig’s disease. This is a deadly neurodegenerative disorder that impacts motor neurons in the brain and spinal cord. Read more FEBRUARY 2025 Weekends with Larry Marino Podcast Read more JANUARY 2025 Former music exec on losing voice to ALS – and finding hope in community; rise in Islamophobia after Bourbon Street attack A diagnosis of amyotrophic lateral sclerosis, or ALS, is difficult for anyone to hear. But that was especially the case for Joe Redmond, a music executive from Denham Springs who spent his career in radio. While he is losing his voice, Joe has been determined to take advantage of all the opportunities he has, including working with the Team Gleason organization, and a new caregiving program called Pathfinders. Read more DECEMBER 2024 Minnetonka woman helping connect ALS community through app "Pathfinders" MINNETONKA, Minn. — A Minnetonka woman is helping connect the ALS community through an app. On Jan. 5, 2022, Faith's son, Scott, was diagnosed with ALS. ALS is a fatal neurological disease that affects nerve cells in the brain and spinal cord. Scott was 50 years old at the time of his diagnosis. He was a marathon runner and avid cyclist. Read more SEPTEMBER 2024 EverythingALS Launches App for ALS Community New version of the app will connect people with ALS while collecting data to support research. EverythingALS, a technology- and data-focused nonprofit, has launched an app to support people living with amyotrophic lateral sclerosis (ALS), their families and caregivers, researchers, and health-care professionals. Read more SEPTEMBER 2024 EverythingALS launches new app version for broader ALS community Patients and caregivers can access resources, contribute to ALS research EverythingALS has launched a new version of its mobile app that now includes community support, artificial intelligence-powered chat assistance, and enhanced research opportunities to better serve people with amyotrophic lateral sclerosis (ALS) and their caregivers. The app, which was previously designed only for people taking part in observational studies, has been expanded to also include patients and caregivers from the broader ALS community, allowing them to access vital information and resources, and to contribute to ALS research. “We invite everyone in the ALS community, from newly diagnosed individuals to long-term patients and caregivers, to explore the new features and benefits of this comprehensive app,” the nonprofit EverythingALS said in its press release . Read more DECEMBER 2024 EverythingALS and Compass UOL partner to advance artificial intelligence and computational biology by training and supporting 2,000 Top Talent to Cure ALS at Amazon web services(AWS) re:Invent 2024 in support from AWS LAS VEGAS, Dec. 4, 2024 /PRNewswire/ --A partnership between Compass UOL, an AI transformation services company, and non-profit EverythingALS is using artificial intelligence to address Amyotrophic Lateral Sclerosis (ALS), one of the most intractable puzzles in medicine. EverythingALS and Compass UOL officially launched their partnership on December 4 at 4:00 PM PT at the annual AWS re:Invent conference at the AWS for Healthcare and Life Sciences booth within the AWS for Industries Pavilion. Read more JUNE 2024 Could Artificial Intelligence hold the key to a cure for ALS? Researchers say yes CLEVELAND — ALS is a deadly disease that slowly attacks the nervous system. Currently, there is no cure, but some researchers believe artificial intelligence could hold the key to eradicating the disease. Good Morning Cleveland anchor Tiffany Tarpley spoke with the founder of EverythingALS, Indu Navar, about an app that uses AI to see how early ALS can be detected. Navar helped create the app after she lost her husband to ALS. She's encouraging people of all ages and backgrounds to download the app to help advance ALS research. Read more MAY 2024 Indu Navar: ALS Awareness Month Read more MAY 2024 St. Petersburg couple participate in speech study for earlier ALS diagnosis ST. PETERSBURG, Fla. — A patient-focused nonprofit organization is using artificial intelligence to help analyze audio and video recordings of patients with ALS and those without the neurological disorder, to advance diagnosis and prognosis of the disease. Read more MAY 2024 EverythingALS CEO Indu Navar and Chairman Bill Nuti talk ALS awareness month with Jim Cramer Read more MARCH 2024 EverythingALS launches AI platform to accelerate ALS research EverythingALS has introduced a platform aimed at advancing amyotrophic lateral sclerosis (ALS) research using artificial intelligence (AI) and machine learning — with the ultimate goal of eradicating the disease and restoring lost motor function to those with ALS and other neurodegenerative disorders. Read more MARCH 2024 EverythingALS Launches the Vision 2030 AI Hub : Charting the Path to an ALS Cure and Advancing Neurodegenerative Disease Research Vision 2030 will utilize advanced technologies and an innovative operating model for research and drug development Read more AUGUST 2023 New $400K grant aims to help ID digital diagnostic markers in ALS A new two-year, $400,000 grant will support studies — by EverythingALS and the Sean M. Healey and AMG Center for ALS at Massachusetts General Hospital (MGH) — aimed at identifying early digital diagnostic markers in amyotrophic lateral sclerosis (ALS). Read more AUGUST 2023 Effort to gather data on A.L.S. BINGHAMTON, NY – (WIVT/WBGH ) On the eve of the annual Walk to Defeat ALS, an effort is underway to bring modern innovation to find ways to better diagnose, treat and ultimately cure the fatal disease. Read more JULY 2023 Daily AI Roundup: Biggest Machine Learning, Robotic And Automation Updates 13th July 2023 This is our AI Daily Roundup . We are covering the top updates from around the world. The updates will feature state-of-the-art capabilities in artificial intelligence (AI) , Machine Learning , Robotic Process Automation, Fintech, and human-system interactions. We cover the role of AI Daily Roundup and its application in various industries and daily lives. Read more JUNE 2023 AI could provide breakthrough for early diagnosis of rare diseases For people living with rare diseases, one of the major challenges is being able to receive a rapid and accurate diagnosis. Often the process takes years, but Ben Hargreaves finds that there is a new wave of research utilising AI that could change this. Read more JUNE 2023 Could AI help diagnose diseases like ALS more quickly? BOULDER, Colo. (KDVR) — Michael Robinson was diagnosed with amyotrophic lateral sclerosis, or ALS, almost eight years ago when he was just 45 years old. “I was late for a meeting and went to go run and couldn’t get my right leg to move, and being a physician and knowing what I know, my immediate thought was I think I have ALS,” the Boulder resident said. Read more JUNE 2023 EverythingALS: Searching for a Cure with AI EverythingALS, a patient-focused non-profit, is currently conducting the world's largest AI-powered ALS study. John Howell is joined by Indu Navar, Founder of EverythingALS, to discuss the details of the study and history behind the non-profit. The study is still taking participants, both those who have ALS and those who don't. For more information, visit everythingals.org. Read more JUNE 2023 Non-profit Conducts Studies to Help with ALS "The way I look at it, as technology is here today. We can make an impact to people with ALS today. So, what we are doing is we're looking at these progression markers and applying this to clinical trials that's happening today. So, we work with about 11 pharma companies that partnered with us on this initiative," Founder and CEO of EverythingALS Indu Navar said. Read more JUNE 2023 Everything ALS works to help doctors and families diagnose the disease faster While reflecting on the process that her family endured while her husband battled the disease, Navar says, "There is something called diagnosis fatigue. And it really creates a lot of very, very deep, deep sorrow and grief just going through the diagnosis because it is, I say, it's death by a thousand cuts." Read more JUNE 2023 Tech entrepreneur aims to use artificial intelligence to speed up diagnoses of ALS DETROIT LAKES — Using artificial intelligence and machine learning, a tech entrepreneur is going after the fatal disease of ALS – also known as Lou Gehrig's Disease. Read more JUNE 2023 Bringing Technology to ALS CARE Indu Navar, founder of EverythingALS, joins Amy & JJ. And, just in time for the Fargo walk. Read more APRIL 2023 "EverythingALS" joins Harvard, MIT and IBM for unique research EverythingALS founder Indu Navar joined Kyla Grogen to discuss the unique research they are conducting with Harvard, MIT, and IBM. Watch the clip to learn how recording your voice for 20 minutes a week could be the key to finding a quicker way to diagnose and treat ALS. Read more APRIL 2024 Listen Up: Emerging Vocal Biomarker Could Aid ALS Drug Development It’s been a disappointing spring for the amyotrophic lateral sclerosis community, with the Phase II failure of Sanofi and Denali Therapeutics’ candidate and Amylyx’s decision to pull Relyvrio from the market . But drugmakers are hopeful that the development and validation of novel biomarkers for the disease, including neurofilament, genetic markers and, more recently, speech, can help improve patient care and expedite the development of effective treatments. Read more MARCH 2024 Deciphering the cellular mechanisms behind ALS At MIT, Fraenkel works in the Department of Biological Engineering and co-directs the Computational Systems Biology graduate program. For the study of ALS, he and his collaborators at Massachusetts General Hospital (MGH), including neurologist and neuroscientist Merit Cudkowicz, were recently awarded $1.25 million each from the nonprofit EverythingALS organization. The strategy behind the gift, Fraenkel says, is to encourage MIT and MGH to increase their collaboration, eventually enlisting other organizations as well, to form a hub for ALS research “to break down barriers in the field and really focus on the core problems.” Read more MARCH 2024 A new way to detect ALS in patients ALS is a crippling disease that affects the nervous system. There is a new and easier way to detect ALS. ALS also known as Lou Gehrig’s disease, affects the nervous system by weakening muscles and ultimately paralyzes the patient. Indu Navar is the CEO and Founder of Everything ALS, she says there is a new effort to help ALS patients by using AI machine learning. Read more MARCH 2024 Citizen-Driven Research Aids Development Of Digital Biomarkers For ALS March 20, 2024 | When it comes to research on amyotrophic lateral sclerosis (ALS), every stakeholder—most especially patients—knows time is of the essence. From diagnosis to death, life expectancy from the debilitating neuromuscular disease can be two years or less. “The time people give us is currency,” says Indu Navar, founder of the nonprofit Peter Cohen Foundation operating as EverythingALS. Read more JANUARY 2024 Citizen-Driven Research Aids Development Of Digital Biomarkers For ALS When it comes to research on amyotrophic lateral sclerosis (ALS), every stakeholder—most especially patients—knows time is of the essence. From diagnosis to death, life expectancy from the debilitating neuromuscular disease can be two years or less. “The time people give us is currency,” says Indu Navar, founder of the nonprofit Peter Cohen Foundation operating as EverythingALS. Read more JANUARY 2024 Governor Hochul proposes historic $25m budget for ALS research in New York A groundbreaking moment in the search for a cure for ALS. Governor Hochul is looking to set aside a historic amount of money for ALS research in New York. She made the announcement in her budget address last week, but in this week's Wellness Wakeup, you'll see for the governor and many others, it's personal. Read more DECEMBER 2023 10 unexpected ways life changes when you become a family caregiver Some family caregivers go into it knowing that caring for a loved one is their fate, while others are unexpectedly thrust into it. But whether it’s expected or not, the family caregiving journey is rarely predictable, says Jody Gastfriend , a licensed clinical social worker, author and senior care consultant. Read more DECEMBER 2023 Slowing ALS with Speech: Study leverages IBM’s AI, creates digital biomarkers EverythingALS is working with clinical research stakeholders from IBM Research, Massachusetts Institute of Technology, and Harvard University in a longitudinal study focused on early disease detection based on patterns noted in audiovisual sessions. Read more OCTOBER 2023 Former tech executive leads nonprofit to help those with ALS Moving from tech entrepreneurship to caregiving was never a step Indu Navar expected to make, but this leap of faith turned out to be transformative. Today, she is making use of both skill sets as the CEO and founder of EverythingALS , a nonprofit patient-led advocacy group focused on creating digital biomarkers for early detection of ALS. Read more SEPTEMBER 2023 EverythingALS Announces Student Fellow Scholarship Awards and Expanded Student Ambassador Program aims to accelerate ALS Research SEATTLE, Sept. 27, 2023 (GLOBE NEWSWIRE) -- EverythingALS, a citizen science research organization dedicated to developing cure for ALS, announced today the Student Fellow Scholarship Awards and the expansion and continued enrollment of student Ambassadors program. Both programs are core pillars of the EverythingALS Care to Cure™ impact model. Read more SEPTEMBER 2023 Local ALS Association Chapter’s ‘Walk to Defeat ALS 2023’ held in Salem SALEM, Va. (WFXR ) — On Sept. 16, different ALS Association Chapters across the nation hosted their annual Walk to Defeat ALS. Our local chapter in Virginia was no different. The event was to raise funds for amyotrophic lateral sclerosis or Lou Gehrig’s disease. It’s a rare progressive neurological disorder that affects nerve cells in the brain and spinal cord resulting in weakened muscles. Currently, it’s a terminal diagnosis, meaning it has no cure. Read more AUGUST 2023 New $400,000 Grant Supports EverythingALS.org and Mass General Hospital (MGH) to Develop NeuroLens, a Digital Diagnostics technology initiative for early detection of Amyotrophic Lateral Sclerosis (ALS) SEATTLE--(BUSINESS WIRE )--EverythingALS today announced it has received $400,000 from ALS Finding a Cure® and The ALS Association to support studies for the identification of early digital diagnostic markers of ALS. Read more AUGUST 2023 Buffalo's ALS ambassador raising awareness ahead of weekend walk ORCHARD PARK, N.Y. (WKBW) — It is a disease that robs people of their ability to walk, talk, swallow and eventually breathe. ALS, often called Lou Gehrig's Disease most commonly afflicts people between the ages of 40 and 70. As many as 30,000 Americans have the disease at any given time. This Saturday, Buffalo will be hosting the Western New York Will Walk to Defeat ALS , at Delaware Park. Read more JULY 2023 Merging as EverythingALS, 2 nonprofits seek to better treatment “We firmly believe that the proliferation of non-profit organizations in this field leads to duplication of efforts, wasting precious time, money, and most importantly, lives,” Bill Nuti, CureALS’ founder and CEO and now chairman of the board of directors for Everything ALS, said in a joint press release . Read more JULY 2023 EverythingALS and CureALS Join Forces to Discover a Cure for ALS “They reflect our commitment to advancing research, improving diagnosis and therapies, leveraging data for analysis and technology integration, and ensuring comprehensive support for people living with ALS and FTD.” Read more JULY 2023 California tech company using artificial intelligence in ALS studies BOULDER, Colo. — More than 5,000 Americans are diagnosed with amyotrophic lateral sclerosis (ALS) each year, and roughly 600 people are here in Colorado, according to the Rocky Mountain chapter of the ALS Association. Read more JUNE 2023 Groundbreaking Nonprofit, CureALS Founded and Launched by Former NCR Chairman and CEO Bill Nuti to Eradicate ALS NEW YORK--(BUSINESS WIRE )--CureALS, a pioneering nonprofit organization dedicated to eliminating ALS (Amyotrophic Lateral Sclerosis) and other complex neurodegenerative diseases such as Alzheimer’s, Parkinson’s, and Frontotemporal Dementia, has officially launched today. Read more APRIL 2023 How AI and Facial Recognition Could Spot Stroke and Other Diseases Researchers are training computer algorithms in efforts to quickly identify ailments and speed treatment. Patients at Johns Hopkins Hospital who are suspected of having a stroke might get an unusual request from physicians: Can we film your face ? The doctors’ goal is to identify stroke patients by facial characteristics instead of waiting for brain scans or blood tests, helping speed both treatment and recovery. Read more APRIL 2023 Non-profit behind world's largest AI-powered ALS study ST. PETERSBURG, Fla. — ALS non-profit EverythingALS is using artificial intelligence and other technologies to help find a way to diagnose ALS and other neurological diseases faster and find a cure. It’s partnering with healthcare companies in the effort and conducting speech research to spot and track early signs of ALS. Read more APRIL 2023 Project CommUNITY Women Breaking Barriers: Indu Navar, Founder of Everything ALS "I made a promise to him that I will keep fighting for him and the disease,” Navar said. “And we need to prevent from other people going through what we went through. I want to keep them alive through this work. And I really feel it was such a terrible experience for us that I really don't wish this on anybody" Read more APRIL 2023 How AI CAN LOOK INTO YOUR EYES AND DIAGNOSE A DEVASTATING BRAIN DISEASE “The eyes are the windows to the soul.” It’s an ancient saying, and it illustrates what we know intuitively to be true – you can understand so much about a person by looking them deep in the eye. But how? And can we use this fact to understand disease? Read more MARCH 2023 STUDY SEEKS TO IMPROVE ALS DIAGNOSES WITH AI Speech recognition patterns can give clues to neurological conditions A study is underway to determine AI’s suitability for diagnosing the neurological disease ALS. The study is using AI-powered virtual assistants to detect potential signs of ALS in a participant’s speech patterns and facial gestures. Read more FEBRUARY 2023 LOCAL RESIDENT REVEALS HIS ALS JOURNEY Learn about the ALS journey of local resident Tommy Culpepper and find out you can support him! - KNWA & FOX24 - Northwest Arkansas & River Valley News + The ALS Association Arkansas Chapter Read more FEBRUARY 2023 What Dr. Chatbot ordereD Your doctor could be a robot sooner than you think. The pandemic and its toll on the health care sector spurred interest in the role artificial intelligence can play in easing burdens and improving efficiency, particularly via chatbots to tackle routine tasks like scheduling appointments and billing issues. But evidence is building that suggests chatbots are already pretty good at giving health advice. Read more JANUARY 2023 Montgomery County man with ALS part of study that aims to find root cause of disease "When a man died, he was said to have gone west," repeated 59-year-old Todd Kelly into a computer. He isn't reading a best-selling novel, but reciting speech to help treat and cure ALS. "The problem with ALS, unlike many other diseases, is they can't find a biomarker. The biomarkers, what you can see, is affected by a treatment," he described. Read more JANUARY 2022 Getting Vocal In December of 2016, Valerie Geerer was doing her normal lunchtime walk with work colleagues when a friend noticed something off about her gait. “I remember she said, ‘Is there something the matter with your foot?’” the fifty-nine-year-old Stamford resident recalls. “I told her I felt fine. A month later I was tripping myself. It was ironic. Six months earlier, my husband Michael and I were climbing mountains in Utah. And suddenly I couldn’t walk without stumbling.” Read more DECEMBER 2022 ALS genetic carrier finds the “path to higher ground” in clinical research ALS genetic carrier finds value in EverythingALS study leveraging digital biomarkers as a means to create tools for early detection of ALS and potentially other neurological diseasese. Read more DECEMBER 2022 New way to detect ALS; early diagnosis critical for treatment LAS VEGAS (KLAS) — Every 90 minutes, someone gets diagnosed with amyotrophic lateral sclerosis, or ALS. It’s a progressive neurodegenerative disease that affects nerve cells in the brain and spinal cord and there is no cure. Read more NOVEMBER 2022 Woman's Husband's Health Journey Inspires Everything ALS NBC10’s Erin Coleman speaks to Everything ALS founder Indu Navar about her husband’s own ALS diagnosis and how the group is working to better ALS research. You can help the fight through Everything ALS or at the 2022 Walk to Defeat ALS. Read more NOVEMBER 2022 Walk to Defeat ALS happening in North Las Vegas Indu Navar, founder of EverythingALS, joined us to talk about how your participation helps raise funds and awareness. WATCH HERE NOVEMBER 2022 Non-profit conducts study to diagnose ALS quicker LANSING, Mich. (WLNS) — In the 150 years since ALS was discovered there is still no cure or single test to diagnose the disease. The demand for more answers is what drove one woman to start up her own non-profit. EverythingALS began its research in 2021 and now they’re working toward diagnosing the disease faster. “I really want to help people who are going through this disease,” said Indu Navar, Founder of EverythingALS. The study analyzes data when it comes to physiological changes and the progression of the disease. Navar says she wants to shift the focus to the brain, something she believes isn’t understood well enough. READ MORE SEPTEMBER 2022 Q&A With Indu Navar, founder of Everything ALS Indu Navar, founder of Everything ALS, speaks with Pharm Exec about how she lost her husband to the disease and how she's trying to improve the way its diagnosed. Indu Navar Diagnosing ALS is a difficult process for patients experiencing symptoms. After the death of her husband, tech entrepreneur Indu Navar founded Everything ALS, and organization she hopes will refine and improve the way ALS and other neurological conditions are diagnosed. READ MORE OCTOBER 2022 New technology helping ALS patients in Louisiana BATON ROUGE, La. (BRPROUD) — ALS, often called Lou Gehrig’s disease, is a progressive motor neuron disease that gradually robs people of their ability to walk, talk, swallow, and eventually breathe. Indu Navar, the founder of EverythingALS, said, “ALS has no known cause or cure and so patients suffer for years not knowing what is wrong and have to go through rigorous testing and a process of elimination to finally get diagnosed. If they are diagnosed, there are no treatments. Life expectancy is two to five years.” READ MORE SEPTEMBER 2022 EverythingALS Joins Forces with Aural Analytics, FeetMe, ZEPHYRx and Others for a First-Of-Its-Kind ALS Research Study SAN FRANCISCO (PRWEB) SEPTEMBER 19, 2022 EverythingALS, a patient-focused non-profit that brings together people living with ALS, caregivers, physicians, researchers, and pharmaceutical companies to collaborate on an open innovation platform using cutting-edge technologies and data science to improve progression measurements for neurological disease like Amyotrophic Lateral Sclerosis (ALS), has initiated a new study, The Radcliff Study, with partners in the quest to find a diagnosis, treatment, and cure for ALS... READ MORE AUGUST 2022 Groundbreaking research involving artificial intelligence could diagnose ALS patients sooner Five thousand people in the U.S. are diagnosed with a neurological disease called ALS every year. Medical experts say it typically takes an average of two years to diagnose, but new research will likely make that timetable a lot shorter. In 2019, Mark Weston and his wife, Kathleen, had their retirement all planned out. "We were all set up for a sail off into the sunset and have a really fun retirement," Weston said. "We had, we bought a house on the coast of Maine several months earlier." A week before the big move, he got a life-changing diagnosis. READ MORE AUGUST 2022 NeuroSense Joins EverythingALS Open Innovation Consortium; Set to Enroll US and EU Patients in Phase IIb Study NeuroSense's support will aid EverythingALS with ground-breaking patient research in a joint effort to develop treatments LOS ALTOS, Calif. and CAMBRIDGE, Mass., Aug. 2, 2022 /PRNewswire/ -- EverythingALS , a patient-focused non-profit that brings together patients, caregivers, physicians, researchers, and pharmaceutical companies using technological innovations and data science to support efforts to improve care for those living with a neurological disease like Amyotrophic Lateral Sclerosis (ALS), today announced NeuroSense Therapeutics Ltd. (NASDAQ: NRSN ) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, as a new collaborator in the effort to identify treatments and a cure for ALS. READ MORE AUGUST 2022 ‘Death by 1,000 cuts:’ How emerging tech could change the journey for ALS patients EverythingALS aims to speed drug development through improved diagnostics. in 2016, Indu Navar’s husband, Peter Cohen, experienced the first symptom of what turned out to be amyotrophic lateral sclerosis (ALS), a progressive degenerative disease commonly known as Lou Gehrig’s disease. EverythingALS founder Indu Navar Permission granted by EverythingALS/Indu Navar “His foot was just acting weird,” says Navar, who founded the California nonprofit EverythingALS two years ago. “We didn’t know where to go, so we went to a chiropractor,” she says. READ MORE JULY 2022 Healthbeat: New ALS research driven by patient-focused non-profit SCRANTON, LACKAWANNA COUNTY— New research is underway to better understand and treat ALS, a difficult disease to diagnose with no known cure. ALS patient Paul Miller of Scranton is one of the participants. The progressive neurodegenerative disease ALS affects as many as 30,000 Americans. There is no known cure despite efforts to better understand it and treat it. ALS is a puzzling disease for certain with so much needing to be learned about it. READ MORE TOMMY EDWARD CULPEPPER,Jr MOVIE CONNOISSEUR JULY 2022 Bentonville man works to help diagnose ALS sooner A Bentonville man is dedicating his life to advocating for people with ALS and trying to help diagnose the disease sooner. “I’m a movie connoisseur,” said Tommy Edward Culpepper, Jr. “I love movies.” For Culpepper, movies have always been his saving grace. Even when he was a kid growing up in St. Louis, Missouri. “I grew up in the Peabody Projects and the home environment wasn’t the greatest,” he said. “Star Wars, Blade Runner, Highlander. Movies like that are excellent getaways for me.” Until he found himself in a nightmare that started in the doctor’s office... READ MORE JULY 2022 These 2 Surprising Traits May Predict ALS, New Research Says How ALS researchers are using an intriguing tool to learn keys of this disease that has at times taken years to diagnose. Plus, one woman's story of why she agreed to participate in this research Amyotrophic lateral sclerosis (sometimes called Lou Gherig’s disease, or ALS ) affects around 15,000 Americans, with about 5,000 receiving a new diagnosis each year, according to the Centers for Disease Control and Prevention. READ MORE JUNE 2022 Continue that momentum from the ALS Ice Bucket Challenge by getting involved in a unique study - New Day NW Researchers want every American to start recording their voice daily. They believe this data could be used to eventually develop cures for ALS. #newdaynw READ MORE MAY 2022 Patients giving voice to ALS research Back in 2014, millions of people poured icy water over their heads to spread ALS awareness and support research for the devastating neurodegenerative disease. Now tech developers want to hear your voices. Brian Andre has been living with ALS for six years. “On average they only give you 2 to 5 years of life after diagnosis and some progress very quickly,” he said. “I’m really in a very small percentage of patients who see little or no progression. … My weakness is in my left side, left leg and arm. So it throws my gait off.” READ MORE INDU NAVAR, CEO - EVERYTHINGALS MAY 2022 Live At 9: Researchers Collecting Audio and Video to Help ALS Detection Remember the summer Americans took time to dump buckets of ice water on their heads to help fight the deadly disease ALS? This summer, there’s a more comfortable way to help researchers learn about ALS and other neurological disorders. Researchers want people to record their voices and upload them for study. READ MORE Austen Eadie-Friedmann before his diagnosis of amyotrophic lateral sclerosis or ALS MAY 2022 A Connecticut man is battling a fatal disease with ‘enormous courage’. Love and his work with an ALS group give him ‘purpose Three years ago Austen Eadie-Friedmann, 38, had a dynamic career in the pharmaceutical/biotech field working for a Fortune 500 company and living in exciting places such as New York City, Boston and Europe, with his husband, William DeGregorio. The couple, now together for 18 years and married for five, loved their life traveling the world, sharing a passion for art. Then the devastating diagnosis arrived... READ MORE INDU NAVAR, CEO - EVERYTHINGALS MAY 2022 How high tech shoes could help doctors better understand ALS MOUNTAIN VIEW, Calif. - There is no cure for ALS, the progressive neurodegenerative disease that affects nerve cells in the brain and spinal cord, but a Silicon Valley nonprofit is hoping to change that. Starting Tuesday, EverythingALS , a Silicon Valley nonprofit and advocacy group, is starting its second research study involving ALS patients, using shoes with high-tech censors to track and study their movements. The study is open to 100 participants in the early stages of ALS, and is still accepting new participants.... READ MORE MAY 2022 Tech Tuesday: Using AI to fight ALS LANSING, Mich. (WLNS) — One non-profit organization is using technological innovations and data science to support those grappling with amyotrophic lateral sclerosis, otherwise known as ALS. EverythingALS was started by Indu Navar. READ MORE INDU NAVAR, CEO - EVERYTHINGALS MAY 2022 Bringing Awareness To ALS And Those Who Suffer From It In this podcast, we are joined by Indu Navar. Indu Navar is the CEO of Everything ALS, a company that prioritizes bringing awareness to Amyotrophic Lateral Sclerosis (ALS) and those who suffer from it. ALS is a neurological condition that affects the victim's motor neurons. This causes muscle atrophy all across the body, which can eventually cause suffocation and even death. LISTEN NOW APR 2022 Be The Good with Kate Cherichello Be the Good with Kate podcast- Kate Cherichello scheduled a taped interview with Indu for Wednesday, March 9th at 3:30pm EST to discuss EverythingALS and the research study. Episode went live on April 29th. LISTEN NOW FEB 28, 2022 MITSUBISHI TANABE PHARMA JOINS EVERYTHINGALS CONSORTIUM TO HELP ACCELERATE BIOMARKER DISCOVERY FOR NEUROLOGICAL DISEASES (San Francisco, CA)-- Today, EverythingALS.org (EALS), a patient-centric, citizen-based California nonprofit accelerating the discovery of digital biomarkers for neurological diseases such as amyotrophic lateral sclerosis (ALS), announced that Mitsubishi Tanabe Pharma Holdings America, Inc. READ MORE FEB 12, 2022 San Francisco based nonprofit launches new ALS research SAN FRANCISCO (KCBS SF) — A San Francisco-based nonprofit is recruiting average people to take part in ALS research. KCBS Radio’s Keith Menconi explains. READ MORE DEC 2021 ALS, Lou Gehrig’s Disease, takes many lives, Everything ALS is doing Deb Fabricatore lost her younger brother to ALS in 2014, and became involved in ALS advocacy. Indu Navar lost her husband in 2019 and immediately stepped up into action by building a nonprofit devoted to honoring her husband. READ MORE Bay Area Nonprofit Seeks 300 Volunteers in ALS Speech Study SAN FRANCISCO (CBS SF) — A Bay Area nonprofit dedicated to advancing research on an incurable — and fatal — disease of the nervous system is looking for 300 more people by the end of this month to participate in the largest-ever research project on the illness. READ MORE NOV 21, 2021 EverythingALS said it needs more than 300 volunteers for its study to combat amyotrophic lateral sclerosis, more commonly known as Lou Gehrig’s disease, an incurable, degenerative illness. READ MORE NOV 21, 2021 Bay Area non-profit looking for volunteers in Lou Gehrig diseases study OCT 2021 EverythingALS Launches “Stories and Innovation in ALS” Podcast October 21, 2021 (Silicon Valley, CA) – For an inside look at how ALS impacts patients and their caregivers as well as the innovations that researchers and clinicians are coming up with to find biomarkers, treatments, and cures for this life-threatening disease, start listening to the EverythingALS podcast , “Stories and Innovation in ALS.” EverythingALS (EALS) was founded in 2020 to help discover biomarkers – which are nonexistent -- and document the progression of ALS by launching the world’s largest speech study with more than 600 participants. READ MORE APRIL 2021 Accelerating Rare Disease Research TEDxSantaCatalinaSchool In this moving, TEDx talk, Indu Navar tells how she lost her husband, Peter Cohen, to ALS and what she is doing to bring together patients, families, researchers and people everywhere to change the way that rare diseases are looked at. WATCH VIDEO Digital Health InfoCast: Machine Learning for a Cause Canada has been an early leader in the AI space and there is no shortage of activity flourishing across the country. Today, we welcome Fanny Sie from Roche Canada and Indu Navar of Everything ALS to talk about machine learning and the End ALS Kaggle Challenge . LISTEN JULY 30, 2021 Indu Navar, CEO and Founder of EverythingALS, explores the roles of Artificial Intelligence, Machine Learning, and Brain Computer Interface in the search for a cure for ALS. She will also share innovative research studies on ALS detection, how Pharma can work with and support ALS patient advocates, and her key leadership lessons for digital health entrepreneurs and innovators. WATCH VIDEO JUNE 25, 2021 Impetus Digital PODCAST JULY 2021 New project to better identify and treat ALS uses AI and data sharing Through the AI CoE, Roche has collaborated with EverythingALS , AnswerALS, the Ontario Brain Institutes and ALS Canada to launch an open data science competition called the End ALS Challenge. READ MORE READ MORE Mar 29, 2021 THE STORY OF MODALITY.AI: HEALTHTECH AWARD WINNER Suendermann-Oeft states that one of the most significant achievements for them has been collaborating with the non-profit organization EverythingALS , as well as MIT, Harvard, and IBM to scale the number of Modality platform users to over 100 within three months for a study focusing on the early detection and improved prognostic accuracy of ALS ... "Jody O'Donnell introduced me to the founders of every Everything ALS , brother and sister, Murgesh Navar and Indu Navar, and Indu lost her husband to ALS a few years ago. Really, we just kind of hit it off from the get-go. Tremendous pair, both kind of serial entrepreneurs; they started multiple companies in the Bay Area and they just brought a passion and energy, a desire to do things quickly and challenge the status quo ... READ MORE April 30, 2021 interview with Katie Pecora for Patients Rising The Roche Canada Artificial Intelligence Centre of Excellence (AI CoE) is excited to collaborate with Answer ALS and EverythingALS to launch an initiative called the End ALS Challenge , with the support of ALS Society of Canada , Ontario Brain Institute (OBI) and NetraMark Corp . The goal is to surface insights through an open data competition.. READ MORE Mar 29, 2021 EndALS Kaggle Challenge to TACKEL ALS EverythingALS Selected to Present at the American Academy of Neurology Virtual Annual Meeting EverythingALS, a California nonprofit dedicated to bringing technological innovations and data science to support people with ALS, has been selected to ... READ MORE April 16, 2021 READ MORE Mar 25, 2021 Roche Canada AI Centre and EverythingALS to tackle ALS The Roche Canada Artificial Intelligence Centre of Excellence (AI CoE) is excited to collaborate with Answer ALS and EverythingALS to launch an initiative called the End ALS Challenge, with the support of ALS Society of Canada, Ontario Brain Institute (OBI) and NetraMark Corp... Roche Canada Artificial Intelligence Centre and EverythingALS opens digital competition to tackle ALS EverythingALS, a California nonprofit dedicated to bringing technological innovations and data science to support people with ALS, has been selected to ... READ MORE Mar 18, 2021

EverythingALS in the News Click here to VIEW our publications Publications SEPTEMBER 2026 EverythingALS and Vision 2030 Announce Expanded International Scientific Advisory Board to Support ALS Research Collaboration International advisory board brings together leading ALS researchers, clinicians, and nonprofit leaders to help guide ALS research through the Allen Institute’s Brain Health Accelerator. SEATTLE--(BUSINESS WIRE )--EverythingALS and Vision 2030 have announced the expansion of the Vision 2030 Scientific Advisory Board, bringing together a distinguished international group of ALS researchers, clinicians, and nonprofit leaders to help guide and support an ALS focused research collaboration with the Allen Institute’s Brain Health Accelerator. Read more SEPTEMBER 2026 New Alzheimer’s blood tests could help patients get answers earlier MADISON, Wis. (WMTV) - Getting answers about Alzheimer’s disease can be a long and complicated process, but new blood tests are giving doctors a simpler way to look for biological signs of the disease. Dr. Nathaniel Chin, a UW Health Alzheimer’s specialist, said the tests can detect proteins associated with Alzheimer’s and give doctors more certainty about what may be causing a patient’s memory symptoms. Read more SEPTEMBER 2026 New App Provides Resources To Caregivers of Neurodegenerative Patients on the Central Coast A new app is getting the attention of local caregivers for patients of neurodegenerative diseases, which can help lead “from care to cure.” The Peter Cohen Foundation introduced an app recently called EverythingALS . “Named after Peter, my husband,” says Indu Navar, EverythingALS founder and app developer. “We have over 24 pharma companies who have partnered with us, about 15 clinics and institutions have partnered with us, and I work with about 7000 ALS families from 60 countries.” Read more AUGUST 2026 Russell Andrews ‘Went Numb’ After ALS Diagnosis, but Says ‘Lending My Voice Is the Least I Can Do’ (Exclusive) For Russell Andrews, being diagnosed with amyotrophic lateral sclerosis (ALS) was something he never saw coming. So, when the 64-year-old actor — best known for his roles in Straight Outta Compton and Better Call Saul — started experiencing symptoms, he didn’t think much of it. “I would feel twitches in my arms. I would feel like I was having pinched nerves consistently in my neck,” he tells PEOPLE. “But my walking was fine, my balance was fine.” Read more AUGUST 2026 Researchers turn to AI to decipher a devastating neurological condition For individuals with amyotrophic lateral sclerosis (ALS), the diagnostic journey is typically a harrowing and expensive year-plus ordeal involving at least three healthcare professionals. ALS, a fatal condition with few options for treatment, slowly robs patients of their ability to move and communicate. Diagnosing the condition can be extremely difficult, according to the ALS Association, a nonprofit group that supports ALS research. Read more JULY 2026 Chris Johnson’s ALS diagnosis sparks Ice Bucket Challenge revival, but expert says awareness alone won’t move the needle Chris Johnson’s ALS diagnosis sent shockwaves through the NFL and the Nashville community, and the outpouring of support has reintroduced the Ice Bucket Challenge to a new generation. But 12 years after the original viral sensation raised millions for medical advancement, the question remains: why is ALS research still so far behind? Read more JULY 2026 Everything ALS founder provides insight on Chris Johnson diagnosis At the end of June, former Tennessee Titans running back Chris Johnson revealed that he has been diagnosed with Amyotrophic Lateral Sclerosis (ALS) at the age of 40. ALS is a neurodegenerative disease with no cure. ALS impacts the nerves in the brain and spinal cord that affect motor skills. The nerves that give signals to the muscles to contract and move become diseased and die off, resulting in an inability to use those muscles. This affects physical movement in the arms and legs, the ability to speak, and even the ability to breathe. Eventually, the disease is fatal. Read more JUNE 2026 Anthropic Launches Claude Science, Illumina's Spatial Insights Tool, Wellcome Sanger Institute, Google DeepMind AI Consortium Hartwig Medical Foundation and Ultima Genomics expand their strategic collaboration; Thermo Fisher launches its Invitrogen E-Gel Power Snap Lite Electrophoresis System; the Pistoia Alliance announces the next phase of its Identification of Medicinal Products Ontology; and more. Read more JUNE 2026 Why Trust Is Clinical Trials' Next Big Breakthrough Clinical trials face major delays, costing sponsors $800,000 per day in lost sales, as 80% fail to meet enrollment targets. Experts link this to a lack of trust rooted in past unethical practices and concerns about data extraction. EverythingALS and Citizen Health pioneer patient-centric models to rebuild trust. EverythingALS, a nonprofit founded by Indu Navar, empowers ALS patients as collaborators via AI trial-matching and biomarker development. Citizen Health, venture-backed and co-founded by Nasha Fitter, focuses on rare diseases and achieves high data-sharing consent by treating patients as partners. Both show trust boosts engagement, improves quality, accelerates research, saves millions in drug development and positions trust as infrastructure. Read more JUNE 2026 Advanced care planning push, skipped checkups and a new Alzheimer's resource A federal proposal on end-of-life planning, why young adults are skipping checkups, a new Alzheimer's tool and heat safety — today's health headlines. CLEVELAND — The Trump administration is pressing hospitals and Medicare patients to make health care decisions before they become incapacitated. A new proposal would require hospitals to report end-of-life decisions starting in 2028, or risk losing payments by 2030. Read more JUNE 2026 New tool helps Alzheimer's families find clinical trials RICHMOND, Va. — A new tool aims to help families caring for a loved one with Alzheimer's disease by making it easier to find treatments and programs. The Alzheimer's Disease Registry Initiative, known as ADRI, is a virtual research platform that connects people with Alzheimer's or dementia and their caregivers to researchers. The goal is to match patients with clinical trials to accelerate breakthroughs in Alzheimer's treatment. Read more JUNE 2026 Seattle's Allen Institute drives $400M push for breakthroughs in neurological disease treatments: HealthLink SEATTLE — A multi-million dollar initiative led by the Allen Institute in Seattle aims to propel new treatments and therapies for some today's most confounding neurological diseases. Neurodegenerative diseases affect an estimated 57 million people worldwide, according to estimates from the Allen Institute. Read more JUNE 2026 New funding towards ALS research; fishermen and oil companies continue battle over rights to drowned land Earlier this month, the organizations EverythingALS and Vision 2030 announced a partnership with the Allen Institute to accelerate research into the progression of amyotrophic lateral sclerosis, also known as Lou Gehrig’s disease or ALS. The disease is a progressive neurodegenerative condition where patients lose the ability to walk, use their hands, talk and eventually breathe. But the new investment will be geared towards finding using AI-powered technology to look for a cure at the cellular level. Read more JUNE 2026 EverythingALS and Vision 2030 Invest in Allen Institute Initiative to Accelerate ALS Research SAN FRANCISCO--(BUSINESS WIRE )--Lou Gehrig Day — EverythingALS, a nonprofit dedicated to accelerating research, technology, and patient access for amyotrophic lateral sclerosis (ALS), and Vision 2030 are partnering with the Allen Institute to accelerate research into ALS disease progression and to identify new targets that could form the basis for novel medicines to treat the disease. This ALS-focused research will be supported by EverythingALS and Vision 2030’s $1M initial investment in the newly launched Allen Institute’s Brain Health Accelerator. The Allen Institute has committed $200M to the Brain Health Accelerator, a research initiative to study neurodegenerative diseases. Read more MAY 2026 Husband's ALS battle inspires new app During ALS Awareness Month, EverythingALS founder Indu Navar is turning personal loss into a mission to transform the way ALS is understood, managed, and treated. After losing her husband Peter to ALS, Indu used her background in technology to create EverythingALS, a platform using artificial intelligence and data to support patients and caregivers, connect people to clinical trials, and help track changes in speech, breathing, and movement. By bringing together patients, researchers, clinicians, and technology, EverythingALS is working to accelerate research, provide better answers, and ultimately help change the future of ALS care. Read more MAY 2026 Using AI to Transform ALS Research and Patient Care Indu Navar, founder and CEO of EverythingALS, discusses how artificial intelligence and remote digital tools are changing the way ALS is studied and monitored. Drawing from her personal experience losing her husband, Peter Cohen, to ALS, she explains how EverythingALS enables people to participate in research from home while helping researchers better understand disease progression. The interview highlights the potential of speech, movement, and other digital data to accelerate clinical trials and the development of new treatments for ALS. MAY 2026 How One Caregiver Is Rethinking ALS, Alzheimer's & Healthcare with Indu Navar This week on Mind What Matters, Elizabeth Humphreys and Nikki DeLoach sit down with entrepreneur, technologist, and healthcare innovator Indu Navar for one of the most eye-opening conversations the podcast has had to date. After losing her husband Peter to ALS, Indu found herself confronting a healthcare system that felt outdated, disconnected, and devastatingly slow. Instead of walking away from that experience, she decided to challenge the system itself. Read more MAY 2026 New AI matchmaker pairs ALS patients with clinical trials in seconds EverythingALS has launched a new online tool called SAVA AI that uses artificial intelligence to instantly match people with amyotrophic lateral sclerosis (ALS) to clinical trials. The platform is available for free through the EverythingALS website or as a mobile app, providing patients with a secure way to find research opportunities they may be eligible for in real time. Read more MAY 2026 HHS Proposes to Restructure Biomedical Research With AI Research breakthroughs tackling complex diseases and chronic illnesses can take years. The U.S. Department of Health and Human Services is hoping to speed that up ten-fold with artificial intelligence-enabled ecosystem of shared research and experimental procedures. The Advanced Research Projects Agency for Health, a unit of HHS, is spearheading a five-year Intelligent Generator of Research grant program with the stated intent of disrupting a centuries-old status quo of research spearheaded by individual labs. Read more APRIL 2026 EverythingALS Launches AI called SAVA AI to Match Patients with Clinical Trials SEATTLE--(BUSINESS WIRE )--EverythingALS, the patient-focused nonprofit leveraging technology and data science to accelerate care and research for ALS, today announced the launch of SAVA, an AI-powered clinical trial matching tool that connects ALS patients with clinical trials they may qualify for. Read more APRIL 2026 Denham Springs man uses his ALS journey to help others navigate the disease BATON ROUGE, La. (WAFB) - This week is Patient Access Week, a time to recognize the people who make sure patients get the help they need when they need it. Joe Redmond has been living with ALS for more than a decade, far outlasting the average survival window of two to four years after a diagnosis. Now, he is using his own experience to light the path for others. Read more MARCH 2026 Congress Approves Record $315 Million for ALS Research Amid New Treatment Efforts Indu Navar is quoted on EverythingALS's open-data platform, its nearly two dozen pharma consortium partners, and the importance of patient-industry collaboration in removing barriers to clinical trial participation. The article also highlights EverythingALS's expert-led discussions and efforts to establish speech metrics as FDA-approved clinical endpoints. Read more FEBRUARY 2026 Why Every Caregiver Needs a One-Page Emergency Plan Part of being a caregiver is to expect the unexpected and to create calm in moments of chaos. That pressure can be immense, so finding ways to lessen it can go a long way. In honor of National Caregivers Day, we asked experts about the best ways to do this. One way is to create a one-page emergency plan, a cheat sheet of all the details, routines and practices necessary to -prevent delay and indecision during emergencies. Read more FEBRUARY 2026 From Tragedy to Innovation: Patient-Led Data Systems and ALS w/ Indu Navar A conversation with Indu Navar We have to care to cure! Indu Navar is the founder of EverythingALS and a leading voice in patient-driven ALS research. After losing her husband to ALS following a long and exhausting diagnostic process, Indu turned her background in technology and data systems toward fixing what she saw as a broken approach to ALS care and research. Read more FEBRUARY 2026 Should You Share Your Health Info With an AI Chatbot? Indu Navar, founder of EverythingALS, weighs in on the risks and benefits of sharing personal health data with AI tools. She argues that patient data is the highest currency available for fighting rare diseases like ALS, and that the potential to accelerate a cure should outweigh privacy concerns — while still recommending basic safety precautions. Read more FEBRUARY 2026 ALS Advances Unite Patients and Pharma on Novel Targets, Biomarker Breakthroughs Indu Navar, CEO and founder of EverythingALS, joins BioSpace's Denatured podcast alongside the Chief Medical Officer of VectorY Therapeutics. The episode covers how patient-pharma collaborations are accelerating clinical trials, the latest advances in ALS biology, and the development of biomarker-driven endpoints. Read more FEBRUARY 2026 Historic ALS Investment Signals New Treatment Momentum Coverage of Congress approving a record $315 million in federal ALS research funding for 2026. Indu Navar is quoted on EverythingALS's pharma consortia, the organization's push for FDA approval of speech metrics as clinical trial outcomes, and its expansion of the expert talks series. Read more FEBRUARY 2026 EverythingALS Advances a New Clinical Research Model for ALS Trials A deep dive into how EverythingALS is modernizing ALS clinical trials with a speech-based digital biomarker awaiting FDA review. The machine learning algorithm, trained on data from over 1,200 participants including the HEALEY ALS Platform Trial at Mass General, matched speech pathologist assessments 96% of the time — and requires only one minute of recorded audio, no clinic visit needed. Read more FEBRUARY 2026 Rare Disease Day Read more Wisconsin Live Desk talks with the founder of EverythingALS ahead of rare disease day. JANUARY 2026 EverythingALS Taps 'Power in the Crowd' to Revamp Research Norms After less than three years of collecting voice samples, the Peter Cohen Foundation / EverythingALS awaits FDA approval of its AI algorithm as a secondary biomarker for tracking ALS progression. Indu Navar discusses how the listener-effort prediction model — the first-ever objective, scalable digital biomarker for any neurological disease — will be deployed in clinical trials as early as Q1 2026, across its consortium of 22 pharma partners. Read more JANUARY 2026 EverythingALS Taps 'Power in the Crowd' to Revamp Research Norms After less than three years of collecting voice samples, the Peter Cohen Foundation / EverythingALS awaits FDA approval of its AI algorithm as a secondary biomarker for tracking ALS progression. Indu Navar discusses how the listener-effort prediction model — the first-ever objective, scalable digital biomarker for any neurological disease — will be deployed in clinical trials as early as Q1 2026, across its consortium of 22 pharma partners. Read more NOVEMBER 2025 Q&A: Caregivers 'the Invisible Backbone' of the Neurodegenerative Disease Journey In recognition of National Family Caregivers Month, Healio interviews Indu Navar about her personal caregiving experience with her husband Peter, the founding of EverythingALS, and how the organization supports caregivers through community groups, education, and participation in remote digital research studies — turning lived experience into contributions to ALS biomarker development. Read more OCTOBER/NOVEMBER 2025 AI Offers New Hope for ALS Patients Seeking Clinical Trial Matches Indu Navar, CEO and founder of EverythingALS, discusses how AI and machine learning are being used to match ALS patients with clinical trials. The piece highlights EverythingALS's role in connecting patients to research opportunities and the potential of technology to accelerate treatment development for those living with the disease. Read more OCTOBER 2025 SAVA AI: Transforming How Patients Find Clinical Trials SAVA AI is an intelligent trial-matching platform that connects patients to the right clinical trials in seconds rather than weeks. Built by EverythingALS, the system combines human insight with advanced large-language-model (LLM) technology developed in partnership with Amazon Web Services. It interprets a person’s natural questions such as “Are there any ALS trials recruiting in Texas?” and delivers personalized, plain-language results drawn from verified, real-time sources like ClinicalTrials.gov . Read more SEPTEMBER 2025 Air Pollution’s Link To Amyotrophic Lateral Sclerosis (ALS) Air pollution from fossil fuels is the main contributor to climate change. The damage caused by air pollution doesn’t stop there; it also contributes to human diseases, suffering, and premature deaths. Indu Navar, an expert researcher, caregiver, and nonprofit founder , answered some questions for us about air pollution exposure and amyotrophic lateral sclerosis (ALS) . She is one of the founders of Everything ALS . Read more SEPTEMBER 2025 3 American Business Women Who Are Making A Difference In The World September 22 is American Business Women’s Day when we celebrate the achievements of the many successful women entrepreneurs and business leaders who are thriving amid the challenges of our ever-changing political and economic environment. Read more SEPTEMBER 2025 Invisible battles: The fights we don’t see until it’s too late High blood pressure, often referred to as the “silent killer,” is one of the most common yet ignored threats to health, affecting nearly 50% of adults in the U.S. Lacking symptoms, it can escalate into a hypertensive crisis triggering stroke, heart attack and kidney damage. The leading expert and chair of the latest American Heart Association guidelines breaks down what the numbers mean, why so many people remain undiagnosed and how small changes in lifestyle can save lives. Read more AUGUST 2025 Confidence Through Health Indu Navar, CEO of EverythingALS.org, provides us insight into the challenges and benefits of merging technology advancements with the healthcare system. In just a few short years, Indu has brought together multiple players in the neurological care area to improve the speed and capacity for patient care. Read more JULY 2025 Research Moves Slowly. Rare Diseases Don’t—So Patients Aren’t Waiting When Casey McPherson became a father, his purpose became clear. He needed to raise his daughter, Rose, to be loving, courageous, healthy and strong. He needed to protect her. Read more JULY 2025 It was already difficult enough for patients and caregivers dealing with severe illness. Indu Navar set up Everything ALS to help people with that process. Now things are about to get more difficult. Indu gives advice on this MM as to her organization and how it can help navigate the ever changing healthcare landscape. Read more MAY 2025 10 Things You Should Never Say to a Caregiver Avoid these platitudes, and learn what to say instead. Read more MAY 2025 KBOO's Lexus Ponce interviews nurse practitioner Martha Beach about how people with serious medical conditions can prepare in the face of more frequent emergencies like wildfires. Read more APRIL 2025 Bay Area app uses AI to help people with early detection of ALS symptoms A former tech executive who lost her husband to amyotrophic lateral sclerosis, ALS, hopes her app will help people with the early detection of ALS symptoms. Read more APRIL 2025 The Ice Bucket Challenge Is Back: Why Some Are Criticizing the 'Rebranding' of the Viral Trend 11 Years Later Students from the University of South Carolina started a recent campaign using the ice bucket challenge to raise mental health awareness Read more APRIL 2025 Everything ALS AI app helps connect thousands to clinical trials Read more MARCH 2025 I started a nonprofit to fight ALS after my husband's death. Here's how tech and AI can help us find a cure. Indu Navar has spent her career in tech, building and investing in organizations in Silicon Valley. She founded the Peter Cohen Foundation and EverythingALS after her husband died of ALS. Cohen had a long tech career, too. He built Amazon Mechanical Turk and AWS at Amazon. Read more MARCH 2025 App connects people with ALS, caregivers to supportive tools, guidance EverythingALS Pathfinders program offers one-on-one support with people diagnosed with ALS MELBOURNE, Fla. – Every 90 minutes, someone gets diagnosed with ALS. And every 90 minutes, someone dies from the disease. There’s no cure and the statistics are discouraging, but there’s a mobile app that’s creating hope for people living with ALS and their caregivers. Read more FEBRUARY 2025 Denham Springs man diagnosed with ALS helping to connect community DENHAM SPRINGS, La. (Louisiana First ) — Joe Redmond had a successful career as a radio and music executive in Louisiana and Tennessee for 40 years. Over time, he started having trouble with his voice and speaking. “I was slurring and often asked to repeat things so I knew something was wrong,” he said. Redmond saw many doctors over five years. Finally, he was diagnosed with Amyotrophic lateral sclerosis (ALS), or Lou Gehrig’s disease. This is a deadly neurodegenerative disorder that impacts motor neurons in the brain and spinal cord. Read more FEBRUARY 2025 Weekends with Larry Marino Podcast Read more JANUARY 2025 Former music exec on losing voice to ALS – and finding hope in community; rise in Islamophobia after Bourbon Street attack A diagnosis of amyotrophic lateral sclerosis, or ALS, is difficult for anyone to hear. But that was especially the case for Joe Redmond, a music executive from Denham Springs who spent his career in radio. While he is losing his voice, Joe has been determined to take advantage of all the opportunities he has, including working with the Team Gleason organization, and a new caregiving program called Pathfinders. Read more DECEMBER 2024 Minnetonka woman helping connect ALS community through app "Pathfinders" MINNETONKA, Minn. — A Minnetonka woman is helping connect the ALS community through an app. On Jan. 5, 2022, Faith's son, Scott, was diagnosed with ALS. ALS is a fatal neurological disease that affects nerve cells in the brain and spinal cord. Scott was 50 years old at the time of his diagnosis. He was a marathon runner and avid cyclist. Read more SEPTEMBER 2024 EverythingALS Launches App for ALS Community New version of the app will connect people with ALS while collecting data to support research. EverythingALS, a technology- and data-focused nonprofit, has launched an app to support people living with amyotrophic lateral sclerosis (ALS), their families and caregivers, researchers, and health-care professionals. Read more SEPTEMBER 2024 EverythingALS launches new app version for broader ALS community Patients and caregivers can access resources, contribute to ALS research EverythingALS has launched a new version of its mobile app that now includes community support, artificial intelligence-powered chat assistance, and enhanced research opportunities to better serve people with amyotrophic lateral sclerosis (ALS) and their caregivers. The app, which was previously designed only for people taking part in observational studies, has been expanded to also include patients and caregivers from the broader ALS community, allowing them to access vital information and resources, and to contribute to ALS research. “We invite everyone in the ALS community, from newly diagnosed individuals to long-term patients and caregivers, to explore the new features and benefits of this comprehensive app,” the nonprofit EverythingALS said in its press release . Read more DECEMBER 2024 EverythingALS and Compass UOL partner to advance artificial intelligence and computational biology by training and supporting 2,000 Top Talent to Cure ALS at Amazon web services(AWS) re:Invent 2024 in support from AWS LAS VEGAS, Dec. 4, 2024 /PRNewswire/ --A partnership between Compass UOL, an AI transformation services company, and non-profit EverythingALS is using artificial intelligence to address Amyotrophic Lateral Sclerosis (ALS), one of the most intractable puzzles in medicine. EverythingALS and Compass UOL officially launched their partnership on December 4 at 4:00 PM PT at the annual AWS re:Invent conference at the AWS for Healthcare and Life Sciences booth within the AWS for Industries Pavilion. Read more JUNE 2024 Could Artificial Intelligence hold the key to a cure for ALS? Researchers say yes CLEVELAND — ALS is a deadly disease that slowly attacks the nervous system. Currently, there is no cure, but some researchers believe artificial intelligence could hold the key to eradicating the disease. Good Morning Cleveland anchor Tiffany Tarpley spoke with the founder of EverythingALS, Indu Navar, about an app that uses AI to see how early ALS can be detected. Navar helped create the app after she lost her husband to ALS. She's encouraging people of all ages and backgrounds to download the app to help advance ALS research. Read more MAY 2024 Indu Navar: ALS Awareness Month Read more MAY 2024 St. Petersburg couple participate in speech study for earlier ALS diagnosis ST. PETERSBURG, Fla. — A patient-focused nonprofit organization is using artificial intelligence to help analyze audio and video recordings of patients with ALS and those without the neurological disorder, to advance diagnosis and prognosis of the disease. Read more MAY 2024 EverythingALS CEO Indu Navar and Chairman Bill Nuti talk ALS awareness month with Jim Cramer Read more MARCH 2024 EverythingALS launches AI platform to accelerate ALS research EverythingALS has introduced a platform aimed at advancing amyotrophic lateral sclerosis (ALS) research using artificial intelligence (AI) and machine learning — with the ultimate goal of eradicating the disease and restoring lost motor function to those with ALS and other neurodegenerative disorders. Read more MARCH 2024 EverythingALS Launches the Vision 2030 AI Hub : Charting the Path to an ALS Cure and Advancing Neurodegenerative Disease Research Vision 2030 will utilize advanced technologies and an innovative operating model for research and drug development Read more AUGUST 2023 New $400K grant aims to help ID digital diagnostic markers in ALS A new two-year, $400,000 grant will support studies — by EverythingALS and the Sean M. Healey and AMG Center for ALS at Massachusetts General Hospital (MGH) — aimed at identifying early digital diagnostic markers in amyotrophic lateral sclerosis (ALS). Read more AUGUST 2023 Effort to gather data on A.L.S. BINGHAMTON, NY – (WIVT/WBGH ) On the eve of the annual Walk to Defeat ALS, an effort is underway to bring modern innovation to find ways to better diagnose, treat and ultimately cure the fatal disease. Read more JULY 2023 Daily AI Roundup: Biggest Machine Learning, Robotic And Automation Updates 13th July 2023 This is our AI Daily Roundup . We are covering the top updates from around the world. The updates will feature state-of-the-art capabilities in artificial intelligence (AI) , Machine Learning , Robotic Process Automation, Fintech, and human-system interactions. We cover the role of AI Daily Roundup and its application in various industries and daily lives. Read more JUNE 2023 AI could provide breakthrough for early diagnosis of rare diseases For people living with rare diseases, one of the major challenges is being able to receive a rapid and accurate diagnosis. Often the process takes years, but Ben Hargreaves finds that there is a new wave of research utilising AI that could change this. Read more JUNE 2023 Could AI help diagnose diseases like ALS more quickly? BOULDER, Colo. (KDVR) — Michael Robinson was diagnosed with amyotrophic lateral sclerosis, or ALS, almost eight years ago when he was just 45 years old. “I was late for a meeting and went to go run and couldn’t get my right leg to move, and being a physician and knowing what I know, my immediate thought was I think I have ALS,” the Boulder resident said. Read more JUNE 2023 EverythingALS: Searching for a Cure with AI EverythingALS, a patient-focused non-profit, is currently conducting the world's largest AI-powered ALS study. John Howell is joined by Indu Navar, Founder of EverythingALS, to discuss the details of the study and history behind the non-profit. The study is still taking participants, both those who have ALS and those who don't. For more information, visit everythingals.org. Read more JUNE 2023 Non-profit Conducts Studies to Help with ALS "The way I look at it, as technology is here today. We can make an impact to people with ALS today. So, what we are doing is we're looking at these progression markers and applying this to clinical trials that's happening today. So, we work with about 11 pharma companies that partnered with us on this initiative," Founder and CEO of EverythingALS Indu Navar said. Read more JUNE 2023 Everything ALS works to help doctors and families diagnose the disease faster While reflecting on the process that her family endured while her husband battled the disease, Navar says, "There is something called diagnosis fatigue. And it really creates a lot of very, very deep, deep sorrow and grief just going through the diagnosis because it is, I say, it's death by a thousand cuts." Read more JUNE 2023 Tech entrepreneur aims to use artificial intelligence to speed up diagnoses of ALS DETROIT LAKES — Using artificial intelligence and machine learning, a tech entrepreneur is going after the fatal disease of ALS – also known as Lou Gehrig's Disease. Read more JUNE 2023 Bringing Technology to ALS CARE Indu Navar, founder of EverythingALS, joins Amy & JJ. And, just in time for the Fargo walk. Read more APRIL 2023 "EverythingALS" joins Harvard, MIT and IBM for unique research EverythingALS founder Indu Navar joined Kyla Grogen to discuss the unique research they are conducting with Harvard, MIT, and IBM. Watch the clip to learn how recording your voice for 20 minutes a week could be the key to finding a quicker way to diagnose and treat ALS. Read more APRIL 2024 Listen Up: Emerging Vocal Biomarker Could Aid ALS Drug Development It’s been a disappointing spring for the amyotrophic lateral sclerosis community, with the Phase II failure of Sanofi and Denali Therapeutics’ candidate and Amylyx’s decision to pull Relyvrio from the market . But drugmakers are hopeful that the development and validation of novel biomarkers for the disease, including neurofilament, genetic markers and, more recently, speech, can help improve patient care and expedite the development of effective treatments. Read more MARCH 2024 Deciphering the cellular mechanisms behind ALS At MIT, Fraenkel works in the Department of Biological Engineering and co-directs the Computational Systems Biology graduate program. For the study of ALS, he and his collaborators at Massachusetts General Hospital (MGH), including neurologist and neuroscientist Merit Cudkowicz, were recently awarded $1.25 million each from the nonprofit EverythingALS organization. The strategy behind the gift, Fraenkel says, is to encourage MIT and MGH to increase their collaboration, eventually enlisting other organizations as well, to form a hub for ALS research “to break down barriers in the field and really focus on the core problems.” Read more MARCH 2024 A new way to detect ALS in patients ALS is a crippling disease that affects the nervous system. There is a new and easier way to detect ALS. ALS also known as Lou Gehrig’s disease, affects the nervous system by weakening muscles and ultimately paralyzes the patient. Indu Navar is the CEO and Founder of Everything ALS, she says there is a new effort to help ALS patients by using AI machine learning. Read more MARCH 2024 Citizen-Driven Research Aids Development Of Digital Biomarkers For ALS March 20, 2024 | When it comes to research on amyotrophic lateral sclerosis (ALS), every stakeholder—most especially patients—knows time is of the essence. From diagnosis to death, life expectancy from the debilitating neuromuscular disease can be two years or less. “The time people give us is currency,” says Indu Navar, founder of the nonprofit Peter Cohen Foundation operating as EverythingALS. Read more JANUARY 2024 Citizen-Driven Research Aids Development Of Digital Biomarkers For ALS When it comes to research on amyotrophic lateral sclerosis (ALS), every stakeholder—most especially patients—knows time is of the essence. From diagnosis to death, life expectancy from the debilitating neuromuscular disease can be two years or less. “The time people give us is currency,” says Indu Navar, founder of the nonprofit Peter Cohen Foundation operating as EverythingALS. Read more JANUARY 2024 Governor Hochul proposes historic $25m budget for ALS research in New York A groundbreaking moment in the search for a cure for ALS. Governor Hochul is looking to set aside a historic amount of money for ALS research in New York. She made the announcement in her budget address last week, but in this week's Wellness Wakeup, you'll see for the governor and many others, it's personal. Read more DECEMBER 2023 10 unexpected ways life changes when you become a family caregiver Some family caregivers go into it knowing that caring for a loved one is their fate, while others are unexpectedly thrust into it. But whether it’s expected or not, the family caregiving journey is rarely predictable, says Jody Gastfriend , a licensed clinical social worker, author and senior care consultant. Read more DECEMBER 2023 Slowing ALS with Speech: Study leverages IBM’s AI, creates digital biomarkers EverythingALS is working with clinical research stakeholders from IBM Research, Massachusetts Institute of Technology, and Harvard University in a longitudinal study focused on early disease detection based on patterns noted in audiovisual sessions. Read more OCTOBER 2023 Former tech executive leads nonprofit to help those with ALS Moving from tech entrepreneurship to caregiving was never a step Indu Navar expected to make, but this leap of faith turned out to be transformative. Today, she is making use of both skill sets as the CEO and founder of EverythingALS , a nonprofit patient-led advocacy group focused on creating digital biomarkers for early detection of ALS. Read more SEPTEMBER 2023 EverythingALS Announces Student Fellow Scholarship Awards and Expanded Student Ambassador Program aims to accelerate ALS Research SEATTLE, Sept. 27, 2023 (GLOBE NEWSWIRE) -- EverythingALS, a citizen science research organization dedicated to developing cure for ALS, announced today the Student Fellow Scholarship Awards and the expansion and continued enrollment of student Ambassadors program. Both programs are core pillars of the EverythingALS Care to Cure™ impact model. Read more SEPTEMBER 2023 Local ALS Association Chapter’s ‘Walk to Defeat ALS 2023’ held in Salem SALEM, Va. (WFXR ) — On Sept. 16, different ALS Association Chapters across the nation hosted their annual Walk to Defeat ALS. Our local chapter in Virginia was no different. The event was to raise funds for amyotrophic lateral sclerosis or Lou Gehrig’s disease. It’s a rare progressive neurological disorder that affects nerve cells in the brain and spinal cord resulting in weakened muscles. Currently, it’s a terminal diagnosis, meaning it has no cure. Read more AUGUST 2023 New $400,000 Grant Supports EverythingALS.org and Mass General Hospital (MGH) to Develop NeuroLens, a Digital Diagnostics technology initiative for early detection of Amyotrophic Lateral Sclerosis (ALS) SEATTLE--(BUSINESS WIRE )--EverythingALS today announced it has received $400,000 from ALS Finding a Cure® and The ALS Association to support studies for the identification of early digital diagnostic markers of ALS. Read more AUGUST 2023 Buffalo's ALS ambassador raising awareness ahead of weekend walk ORCHARD PARK, N.Y. (WKBW) — It is a disease that robs people of their ability to walk, talk, swallow and eventually breathe. ALS, often called Lou Gehrig's Disease most commonly afflicts people between the ages of 40 and 70. As many as 30,000 Americans have the disease at any given time. This Saturday, Buffalo will be hosting the Western New York Will Walk to Defeat ALS , at Delaware Park. Read more JULY 2023 Merging as EverythingALS, 2 nonprofits seek to better treatment “We firmly believe that the proliferation of non-profit organizations in this field leads to duplication of efforts, wasting precious time, money, and most importantly, lives,” Bill Nuti, CureALS’ founder and CEO and now chairman of the board of directors for Everything ALS, said in a joint press release . Read more JULY 2023 EverythingALS and CureALS Join Forces to Discover a Cure for ALS “They reflect our commitment to advancing research, improving diagnosis and therapies, leveraging data for analysis and technology integration, and ensuring comprehensive support for people living with ALS and FTD.” Read more JULY 2023 California tech company using artificial intelligence in ALS studies BOULDER, Colo. — More than 5,000 Americans are diagnosed with amyotrophic lateral sclerosis (ALS) each year, and roughly 600 people are here in Colorado, according to the Rocky Mountain chapter of the ALS Association. Read more JUNE 2023 Groundbreaking Nonprofit, CureALS Founded and Launched by Former NCR Chairman and CEO Bill Nuti to Eradicate ALS NEW YORK--(BUSINESS WIRE )--CureALS, a pioneering nonprofit organization dedicated to eliminating ALS (Amyotrophic Lateral Sclerosis) and other complex neurodegenerative diseases such as Alzheimer’s, Parkinson’s, and Frontotemporal Dementia, has officially launched today. Read more APRIL 2023 How AI and Facial Recognition Could Spot Stroke and Other Diseases Researchers are training computer algorithms in efforts to quickly identify ailments and speed treatment. Patients at Johns Hopkins Hospital who are suspected of having a stroke might get an unusual request from physicians: Can we film your face ? The doctors’ goal is to identify stroke patients by facial characteristics instead of waiting for brain scans or blood tests, helping speed both treatment and recovery. Read more APRIL 2023 Non-profit behind world's largest AI-powered ALS study ST. PETERSBURG, Fla. — ALS non-profit EverythingALS is using artificial intelligence and other technologies to help find a way to diagnose ALS and other neurological diseases faster and find a cure. It’s partnering with healthcare companies in the effort and conducting speech research to spot and track early signs of ALS. Read more APRIL 2023 Project CommUNITY Women Breaking Barriers: Indu Navar, Founder of Everything ALS "I made a promise to him that I will keep fighting for him and the disease,” Navar said. “And we need to prevent from other people going through what we went through. I want to keep them alive through this work. And I really feel it was such a terrible experience for us that I really don't wish this on anybody" Read more APRIL 2023 How AI CAN LOOK INTO YOUR EYES AND DIAGNOSE A DEVASTATING BRAIN DISEASE “The eyes are the windows to the soul.” It’s an ancient saying, and it illustrates what we know intuitively to be true – you can understand so much about a person by looking them deep in the eye. But how? And can we use this fact to understand disease? Read more MARCH 2023 STUDY SEEKS TO IMPROVE ALS DIAGNOSES WITH AI Speech recognition patterns can give clues to neurological conditions A study is underway to determine AI’s suitability for diagnosing the neurological disease ALS. The study is using AI-powered virtual assistants to detect potential signs of ALS in a participant’s speech patterns and facial gestures. Read more FEBRUARY 2023 LOCAL RESIDENT REVEALS HIS ALS JOURNEY Learn about the ALS journey of local resident Tommy Culpepper and find out you can support him! - KNWA & FOX24 - Northwest Arkansas & River Valley News + The ALS Association Arkansas Chapter Read more FEBRUARY 2023 What Dr. Chatbot ordereD Your doctor could be a robot sooner than you think. The pandemic and its toll on the health care sector spurred interest in the role artificial intelligence can play in easing burdens and improving efficiency, particularly via chatbots to tackle routine tasks like scheduling appointments and billing issues. But evidence is building that suggests chatbots are already pretty good at giving health advice. Read more JANUARY 2023 Montgomery County man with ALS part of study that aims to find root cause of disease "When a man died, he was said to have gone west," repeated 59-year-old Todd Kelly into a computer. He isn't reading a best-selling novel, but reciting speech to help treat and cure ALS. "The problem with ALS, unlike many other diseases, is they can't find a biomarker. The biomarkers, what you can see, is affected by a treatment," he described. Read more JANUARY 2022 Getting Vocal In December of 2016, Valerie Geerer was doing her normal lunchtime walk with work colleagues when a friend noticed something off about her gait. “I remember she said, ‘Is there something the matter with your foot?’” the fifty-nine-year-old Stamford resident recalls. “I told her I felt fine. A month later I was tripping myself. It was ironic. Six months earlier, my husband Michael and I were climbing mountains in Utah. And suddenly I couldn’t walk without stumbling.” Read more DECEMBER 2022 ALS genetic carrier finds the “path to higher ground” in clinical research ALS genetic carrier finds value in EverythingALS study leveraging digital biomarkers as a means to create tools for early detection of ALS and potentially other neurological diseasese. Read more DECEMBER 2022 New way to detect ALS; early diagnosis critical for treatment LAS VEGAS (KLAS) — Every 90 minutes, someone gets diagnosed with amyotrophic lateral sclerosis, or ALS. It’s a progressive neurodegenerative disease that affects nerve cells in the brain and spinal cord and there is no cure. Read more NOVEMBER 2022 Woman's Husband's Health Journey Inspires Everything ALS NBC10’s Erin Coleman speaks to Everything ALS founder Indu Navar about her husband’s own ALS diagnosis and how the group is working to better ALS research. You can help the fight through Everything ALS or at the 2022 Walk to Defeat ALS. Read more NOVEMBER 2022 Walk to Defeat ALS happening in North Las Vegas Indu Navar, founder of EverythingALS, joined us to talk about how your participation helps raise funds and awareness. WATCH HERE NOVEMBER 2022 Non-profit conducts study to diagnose ALS quicker LANSING, Mich. (WLNS) — In the 150 years since ALS was discovered there is still no cure or single test to diagnose the disease. The demand for more answers is what drove one woman to start up her own non-profit. EverythingALS began its research in 2021 and now they’re working toward diagnosing the disease faster. “I really want to help people who are going through this disease,” said Indu Navar, Founder of EverythingALS. The study analyzes data when it comes to physiological changes and the progression of the disease. Navar says she wants to shift the focus to the brain, something she believes isn’t understood well enough. READ MORE SEPTEMBER 2022 Q&A With Indu Navar, founder of Everything ALS Indu Navar, founder of Everything ALS, speaks with Pharm Exec about how she lost her husband to the disease and how she's trying to improve the way its diagnosed. Indu Navar Diagnosing ALS is a difficult process for patients experiencing symptoms. After the death of her husband, tech entrepreneur Indu Navar founded Everything ALS, and organization she hopes will refine and improve the way ALS and other neurological conditions are diagnosed. READ MORE OCTOBER 2022 New technology helping ALS patients in Louisiana BATON ROUGE, La. (BRPROUD) — ALS, often called Lou Gehrig’s disease, is a progressive motor neuron disease that gradually robs people of their ability to walk, talk, swallow, and eventually breathe. Indu Navar, the founder of EverythingALS, said, “ALS has no known cause or cure and so patients suffer for years not knowing what is wrong and have to go through rigorous testing and a process of elimination to finally get diagnosed. If they are diagnosed, there are no treatments. Life expectancy is two to five years.” READ MORE SEPTEMBER 2022 EverythingALS Joins Forces with Aural Analytics, FeetMe, ZEPHYRx and Others for a First-Of-Its-Kind ALS Research Study SAN FRANCISCO (PRWEB) SEPTEMBER 19, 2022 EverythingALS, a patient-focused non-profit that brings together people living with ALS, caregivers, physicians, researchers, and pharmaceutical companies to collaborate on an open innovation platform using cutting-edge technologies and data science to improve progression measurements for neurological disease like Amyotrophic Lateral Sclerosis (ALS), has initiated a new study, The Radcliff Study, with partners in the quest to find a diagnosis, treatment, and cure for ALS... READ MORE AUGUST 2022 Groundbreaking research involving artificial intelligence could diagnose ALS patients sooner Five thousand people in the U.S. are diagnosed with a neurological disease called ALS every year. Medical experts say it typically takes an average of two years to diagnose, but new research will likely make that timetable a lot shorter. In 2019, Mark Weston and his wife, Kathleen, had their retirement all planned out. "We were all set up for a sail off into the sunset and have a really fun retirement," Weston said. "We had, we bought a house on the coast of Maine several months earlier." A week before the big move, he got a life-changing diagnosis. READ MORE AUGUST 2022 NeuroSense Joins EverythingALS Open Innovation Consortium; Set to Enroll US and EU Patients in Phase IIb Study NeuroSense's support will aid EverythingALS with ground-breaking patient research in a joint effort to develop treatments LOS ALTOS, Calif. and CAMBRIDGE, Mass., Aug. 2, 2022 /PRNewswire/ -- EverythingALS , a patient-focused non-profit that brings together patients, caregivers, physicians, researchers, and pharmaceutical companies using technological innovations and data science to support efforts to improve care for those living with a neurological disease like Amyotrophic Lateral Sclerosis (ALS), today announced NeuroSense Therapeutics Ltd. (NASDAQ: NRSN ) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, as a new collaborator in the effort to identify treatments and a cure for ALS. READ MORE AUGUST 2022 ‘Death by 1,000 cuts:’ How emerging tech could change the journey for ALS patients EverythingALS aims to speed drug development through improved diagnostics. in 2016, Indu Navar’s husband, Peter Cohen, experienced the first symptom of what turned out to be amyotrophic lateral sclerosis (ALS), a progressive degenerative disease commonly known as Lou Gehrig’s disease. EverythingALS founder Indu Navar Permission granted by EverythingALS/Indu Navar “His foot was just acting weird,” says Navar, who founded the California nonprofit EverythingALS two years ago. “We didn’t know where to go, so we went to a chiropractor,” she says. READ MORE JULY 2022 Healthbeat: New ALS research driven by patient-focused non-profit SCRANTON, LACKAWANNA COUNTY— New research is underway to better understand and treat ALS, a difficult disease to diagnose with no known cure. ALS patient Paul Miller of Scranton is one of the participants. The progressive neurodegenerative disease ALS affects as many as 30,000 Americans. There is no known cure despite efforts to better understand it and treat it. ALS is a puzzling disease for certain with so much needing to be learned about it. READ MORE TOMMY EDWARD CULPEPPER,Jr MOVIE CONNOISSEUR JULY 2022 Bentonville man works to help diagnose ALS sooner A Bentonville man is dedicating his life to advocating for people with ALS and trying to help diagnose the disease sooner. “I’m a movie connoisseur,” said Tommy Edward Culpepper, Jr. “I love movies.” For Culpepper, movies have always been his saving grace. Even when he was a kid growing up in St. Louis, Missouri. “I grew up in the Peabody Projects and the home environment wasn’t the greatest,” he said. “Star Wars, Blade Runner, Highlander. Movies like that are excellent getaways for me.” Until he found himself in a nightmare that started in the doctor’s office... READ MORE JULY 2022 These 2 Surprising Traits May Predict ALS, New Research Says How ALS researchers are using an intriguing tool to learn keys of this disease that has at times taken years to diagnose. Plus, one woman's story of why she agreed to participate in this research Amyotrophic lateral sclerosis (sometimes called Lou Gherig’s disease, or ALS ) affects around 15,000 Americans, with about 5,000 receiving a new diagnosis each year, according to the Centers for Disease Control and Prevention. READ MORE JUNE 2022 Continue that momentum from the ALS Ice Bucket Challenge by getting involved in a unique study - New Day NW Researchers want every American to start recording their voice daily. They believe this data could be used to eventually develop cures for ALS. #newdaynw READ MORE MAY 2022 Patients giving voice to ALS research Back in 2014, millions of people poured icy water over their heads to spread ALS awareness and support research for the devastating neurodegenerative disease. Now tech developers want to hear your voices. Brian Andre has been living with ALS for six years. “On average they only give you 2 to 5 years of life after diagnosis and some progress very quickly,” he said. “I’m really in a very small percentage of patients who see little or no progression. … My weakness is in my left side, left leg and arm. So it throws my gait off.” READ MORE INDU NAVAR, CEO - EVERYTHINGALS MAY 2022 Live At 9: Researchers Collecting Audio and Video to Help ALS Detection Remember the summer Americans took time to dump buckets of ice water on their heads to help fight the deadly disease ALS? This summer, there’s a more comfortable way to help researchers learn about ALS and other neurological disorders. Researchers want people to record their voices and upload them for study. READ MORE Austen Eadie-Friedmann before his diagnosis of amyotrophic lateral sclerosis or ALS MAY 2022 A Connecticut man is battling a fatal disease with ‘enormous courage’. Love and his work with an ALS group give him ‘purpose Three years ago Austen Eadie-Friedmann, 38, had a dynamic career in the pharmaceutical/biotech field working for a Fortune 500 company and living in exciting places such as New York City, Boston and Europe, with his husband, William DeGregorio. The couple, now together for 18 years and married for five, loved their life traveling the world, sharing a passion for art. Then the devastating diagnosis arrived... READ MORE INDU NAVAR, CEO - EVERYTHINGALS MAY 2022 How high tech shoes could help doctors better understand ALS MOUNTAIN VIEW, Calif. - There is no cure for ALS, the progressive neurodegenerative disease that affects nerve cells in the brain and spinal cord, but a Silicon Valley nonprofit is hoping to change that. Starting Tuesday, EverythingALS , a Silicon Valley nonprofit and advocacy group, is starting its second research study involving ALS patients, using shoes with high-tech censors to track and study their movements. The study is open to 100 participants in the early stages of ALS, and is still accepting new participants.... READ MORE MAY 2022 Tech Tuesday: Using AI to fight ALS LANSING, Mich. (WLNS) — One non-profit organization is using technological innovations and data science to support those grappling with amyotrophic lateral sclerosis, otherwise known as ALS. EverythingALS was started by Indu Navar. READ MORE INDU NAVAR, CEO - EVERYTHINGALS MAY 2022 Bringing Awareness To ALS And Those Who Suffer From It In this podcast, we are joined by Indu Navar. Indu Navar is the CEO of Everything ALS, a company that prioritizes bringing awareness to Amyotrophic Lateral Sclerosis (ALS) and those who suffer from it. ALS is a neurological condition that affects the victim's motor neurons. This causes muscle atrophy all across the body, which can eventually cause suffocation and even death. LISTEN NOW APR 2022 Be The Good with Kate Cherichello Be the Good with Kate podcast- Kate Cherichello scheduled a taped interview with Indu for Wednesday, March 9th at 3:30pm EST to discuss EverythingALS and the research study. Episode went live on April 29th. LISTEN NOW FEB 28, 2022 MITSUBISHI TANABE PHARMA JOINS EVERYTHINGALS CONSORTIUM TO HELP ACCELERATE BIOMARKER DISCOVERY FOR NEUROLOGICAL DISEASES (San Francisco, CA)-- Today, EverythingALS.org (EALS), a patient-centric, citizen-based California nonprofit accelerating the discovery of digital biomarkers for neurological diseases such as amyotrophic lateral sclerosis (ALS), announced that Mitsubishi Tanabe Pharma Holdings America, Inc. READ MORE FEB 12, 2022 San Francisco based nonprofit launches new ALS research SAN FRANCISCO (KCBS SF) — A San Francisco-based nonprofit is recruiting average people to take part in ALS research. KCBS Radio’s Keith Menconi explains. READ MORE DEC 2021 ALS, Lou Gehrig’s Disease, takes many lives, Everything ALS is doing Deb Fabricatore lost her younger brother to ALS in 2014, and became involved in ALS advocacy. Indu Navar lost her husband in 2019 and immediately stepped up into action by building a nonprofit devoted to honoring her husband. READ MORE Bay Area Nonprofit Seeks 300 Volunteers in ALS Speech Study SAN FRANCISCO (CBS SF) — A Bay Area nonprofit dedicated to advancing research on an incurable — and fatal — disease of the nervous system is looking for 300 more people by the end of this month to participate in the largest-ever research project on the illness. READ MORE NOV 21, 2021 EverythingALS said it needs more than 300 volunteers for its study to combat amyotrophic lateral sclerosis, more commonly known as Lou Gehrig’s disease, an incurable, degenerative illness. READ MORE NOV 21, 2021 Bay Area non-profit looking for volunteers in Lou Gehrig diseases study OCT 2021 EverythingALS Launches “Stories and Innovation in ALS” Podcast October 21, 2021 (Silicon Valley, CA) – For an inside look at how ALS impacts patients and their caregivers as well as the innovations that researchers and clinicians are coming up with to find biomarkers, treatments, and cures for this life-threatening disease, start listening to the EverythingALS podcast , “Stories and Innovation in ALS.” EverythingALS (EALS) was founded in 2020 to help discover biomarkers – which are nonexistent -- and document the progression of ALS by launching the world’s largest speech study with more than 600 participants. READ MORE APRIL 2021 Accelerating Rare Disease Research TEDxSantaCatalinaSchool In this moving, TEDx talk, Indu Navar tells how she lost her husband, Peter Cohen, to ALS and what she is doing to bring together patients, families, researchers and people everywhere to change the way that rare diseases are looked at. WATCH VIDEO Digital Health InfoCast: Machine Learning for a Cause Canada has been an early leader in the AI space and there is no shortage of activity flourishing across the country. Today, we welcome Fanny Sie from Roche Canada and Indu Navar of Everything ALS to talk about machine learning and the End ALS Kaggle Challenge . LISTEN JULY 30, 2021 Indu Navar, CEO and Founder of EverythingALS, explores the roles of Artificial Intelligence, Machine Learning, and Brain Computer Interface in the search for a cure for ALS. She will also share innovative research studies on ALS detection, how Pharma can work with and support ALS patient advocates, and her key leadership lessons for digital health entrepreneurs and innovators. WATCH VIDEO JUNE 25, 2021 Impetus Digital PODCAST JULY 2021 New project to better identify and treat ALS uses AI and data sharing Through the AI CoE, Roche has collaborated with EverythingALS , AnswerALS, the Ontario Brain Institutes and ALS Canada to launch an open data science competition called the End ALS Challenge. READ MORE READ MORE Mar 29, 2021 THE STORY OF MODALITY.AI: HEALTHTECH AWARD WINNER Suendermann-Oeft states that one of the most significant achievements for them has been collaborating with the non-profit organization EverythingALS , as well as MIT, Harvard, and IBM to scale the number of Modality platform users to over 100 within three months for a study focusing on the early detection and improved prognostic accuracy of ALS ... "Jody O'Donnell introduced me to the founders of every Everything ALS , brother and sister, Murgesh Navar and Indu Navar, and Indu lost her husband to ALS a few years ago. Really, we just kind of hit it off from the get-go. Tremendous pair, both kind of serial entrepreneurs; they started multiple companies in the Bay Area and they just brought a passion and energy, a desire to do things quickly and challenge the status quo ... READ MORE April 30, 2021 interview with Katie Pecora for Patients Rising The Roche Canada Artificial Intelligence Centre of Excellence (AI CoE) is excited to collaborate with Answer ALS and EverythingALS to launch an initiative called the End ALS Challenge , with the support of ALS Society of Canada , Ontario Brain Institute (OBI) and NetraMark Corp . The goal is to surface insights through an open data competition.. READ MORE Mar 29, 2021 EndALS Kaggle Challenge to TACKEL ALS EverythingALS Selected to Present at the American Academy of Neurology Virtual Annual Meeting EverythingALS, a California nonprofit dedicated to bringing technological innovations and data science to support people with ALS, has been selected to ... READ MORE April 16, 2021 READ MORE Mar 25, 2021 Roche Canada AI Centre and EverythingALS to tackle ALS The Roche Canada Artificial Intelligence Centre of Excellence (AI CoE) is excited to collaborate with Answer ALS and EverythingALS to launch an initiative called the End ALS Challenge, with the support of ALS Society of Canada, Ontario Brain Institute (OBI) and NetraMark Corp... Roche Canada Artificial Intelligence Centre and EverythingALS opens digital competition to tackle ALS EverythingALS, a California nonprofit dedicated to bringing technological innovations and data science to support people with ALS, has been selected to ... READ MORE Mar 18, 2021

EverythingALS is a patient-focused non-profit, part of Peter Cohen Foundation (PCF) a 501(3)c organization. Our mission is to support efforts to care for ALS patients and work to find a cure by creating a platform for direct engagement with patients, caregivers, advocates, and researchers. ALS is a neurodegenerative disease with no treatments . Every 90 minutes someone is diagnosed A patient-focused non-profit bringing technological innovations and data science to support efforts, from care to cure, for people with ALS. Our Research > Latest News > Next ALS Expert Event > Download the EverythingALS App The Power of Together Take action, Join this mov e me nt This map represents our strong growing ALS community across 44 countries How did you hear about us? Submit Contact Care to Cure for ALS EverythingALS is a patient-focused non-profit bringing technological innovations and data science to support efforts -- from care to cure -- for people with ALS, by offering a open-data platform for direct engagement with patients, caregivers, researchers and drug companies. Care for People living with ALS As patient advocates, we host bi-monthly community meetings that are designed to provide patients and caregivers with the support and information that they will need throughout their ALS journey. Meet our teammate, McFinn Lovere, Spiritual Guide and ALS Reversal #42. His blogs are inspiring, and can be accessed by clicking the link below. https://mcfinn.medium.com/ Finding a cure for ALS Technology will be the key enabler for the innovation to end ALS. We support efforts to find a cure for ALS by creating a platform for direct engagement with patients, researchers and cutting edge Cloud and AI technologies. Sponsored Projects Develop speech analysis - audio and facial metrics - for early detection, clinical endpoints and better voice recognition tools for ALS in collaboration with MIT, MGH, UT Austin and Google. Funding for the first ALS Platform trial at Mass General by Dr.Merit Cudkowitz. Supporting AnswerALS and Gladstone Institute with multi-omics analysis with machine learning and big data to uncover ALS causes, subtypes, pathways, and drug targets. EverythingALS Join us on Social Media There are many ways to be involved and engaged on day-to-day conversations Join our active Facebook group. We share all our important events, research and day-to-day annoucements Follow us on twitter. We will regularity tweet announcements and research findings. Follow us on Instagram where our advocates and students share inspiring stories. Join our LinkedIn group. We will share active research ideas and dialogue. Subscribe to our YouTube channel. We will post our ALS Talk series content on YouTube channel. As seen on

Dont' miss an event, watch the past ALS Talk series from worls renowned ALS Experts Subscribe to Youtube channel Videos All Categories Play Video Play Video 01:32:29 Global Collaboration to Disrupt ALS with Dr. David Taylor In this Expert Talk, Dr. David Taylor shares insights into the latest developments shaping ALS research in 2026. This session highlights some of the most important areas of progress in ALS research, including international collaboration, artificial intelligence, increased investment in research, advances in clinical trials, and new approaches to understanding and treating ALS. Dr. Taylor also discusses the growing focus on identifying ALS earlier and developing treatments that are better matched to individual patients. Dr. Taylor explores how researchers around the world are working together to accelerate progress, how new technologies and data are helping scientists better understand ALS, and how clinical trials are evolving to test potential treatments more effectively. He also discusses promising areas of research, including TDP43, biomarkers such as neurofilament, genetic testing, and efforts to understand ALS before symptoms begin. Throughout the discussion, Dr. Taylor highlights the importance of bringing researchers, people living with ALS, organizations, and industry together to move research forward. He also addresses questions about early detection, genetics, clinical trials, emerging treatments, and what the future may hold for ALS research. In this talk, we cover: • The latest developments in ALS research • Global collaboration and the importance of working together • The growing role of AI and new technologies in ALS research • How clinical trials are evolving • Personalized approaches to ALS treatment • New research into TDP43 and other potential treatment targets • Biomarkers and efforts to detect ALS earlier • Genetic testing and understanding the causes of ALS • Research into ALS before symptoms appear • Data sharing and collaboration across the ALS community • The future of ALS research and treatment 📲 Download the EverythingALS App • Google Play: http://bit.ly/4nXqIYy • App Store: https://bit.ly/42tPBmh Follow EverythingALS: ► Website: https://www.everythingals.org ► X: https://x.com/everything_als ► LinkedIn: https://www.linkedin.com/company/everythingals ► Facebook: https://www.facebook.com/everythingals ► Subscribe for more Expert Talks: https://www.youtube.com/@UCpABF6CdW2-0WWmrQEMyq_w #ExpertTalk #EverythingALS #ALSResearch #ALSCommunity #ALS #ClinicalResearch #ClinicalTrials #AI #Biomarkers #Genetics #TDP43 #Neurofilament #DavidTaylor Play Video Play Video 01:33:55 Citizen Research: You Don't Have to Be a Scientist to Think Critically About Research | September 2 Welcome to a new session of Citizen Research with Dr. Terry Heiman-Patterson and Dr. Lyle Ostrow. In this session, we explore an important idea at the heart of EverythingALS Citizen Research: You don’t have to be a scientist to think critically about research. We are joined by Dr. Terry Heiman-Patterson, MD — Director of the MDA ALS Center of Hope and Director of Neurodegenerative Disorders at Temple University — alongside Dr. Lyle Ostrow, MD, PhD, neurologist, ALS researcher, Director of the Temple Neuromuscular Pathology Lab and Temple ALS Postmortem Core, and Chair of the Programmatic Panel for the Department of Defense ALS Research Program (ALSRP), for an engaging discussion on how patients, caregivers, and the broader ALS community can better understand, evaluate, and interpret scientific research. As ALS research continues to evolve, understanding how to assess scientific evidence has never been more important. This session provides a practical framework for reading research papers, understanding the peer review process, evaluating potential therapies, and distinguishing promising findings from what the available evidence can actually support. In this talk, we cover: • Why critical thinking is essential when evaluating ALS research • How to read and evaluate research papers and potential therapies • The difference between preprints and peer-reviewed research • How to assess study findings, evidence, limitations, and relevance to patients • How to understand what additional evidence is needed before drawing conclusions about emerging ALS therapies Citizen Research is about making science more accessible, collaborative, and empowering for everyone affected by ALS. Conversations like this help bridge the gap between complex research and real-world understanding, ensuring that the ALS community remains informed, engaged, and connected. 📲 Download the EverythingALS App • Google Play: http://bit.ly/4nXqIYy • App Store: https://bit.ly/42tPBmh Follow EverythingALS: ► Website: https://www.everythingals.org ► X: https://x.com/everything_als ► LinkedIn: https://www.linkedin.com/company/everythingals ► Facebook: https://www.facebook.com/everythingals ► Subscribe for more Expert Talks: https://www.youtube.com/@EverythingALS #EverythingALS #CitizenResearch #ALSResearch #ALSCommunity #ClinicalTrials #ALSScience #NeurodegenerativeDisease #ResearchLiteracy #CriticalThinking #ALSAwareness #PeerReview 🔔 If you are passionate about advancing ALS research and understanding, like, subscribe, and turn on notifications. Sharing this episode helps expand awareness and keep important scientific conversations moving forward. Play Video Play Video 01:34:27 The ALSTARS Trial: Updates on the COYA 302 Clinical Trial and the Path Ahead In this Expert Talk, Dr. Tyrell Simkins and Dr. James Berry explore The ALSTARS Trial: Updates on the COYA 302 Clinical Trial and the Path Ahead. This session highlights the role of the immune system in ALS, the importance of inflammation in disease, and the role of regulatory T cells in helping regulate the immune response. Dr. Simkins and Dr. Berry discuss what regulatory T cells do, what may go wrong in ALS, and how these cells may represent an emerging area of therapeutic research. They also provide an overview of COYA 302, an investigational therapeutic approach that combines two existing medicines, and share early observations from the first four people treated. The speakers explain how the ALSTARS clinical trial is designed, including randomization, placebo control, the extension phase, and the injections involved in the study. They also discuss what clinical trial participation looks like and the importance of carefully evaluating early findings before broader conclusions can be drawn. Throughout the discussion, Dr. Simkins and Dr. Berry explore the path ahead for COYA 302 and the ALSTARS trial, including what needs to happen before researchers can better understand the potential of this approach for people living with ALS. In this talk, we cover: • The role of the immune system and inflammation in ALS • What regulatory T cells do and what may go wrong in ALS • An introduction to COYA 302 and its therapeutic approach • Early observations from the first four people treated • How the ALSTARS clinical trial is designed • What participation in the ALSTARS trial involves • The path ahead for COYA 302 and the ALSTARS trial 📲 Download the EverythingALS App • Google Play: http://bit.ly/4nXqIYy • App Store: https://bit.ly/42tPBmh Follow EverythingALS: ► Website: https://www.everythingals.org ► X: https://x.com/everything_als ► LinkedIn: https://www.linkedin.com/company/everythingals ► Facebook: https://www.facebook.com/everythingals ► Subscribe for more Expert Talks: https://www.youtube.com/@EverythingALS #ExpertTalk #EverythingALS #ALSResearch #ALSCommunity #ALS #ALSTARS #COYA302 #ClinicalTrials #Immunology #RegulatoryTCells #ALSInnovation #ClinicalResearch #TyrellSimkins #JamesBerry Play Video Play Video 01:37:01 Citizen Research: You Don't Have to Be a Scientist to Think Critically About Research Welcome to a new session of Citizen Research with Dr. Terry Heiman-Patterson and Dr. Lyle Ostrow. In this session, we explore an important idea at the heart of EverythingALS Citizen Research: You don’t have to be a scientist to think critically about research. We are joined by Dr. Terry Heiman-Patterson, MD — Director of the MDA ALS Center of Hope and Director of Neurodegenerative Disorders at Temple University — alongside Dr. Lyle Ostrow, MD, PhD, neurologist, ALS researcher, Director of the Temple Neuromuscular Pathology Lab and Temple ALS Postmortem Core, and Chair of the Programmatic Panel for the Department of Defense ALS Research Program (ALSRP), for an engaging discussion on how patients, caregivers, and the broader ALS community can better understand, evaluate, and interpret scientific research. As ALS research continues to evolve, understanding how to assess scientific evidence has never been more important. This session explains how biomarkers are used in clinical trials, why they matter, how different types of biomarkers serve different purposes, and how they can help researchers better understand treatment effects and improve future trial design. In this talk, we cover: • Why critical thinking is essential when evaluating ALS research • What biomarkers are, why they matter, and how they're used in ALS clinical trials • The different types of biomarkers and what each one tells us • How biomarkers help researchers understand why clinical trials succeed or fail • Real-world ALS clinical trial case studies, including ATLAS, VALOR, BIIB078, ceftriaxone, and lithium • Why target engagement doesn't always translate into clinical benefit • The importance of donated biospecimens and postmortem research in advancing ALS discovery • Practical tips for interpreting scientific studies, emerging therapies, and research headlines Citizen Research is about making science more accessible, collaborative, and empowering for everyone affected by ALS. Conversations like this help bridge the gap between complex research and real-world understanding, ensuring that the ALS community remains informed, engaged, and connected. 📲 Download the EverythingALS App • Google Play: http://bit.ly/4nXqIYy • App Store: https://bit.ly/42tPBmh Follow EverythingALS: ► Website: https://www.everythingals.org ► X: https://x.com/everything_als ► LinkedIn: / everythingals ► Facebook: / everythingals ► Subscribe for more Expert Talks: / @everythingals #EverythingALS #CitizenResearch #ALSResearch #ALSCommunity #ClinicalTrials #ALSScience #NeurodegenerativeDisease #ResearchLiteracy #CriticalThinking #ALSAwareness #biomarkers 🔔 If you are passionate about advancing ALS research and understanding, like, subscribe, and turn on notifications. Sharing this episode helps expand awareness and keep important scientific conversations moving forward. Play Video Play Video 01:03:52 Recent Genomic and Proteomic Advances in ALS/FTD with Dr. Bryan Traynor In this Expert Talk, Dr. Bryan Traynor shares insights into Recent genomic and proteomic advances in ALS/FTD. This session highlights the latest advances in ALS and FTD genetics, genomics, proteomics, and biomarker research. Dr. Traynor discusses how genetic discoveries, plasma proteomics, and emerging diagnostic approaches are improving our understanding of disease biology, supporting earlier diagnosis, and shaping the future of clinical trials and therapeutic development. Dr. Traynor examines the role of the C9orf72 repeat expansion in ALS and FTD, explores how genetics influences disease variability, and discusses the growing potential of plasma proteomics to identify biomarkers that may enable earlier diagnosis and prevention trials. He also shares insights into drug repurposing research, including ongoing work evaluating acamprosate as a potential therapeutic approach for C9orf72-associated ALS and FTD. Throughout the discussion, Dr. Traynor highlights how advances in genomics, proteomics, and biomarker discovery are transforming ALS research and helping move the field toward more precise diagnostics, improved clinical trial design, and future targeted therapies. In this talk, we cover: • Introduction to ALS and the genetics of ALS/FTD • The role of the C9orf72 repeat expansion in ALS and FTD • How genetics influences disease variability • Plasma proteomics and emerging biomarkers for ALS • Drug repurposing research and the acamprosate clinical trial • New approaches to ALS diagnosis and prevention trials • The future of genomics, proteomics, and precision medicine in ALS research 📲 Download the EverythingALS App • Google Play: http://bit.ly/4nXqIYy • App Store: https://bit.ly/42tPBmh Follow EverythingALS: ► Website: https://www.everythingals.org ► X: https://x.com/everything_als ► LinkedIn: https://www.linkedin.com/company/everythingals ► Facebook: https://www.facebook.com/everythingals ► Subscribe for more Expert Talks: https://www.youtube.com/@EverythingALS #ExpertTalk #EverythingALS #ALSResearch #ALSCommunity #ALS #FTD #Biomarkers #Genomics #Proteomics #Neurology #ClinicalResearch #BryanTraynor Play Video Play Video 01:31:53 Citizen Research, July 8, 2026 Welcome to a new session of Citizen Research with Dr. Terry Heiman-Patterson and Dr. Lyle Ostrow. In this session, we explore an important idea at the heart of EverythingALS Citizen Research: You don’t have to be a scientist to think critically about research. We are joined by Dr. Terry Heiman-Patterson, MD - Director of the MDA ALS Center of Hope and Director of Neurodegenerative Disorders at Temple University - alongside Dr. Lyle Ostrow, neurologist, researcher, and Director of the Neuromuscular Pathology Lab at Temple University, for a thoughtful discussion on how patients, caregivers, and the broader ALS community can better understand and evaluate scientific information. As ALS research continues to evolve rapidly, new studies, therapies, and headlines emerge almost daily. This session is designed to help the community navigate that information with greater clarity, confidence, and critical thinking. In this talk, we cover: • Intranasal Exosome & Secretome Therapy for ALS • Two studies from the same research group, appraised in turn • Paper 1: A multi-disease study involving ALS, Kennedy disease, CMS, and Lewy body dementia (n = 18) • Paper 2: An ALS-only follow-up study (n = 70) • The rationale, methods, and findings presented in each paper • How these studies compare against the ALSUntangled "Ten Red Flags" framework • A closer look at the Prodromos Clinic website and the claims presented there Citizen Research is about making science more accessible, collaborative, and empowering for everyone affected by ALS. Conversations like this help bridge the gap between complex research and real-world understanding — ensuring that the ALS community remains informed, engaged, and connected. 📲 Download the EverythingALS App • Google Play: http://bit.ly/4nXqIYy • App Store: https://bit.ly/42tPBmh Follow EverythingALS: ► Website: https://www.everythingals.org ► X: https://x.com/everything_als ► LinkedIn: https://www.linkedin.com/company/everythingals ► Facebook: https://www.facebook.com/everythingals ► Subscribe for more Expert Talks: https://www.youtube.com/@EverythingALS #EverythingALS #CitizenResearch #ALSResearch #ALSCommunity #ClinicalTrials #ALSScience #NeurodegenerativeDisease #ResearchLiteracy #CriticalThinking #ALSAwareness #ExpertTalk 🔔 If you are passionate about advancing ALS research and understanding, like, subscribe, and turn on notifications. Sharing this episode helps expand awareness and keep important scientific conversations moving forward. Load More

Speaker Kit ALS Expert Talk Series. Dear Speaker, We are excited to host you at our upcoming ALS Expert Talk Series. Our community looks forward to hearing from you. Please feel free to Share the announcement to your social media network and tag us. We have shared our social media handles below. Citizen Research Invite your followers, community, and colleagues to the Expert Talk event by clicking on the social media icons below. You can also download the event graphic for sharing. Facebook LinkedIn X Download Event Graphic

EverythingALS is a patient-focused non-profit, part of Peter Cohen Foundation (PCF) a 501(3)c organization. Our mission is to support efforts to care for ALS patients and work to find a cure by creating a platform for direct engagement with patients, caregivers, advocates, and researchers. Register below to join the event Citizen Research Sep 30th, 2026 | 4PM PT, 7PM ET Citizen Research on Sept 30th Sep 30, 2026, 7:00 PM EDT Register Now Dr. Terry Heiman-Patterson M.D. Lewis Katz School of Medicine at Temple University Terry Heiman-Patterson is Director of Neurodegenerative Disorders at Temple University. She is also the Director of the MDA/ALS Center of Hope , including the clinical and laboratory research programs, and active with the Northeast ALS Consortium . A leader in her field, she has published more than 90 papers, abstracts, and chapters on ALS and related motor neuron diseases. She has dedicated her career to optimizing clinical care for people living with ALS and conducting research toward a treatment and cure. Dr. Lyle Ostrow Ph.D. Lewis Katz School of Medicine at Temple University Lyle Ostrow is a neurologist, ALS and muscle disorder researcher, and Director of the Temple Neuromuscular Pathology Lab and the Temple ALS Postmortem Core & Guamanian ALS-PDC Resources. He serves on the Scientific Advisory Boards for Everything ALS and the ALS Network, and the Board of Directors of the ALS Hope Foundation. Dr. Ostrow is the longstanding Chair of the Programmatic Panel for the Department of Defense ALS Research Program (ALSRP), the largest dedicated annual funder ($40M/year) of ALS therapeutic discovery and validation. He led ALSRP efforts to develop and refine funding mechanisms to support the development of new innovative therapeutic ideas, emphasize biomarker development, and encourage open data and resource sharing. He has ALS research grant funding from NIH, serves on several ALS steering committees and review panels, and is widely recognized for his clinical leadership, translational research, and commitment to improving care and accelerating therapies for ALS. Learn more about Events FUTURE EVENTS RSVP for Future Events PAST EVENTS View All Past Events

EverythingALS is a patient-focused non-profit, part of Peter Cohen Foundation (PCF) a 501(3)c organization. Our mission is to support efforts to care for ALS patients and work to find a cure by creating a platform for direct engagement with patients, caregivers, advocates, and researchers. Fireside Cha t JOIN US J oin us for an opportunity to be with caring people who w ish to chat, listen, share, and learn. Fireside Chat with the Pathfinders Wed, Sep 23 Virtual Event REGISTER Our Hosts McFinn Lovere ALS Advocate & Pathfinder McFinn Lovere was diagnosed with ALS in 2006 at the UCSF, he was only able to move his head and two fingers. His spirituality and team of caretakers gave him HOPE and he is documented as the 42nd "ALS Reversal" by Dr.Bedlack. At EverythingALS, he aims to bring meaning, hope, and an uplifting atmosphere to a community that he knows very intimately and one that needs it most. His email address is mcfinn@everythingals.org Kathleen McCallum Pathfinder Kathleen McCallum, and for the past two years, I have been helping my friend Willard, who was diagnosed with ALS in 2022. There is hope, and if I can help provide it for you, please contact me at kathleen@everythingals.org Faith Oremland Pathfinder Faith Oremland's son was diagnosed with ALS in January 2022. If you are dealing with the challenges of being a parent to a child with ALS, issues with family communications, and learning how to live positively in the face of ALS, please get in touch with me at faith@everythingals.org Joe Redmond Pathfinder Joe Redmond was diagnosed with ALS in 2012. If I can make your journey any easier, or if you have any questions, let me help you find answers. My hope is to be the resource you need. Reach out to me at joe@everythingals.org Monica Martinez Pathfinder Monica Martinez was diagnosed with ALS in 2023. Welcome to Pathfinders! We are here to support, guide, and walk with you on this journey. You are not alone! WE GOT THIS! TOGETHER WE ARE BETTER THAN ALS! Reach out to me at monica@everythingals.org Anthony (Tony) Martin Varela Pathfinder Anthony (Tony) Martin Varela was diagnosed with ALS in April of 2023. I keep a positive outlook as much as I can, but staying busy seems to keep my mind off of it and works the best. I am looking forward to helping in any way I can. Reach out to me at tony@everythingals.org Wilbert Greenfield Pathfinder Wilbert Greenfield is 54 years of age. Living with ALS has taught me resilience and to cherish every moment. I adapt creatively, find joy in small victories, raise awareness, support others, and anchor myself in faith, strength, and hope.. Reach out to me at will@everythingals.org Lynn Brielmaier Pathfinder Lynn Brielmaier is an electronics engineer with ALS and is completely paralyzed. He designed a fast, custom AAC eye-gaze computer at about half the cost of standard options. Lynn serves as a Person with Lived Experience (PWLE) advisor to the NIH, FDA, and the ALL ALS Natural History Study, and contributes to neuroethics work around Brain-Computer Interfaces. Reach out to me at lynn@everythingals.org Willard Blackwell Pathfinder Willard Blackwell was diagnosed with ALS in May of 2022. A professional singer and musician leading the Gator Nation Band. John Hudacek Pathfinder John Hudacek was diagnosed with ALS in November 2021. He is a slow progressor. Now is the time to discover the hidden strength in each of us. I am honored to hold your hand on this journey, reach me at john@everythingals.org Ivonne Vaughn Pathfinder Ivonne Vaughn was diagnosed with ALS in January of 2025. My goal is to help and encourage those with ALS (pALS), those caring for ALS loved ones (cALS) and to share the HOPE I have in my ALS journey. We all need good listeners in our lives. As a Pathfinder, I am here to listen, support, and encourage you. Reach out to me at ivonne@everythingals.org . Shawn Penno Pathfinder Shawn Penno was diagnosed with ALS in September 2023. He has been a care aide for 25 years, 2 in long-term care and the rest in the Community. Please reach out if you need someone to 'vent' to, help with problems, or someone to talk to alleviate the isolation shawn@everythingals.org Cathy Cummins Pathfinder Cathy Cummins was diagnosed with ALS in 2008. Chiropractor, professor, and former elite athlete, now living with ALS and dedicated to guiding others through resilience and adaptation. As a Pathfinder, I share insights from my healing journey to inspire strength and community. Reach out to me at cathy@everythingals.org Chris OBryan Pathfinder Chris OBryan was diagnosed with slow progressing ALS in 2014. I’ve lived with familial ALS since 2014, shaped by my mother’s journey. I’ve learned each path differs, value preparation, accept ups and downs, and offer support so no one feels alone. Reach out to me at chris@everythingals.org Tim Fulham Pathfinder Tim Fulham was diagnosed with ALS in 2024. I’m a former high school biology teacher and longtime pharmaceutical and medical sales leader who later returned to the classroom. After being diagnosed with ALS, I began sharing my journey to support others. I focus on gratitude, resilience, and living fully each day with my family and loved ones. Reach out to me at tim@everythingals.org Peggy Merrill Pathfinder Peggy Merrill is a yoga teacher and studio owner living with Motor Neuron Disease, which began with difficulties speaking. She used her Covid-era recorded practices to create a custom ElevenLabs voice clone, which she now uses to create new yoga and meditation practices for the ALS/PLS/MND community. As an ElevenLabs ambassador, she is happy to assist with communication challenges and offer support to pALS and cALS alike. Reach out to me at peggy@everythingals.org Terry Small Pathfinder Terry Small is a husband, caregiver, and advocate who cared for his wife through her rapid ALS journey. His wife was a dietitian, making nutrition an important part of their experience. Terry learned firsthand about caregiving, advocacy, and navigating rapid changes. As a Pathfinder, he wants to share his experience and support others facing ALS, especially those experiencing rapid progression. Reach out to me at terry@everythingals.org

Fund the CureC9 Program A program within EverythingALS, directed by an independent Scientific Advisory Board, built to prevent and cure C9orf72 disease. Give to the program and let the board direct your gift, or name the project you want to fund. Gifts to the CureC9 Program are tax-deductible. EverythingALS is a brand of Peter Cohen Foundation, a non-profit 501(c)(3): EIN 84-3055901. The CureC9 Program is a research program of EverythingALS. Project First Flagship: Optimizing CNS delivery for genetic therapies. The rate-limiting step for any genetic therapy aimed at the central nervous system is not the editing chemistry but the delivery. Solving delivery is the precondition for any C9orf72 (C9) gene therapy reaching patients safely, and a delivery system optimized in C9 will apply to every genetic and sporadic form of ALS and FTD, and to other neurodegenerative and neurodevelopmental diseases that share the same bottleneck. This is the SAB’s first approved project. Click here to learn more about the project. Technical Explanations Unlock gene therapy in the brain. Current Flagship Five-Year Roadmap to Solving the Delivery Problem in the Brain and Spinal Cord: Unlocking CRISPR for C9 ALS and FTD The CureC9 Program is a program within EverythingALS, a 501(c)(3) nonprofit. EverythingALS takes no overhead on CureC9 Program gifts. Every tax-deductible dollar flows through EverythingALS to the receiving academic institution, where we negotiate indirect costs below 10 percent — against a research-industry average closer to 60 percent. For a $1 million gift, this is the difference between roughly $400,000 and more than $900,000 reaching the bench. Simplified Explanation A five-year plan to deliver the first CRISPR gene therapy for C9orf72 ALS and FTD. The CRISPR therapy itself is already built. Funding goes entirely to solving the delivery problem — identifying the optimal vehicle to shuttle CRISPR to the brain and spinal cord. PC: Peter Cohen Make a gift 100% of your gift goes to C9orf72 research. Leave the project blank and the Scientific Advisory Board directs it; name a project and it goes there. Select the fund you wish to donate to * CureC9 Program Fund Flagship: Unlock gene therapy in the brain Donation Type * One-time Monthly CureC9 Program Flagship Fund Select Donation Amount CureC9 Program Flagship Fund Directed by the Scientific Advisory Board to the CureC9 project where it is needed most. Make Another Donation Donation Amount $ Is this donation in honor or memory of someone? * Yes No In honor / memory of For gifts over $25,000, to pay by check or wire transfer (note the 7% credit card transaction fee vs. flat $25 by these methods), or to fund a project in full, email indu@everythingals.org ; yentli@curec9.com with the subject line "I want to give a substantial gift to the CureC9 Program." Donate Redirecting to Payment Screen.. Talk to us about a transformative gift Funding Model How the CureC9 Program moves donor dollars. EverythingALS is a 501(c)(3) of the Peter Cohen Foundation, so every donation is fully tax-deductible. EverythingALS takes no overhead from CureC9 Program gifts. At each funded institution we negotiate indirect cost rates below 10 percent, against a research-industry average closer to 60 percent. For a $1 million gift, this is the difference between roughly $400,000 and more than $900,000 reaching the bench. Undesignated gifts are allocated by the Scientific Advisory Board at its next meeting. Designated gifts go to the named project; if that project is fully funded or closes, the board redirects the balance to the closest CureC9 project and informs you. Tax Deductibility Legal entity: Peter Cohen Foundation, operating as EverythingALS EIN: 84-3055901 501(c)(3) charitable organization, tax-exempt since December 2019 Registered address: 1000 15th Ave E, Seattle, WA 98112-3912 The CureC9 Program is a research program of EverythingALS. All gifts are processed by the Peter Cohen Foundation for tax purposes. Scientific Advisory Board Cure C9 is guided by an international advisory board of leading experts in ALS, neurodegeneration, and therapeutic development. These scientists help identify the most promising research directions and ensure that funding is directed toward projects with the highest potential to change outcomes for patients. SAB members advise on scientific direction; some SAB members also lead funded projects through their own labs. Daniel Mordes (MD, PhD) Dr. Mordes is an Assistant Professor and board-certified neuropathologist at UCSF. His work connects C9 dipeptide repeat toxicity to changes in gene expression through SRSF7 and links TBK1 (another ALS-associated protein) to the C9ORF72 protein complex. His lab is building a “wiring diagram” of C9 disease, mapping the molecular nodes that are disrupted and how they converge on TDP-43 dysfunction. With collaborators in Boston, he has recently demonstrated a shared molecular pathology between ALS and advanced forms of chronic traumatic encephalopathy (CTE) in individuals with a history of playing contact sports. Together, these insights define how cellular systems fail in neurodegenerative disease and help turn “we know the gene” into actionable therapeutic targets. Renzo Mancuso (PhD) Dr. Mancuso is a group leader and Deputy Director at the VIB–Center for Molecular Neurology, Belgium. He obtained his PhD in Barcelona in 2014 and since then his primary focus has been to investigate the underlying molecular mechanisms that drive Alzheimer’s disease (AD) and Frontotemporal degeneration (FTD), with special focus on inflammatory networks and particularly the contribution of microglia. In his lab, research is performed using a wide range of techniques and technologies, including classical mouse models, iPSC and cutting-edge humanised mouse systems to determine the immune component of these disorders and determine how genetics alter microglial function and contribute to the initiation and perpetuation of brain disease. Dr. Mancuso has been awarded with several young investigator awards (including the Grand Prix by the French Alzheimer’s foundation, ARUK), for his seminal contributions to our understanding of microglial pathogenic mechanisms. He has also received several prestigious grants, including an ERC Starting Grant to investigate neuro-glia interactions in AD. Dr. Christopher Donnelly, (PhD) Dr. Donnelly, Ph.D., is an Associate Professor of Neurology at the Peter O’Donnell Jr. Brain Institute at UT Southwestern and Neuromuscular Section Chief. He earned his Ph.D. from the University of Delaware, where he studied axonal RNA transport and local translation in nerve regeneration with Dr. Jeff Twiss, and completed postdoctoral training with Dr. Jeff Rothstein at Johns Hopkins School of Medicine, investigating cellular dysfunction in C9orf72-associated ALS and FTD. Prior to joining UT Southwestern in 2026, he was the founding Scientific Director of the LiveLikeLou Center for ALS Research at the University of Pittsburgh School of Medicine. The Donnelly lab focuses on the molecular mechanisms underlying neurodegenerative disease, with an emphasis on how dysfunction of RNA-binding proteins, including TDP-43 and FUS, drives pathology and neuronal vulnerability in C9orf72 and sporadic ALS/FTLD. His laboratory investigates how RNA regulates protein function and phase behavior, and how defects in nuclear and axonal transport and pathogenic protein interactions drive ALS/FTLD. The goal of this work is to identify strategies to restore normal protein function in disease. The Donnelly lab integrates patient-derived neuronal models with RNA-based therapeutic approaches to target disease mechanisms. Dr. Donnelly’s prior research identified key disease pathways, including nucleocytoplasmic transport defects, and advanced therapeutic strategies targeting toxic C9orf72 gene products with antisense oligonucleotide (ASO) therapies. More recently, his lab developed short RNA oligonucleotides (bait/chaperone RNAs) approaches to reverse pathological protein aggregation and restore physiological function in ALS/FTLD. Steven Boeynaems, (PhD) Dr. Boeynaems is an Assistant Professor in Molecular and Human Genetics at Baylor College of Medicine, an Investigator at the Duncan Neurological Research Institute at Texas Children’s Hospital, and a Faculty Member of the Therapeutic Innovation Center, the Dan L Duncan Comprehensive Cancer Center, and the Center for Alzheimer’s and Neurodegenerative Diseases. He is a CPRIT Scholar in Cancer Research and an NIH Director’s New Innovator. Dr. Boeynaems has over a decade of expertise in the study of tandem repeats and protein aggregation in human disease and has contributed important insights into the pathophysiology of C9orf72 ALS/FTD. Dr. Zachary McEachin, (PhD) Dr. McEachin is an assistant professor in Human Genetics and Cell Biology at Emory University. His laboratory is focused on understanding the molecular mechanisms underlying neurodegenerative disease, particularly repeat expansion disorders such as C9orf72-ALS/FTD. His research integrates multiomic analyses with diverse experimental models to uncover how genetic and molecular alterations contribute to disease pathogenesis and to identify new therapeutic targets for neurodegeneration. Dr. Paymaan Jafar-Nejad (MD) Dr. Jafar-Nejad, MD, is a scientific leader in RNA therapeutics and currently serves as Executive Director at Ionis Pharmaceuticals, Inc., a pioneering biotechnology company in RNA-targeted drug discovery and development. He brings more than two decades of experience in neuroscience and RNA biology, including over a decade focused on oligonucleotide therapeutics, and has contributed to a substantial body of scientific publications in the field. Dr. Jafar-Nejad earned his medical degree from Tehran University of Medical Sciences and completed postdoctoral training in Dr. Huda Zoghbi’s laboratory at Baylor College of Medicine, where he investigated mechanisms of neurodegeneration. At Ionis, he has led research programs in neurology and rare diseases, advancing RNA-based therapies into clinical trials for ALS, Angelman syndrome, genetic epileptic encephalopathies, and related disorders. In recognition of this work, he and his colleagues received the 2023 Lalji & Family ALS Endowed Award for Innovative Healing from the Healey & AMG Center at Massachusetts General Hospital. Claire Clelland (MD, PhD) Dr. Clelland is building what every C9 carrier hopes for: a one-time fix at the genomic level. Her CRISPR work has shown the most complete reversal of C9 pathology demonstrated to date in patient-derived neurons. She is now partnering with Denali Therapeutics to solve the hardest remaining problem: getting that edit into the brain via a simple IV infusion. A project she is not yet public about is her work screening and optimizing gene therapy for the CNS using brain-dead trauma patients. This use of humans to improve gene therapy in a compartment nobody has successfully targeted is nearly unparalleled in utility for C9 and other neurological diseases. The cost for a first-in-human dose is ~$12M. This is one of the projects that should be proposed for funding by CureC9. Dr. Clelland chose C9orf72 because her patients have FTD. The most common cause of familial FTD is the C9 repeat expansion, so to cure FTD she needs to cure C9. Beyond the science, she brings a focus on translation that keeps every conversation grounded in what actually matters: getting a therapy to patients. Jenna Gregory (MD, PhD) Dr. Gregory is developing an early warning system for neurodegenerative disease, focused on detecting pathology long before clinical symptoms appear. Her work with RNA aptamers identifies TDP-43 pathology with unprecedented sensitivity, and her skin biopsy research has demonstrated detectable pathology up to 26.5 years before diagnosis, opening the possibility of transforming presymptomatic monitoring from a source of uncertainty into a strategy for timely intervention. Her research is driven by a central question: not just what is happening in disease progression, but when it can first be detected and acted upon. Beyond her own laboratory, Dr. Gregory serves as a co-investigator on a research program using synchrotron X-ray fluorescence imaging at the European Synchrotron Radiation Facility to investigate the C9orf72 paradox. Her team leads the pathomolecular profiling and low-field MRI platform aimed at translating nanoscale metal–aggregate signatures into a scalable diagnostic tool. She also builds and leads large presymptomatic research cohorts designed to enable early-stage disease discovery and intervention trials. As a practising pathologist and clinical lead for a major tissue bank, she integrates patient-derived biospecimens, clinical phenotyping, and molecular pathology to create resources that support collaborative discovery across the ALS research community. A gift to the CureC9 Program is the most powerful statement you can make in support of the people living with C9-driven ALS and FTD, and the carriers waiting for a treatment that does not yet exist. Your donation funds the research most likely to materially alter C9 disease — vetted by a Scientific Advisory Board drawn from leading ALS/FTD scientists. Every dollar flows through the Peter Cohen Foundation with no overhead, and at indirect cost rates below 10 percent at each funded institution. Your generosity makes it possible for the CureC9 Program to fund its first approved project and the work that follows. With your support, we will deliver the platform on which the next generation of genetic ALS and FTD therapies is built, and bring treatments within reach of the community that needs them most. Where possible, we commit to translating findings beyond C9 ALS/FTD. Tax Disclosure Gifts to the CureC9 Program are tax-deductible. EverythingALS is a brand of Peter Cohen Foundation, a non-profit 501(c)(3): EIN 84-3055901. The CureC9 Program is a research program of EverythingALS.

Fund the CureC9 Program A program within EverythingALS, directed by an independent Scientific Advisory Board, built to prevent and cure C9orf72 disease. Give to the program and let the board direct your gift, or name the project you want to fund. Gifts to the CureC9 Program are tax-deductible. EverythingALS is a brand of Peter Cohen Foundation, a non-profit 501(c)(3): EIN 84-3055901. The CureC9 Program is a research program of EverythingALS. Project First Flagship: Optimizing CNS delivery for genetic therapies. The rate-limiting step for any genetic therapy aimed at the central nervous system is not the editing chemistry but the delivery. Solving delivery is the precondition for any C9orf72 (C9) gene therapy reaching patients safely, and a delivery system optimized in C9 will apply to every genetic and sporadic form of ALS and FTD, and to other neurodegenerative and neurodevelopmental diseases that share the same bottleneck. This is the SAB’s first approved project. Click here to learn more about the project. Technical Explanations Unlock gene therapy in the brain. Current Flagship Five-Year Roadmap to Solving the Delivery Problem in the Brain and Spinal Cord: Unlocking CRISPR for C9 ALS and FTD The CureC9 Program is a program within EverythingALS, a 501(c)(3) nonprofit. EverythingALS takes no overhead on CureC9 Program gifts. Every tax-deductible dollar flows through EverythingALS to the receiving academic institution, where we negotiate indirect costs below 10 percent — against a research-industry average closer to 60 percent. For a $1 million gift, this is the difference between roughly $400,000 and more than $900,000 reaching the bench. Simplified Explanation A five-year plan to deliver the first CRISPR gene therapy for C9orf72 ALS and FTD. The CRISPR therapy itself is already built. Funding goes entirely to solving the delivery problem — identifying the optimal vehicle to shuttle CRISPR to the brain and spinal cord. PC: Peter Cohen CureC9 Program Flagship Fund 100% of your generous donation will be applied to advance critical ALS & FTD research. Donation Type * One-time Monthly CureC9 Program Flagship Fund Select Donation Amount CureC9 Program Flagship Fund Make Another Donation Funds a meaningful block of the SAB-approved flagship. Donation Amount $ Is this donation in honor or memory of someone? * Yes No In honor / memory of For large donations, (over $25,000) please email speech@everythingals.org and info.curec9@gmail.com with subject line: "I want to give a substantial gift to the CureC9 Program" Donate Redirecting to Payment Screen.. Talk to us about a transformative gift Funding Model How the CureC9 Program moves donor dollars. EverythingALS is a 501(c)(3) of the Peter Cohen Foundation, so every donation is fully tax-deductible. EverythingALS takes no overhead from CureC9 Program gifts. At each funded institution we negotiate indirect cost rates below 10 percent, against a research-industry average closer to 60 percent. For a $1 million gift, this is the difference between roughly $400,000 and more than $900,000 reaching the bench. Tax Deductibility Legal entity: Peter Cohen Foundation, operating as EverythingALS EIN: 84-3055901 501(c)(3) charitable organization, tax-exempt since December 2019 Registered address: 1000 15th Ave E, Seattle, WA 98112-3912 The CureC9 Program is a research program of EverythingALS. All gifts are processed by the Peter Cohen Foundation for tax purposes. Scientific Advisory Board Cure C9 is guided by an international advisory board of leading experts in ALS, neurodegeneration, and therapeutic development. These scientists help identify the most promising research directions and ensure that funding is directed toward projects with the highest potential to change outcomes for patients. SAB members advise on scientific direction; some SAB members also lead funded projects through their own labs. Daniel Mordes (MD, PhD) Dr. Mordes is an Assistant Professor and board-certified neuropathologist at UCSF. His work connects C9 dipeptide repeat toxicity to changes in gene expression through SRSF7 and links TBK1 (another ALS-associated protein) to the C9ORF72 protein complex. His lab is building a “wiring diagram” of C9 disease, mapping the molecular nodes that are disrupted and how they converge on TDP-43 dysfunction. With collaborators in Boston, he has recently demonstrated a shared molecular pathology between ALS and advanced forms of chronic traumatic encephalopathy (CTE) in individuals with a history of playing contact sports. Together, these insights define how cellular systems fail in neurodegenerative disease and help turn “we know the gene” into actionable therapeutic targets. Renzo Mancuso (PhD) Dr. Mancuso is a group leader and Deputy Director at the VIB–Center for Molecular Neurology, Belgium. He obtained his PhD in Barcelona in 2014 and since then his primary focus has been to investigate the underlying molecular mechanisms that drive Alzheimer’s disease (AD) and Frontotemporal degeneration (FTD), with special focus on inflammatory networks and particularly the contribution of microglia. In his lab, research is performed using a wide range of techniques and technologies, including classical mouse models, iPSC and cutting-edge humanised mouse systems to determine the immune component of these disorders and determine how genetics alter microglial function and contribute to the initiation and perpetuation of brain disease. Dr. Mancuso has been awarded with several young investigator awards (including the Grand Prix by the French Alzheimer’s foundation, ARUK), for his seminal contributions to our understanding of microglial pathogenic mechanisms. He has also received several prestigious grants, including an ERC Starting Grant to investigate neuro-glia interactions in AD. Dr. Christopher Donnelly, (PhD) Dr. Donnelly, Ph.D., is an Associate Professor of Neurology at the Peter O’Donnell Jr. Brain Institute at UT Southwestern and Neuromuscular Section Chief. He earned his Ph.D. from the University of Delaware, where he studied axonal RNA transport and local translation in nerve regeneration with Dr. Jeff Twiss, and completed postdoctoral training with Dr. Jeff Rothstein at Johns Hopkins School of Medicine, investigating cellular dysfunction in C9orf72-associated ALS and FTD. Prior to joining UT Southwestern in 2026, he was the founding Scientific Director of the LiveLikeLou Center for ALS Research at the University of Pittsburgh School of Medicine. The Donnelly lab focuses on the molecular mechanisms underlying neurodegenerative disease, with an emphasis on how dysfunction of RNA-binding proteins, including TDP-43 and FUS, drives pathology and neuronal vulnerability in C9orf72 and sporadic ALS/FTLD. His laboratory investigates how RNA regulates protein function and phase behavior, and how defects in nuclear and axonal transport and pathogenic protein interactions drive ALS/FTLD. The goal of this work is to identify strategies to restore normal protein function in disease. The Donnelly lab integrates patient-derived neuronal models with RNA-based therapeutic approaches to target disease mechanisms. Dr. Donnelly’s prior research identified key disease pathways, including nucleocytoplasmic transport defects, and advanced therapeutic strategies targeting toxic C9orf72 gene products with antisense oligonucleotide (ASO) therapies. More recently, his lab developed short RNA oligonucleotides (bait/chaperone RNAs) approaches to reverse pathological protein aggregation and restore physiological function in ALS/FTLD. Steven Boeynaems, (PhD) Dr. Boeynaems is an Assistant Professor in Molecular and Human Genetics at Baylor College of Medicine, an Investigator at the Duncan Neurological Research Institute at Texas Children’s Hospital, and a Faculty Member of the Therapeutic Innovation Center, the Dan L Duncan Comprehensive Cancer Center, and the Center for Alzheimer’s and Neurodegenerative Diseases. He is a CPRIT Scholar in Cancer Research and an NIH Director’s New Innovator. Dr. Boeynaems has over a decade of expertise in the study of tandem repeats and protein aggregation in human disease and has contributed important insights into the pathophysiology of C9orf72 ALS/FTD. Dr. Zachary McEachin, (PhD) Dr. McEachin is an assistant professor in Human Genetics and Cell Biology at Emory University. His laboratory is focused on understanding the molecular mechanisms underlying neurodegenerative disease, particularly repeat expansion disorders such as C9orf72-ALS/FTD. His research integrates multiomic analyses with diverse experimental models to uncover how genetic and molecular alterations contribute to disease pathogenesis and to identify new therapeutic targets for neurodegeneration. Dr. Paymaan Jafar-Nejad (MD) Dr. Jafar-Nejad, MD, is a scientific leader in RNA therapeutics and currently serves as Executive Director at Ionis Pharmaceuticals, Inc., a pioneering biotechnology company in RNA-targeted drug discovery and development. He brings more than two decades of experience in neuroscience and RNA biology, including over a decade focused on oligonucleotide therapeutics, and has contributed to a substantial body of scientific publications in the field. Dr. Jafar-Nejad earned his medical degree from Tehran University of Medical Sciences and completed postdoctoral training in Dr. Huda Zoghbi’s laboratory at Baylor College of Medicine, where he investigated mechanisms of neurodegeneration. At Ionis, he has led research programs in neurology and rare diseases, advancing RNA-based therapies into clinical trials for ALS, Angelman syndrome, genetic epileptic encephalopathies, and related disorders. In recognition of this work, he and his colleagues received the 2023 Lalji & Family ALS Endowed Award for Innovative Healing from the Healey & AMG Center at Massachusetts General Hospital. Claire Clelland (MD, PhD) Dr. Clelland is building what every C9 carrier hopes for: a one-time fix at the genomic level. Her CRISPR work has shown the most complete reversal of C9 pathology demonstrated to date in patient-derived neurons. She is now partnering with Denali Therapeutics to solve the hardest remaining problem: getting that edit into the brain via a simple IV infusion. A project she is not yet public about is her work screening and optimizing gene therapy for the CNS using brain-dead trauma patients. This use of humans to improve gene therapy in a compartment nobody has successfully targeted is nearly unparalleled in utility for C9 and other neurological diseases. The cost for a first-in-human dose is ~$10M. This is one of the projects that should be proposed for funding by CureC9. Dr. Clelland chose C9orf72 because her patients have FTD. The most common cause of familial FTD is the C9 repeat expansion, so to cure FTD she needs to cure C9. Beyond the science, she brings a focus on translation that keeps every conversation grounded in what actually matters: getting a therapy to patients. Jenna Gregory (MD, PhD) Dr. Gregory is developing an early warning system for neurodegenerative disease, focused on detecting pathology long before clinical symptoms appear. Her work with RNA aptamers identifies TDP-43 pathology with unprecedented sensitivity, and her skin biopsy research has demonstrated detectable pathology up to 26.5 years before diagnosis, opening the possibility of transforming presymptomatic monitoring from a source of uncertainty into a strategy for timely intervention. Her research is driven by a central question: not just what is happening in disease progression, but when it can first be detected and acted upon. Beyond her own laboratory, Dr. Gregory serves as a co-investigator on a research program using synchrotron X-ray fluorescence imaging at the European Synchrotron Radiation Facility to investigate the C9orf72 paradox. Her team leads the pathomolecular profiling and low-field MRI platform aimed at translating nanoscale metal–aggregate signatures into a scalable diagnostic tool. She also builds and leads large presymptomatic research cohorts designed to enable early-stage disease discovery and intervention trials. As a practising pathologist and clinical lead for a major tissue bank, she integrates patient-derived biospecimens, clinical phenotyping, and molecular pathology to create resources that support collaborative discovery across the ALS research community. A gift to the CureC9 Program is the most powerful statement you can make in support of the people living with C9-driven ALS and FTD, and the carriers waiting for a treatment that does not yet exist. Your donation funds the research most likely to materially alter C9 disease — vetted by a Scientific Advisory Board drawn from leading ALS/FTD scientists. Every dollar flows through the Peter Cohen Foundation with no overhead, and at indirect cost rates below 10 percent at each funded institution. Your generosity makes it possible for the CureC9 Program to fund its first approved project and the work that follows. With your support, we will deliver the platform on which the next generation of genetic ALS and FTD therapies is built, and bring treatments within reach of the community that needs them most. Where possible, we commit to translating findings beyond C9 ALS/FTD. Tax Disclosure Gifts to the CureC9 Program are tax-deductible. EverythingALS is a brand of Peter Cohen Foundation, a non-profit 501(c)(3): EIN 84-3055901. The CureC9 Program is a research program of EverythingALS.

EverythingALS in the News Click here to VIEW our publications Publications SEPTEMBER 2026 New Alzheimer’s blood tests could help patients get answers earlier MADISON, Wis. (WMTV) - Getting answers about Alzheimer’s disease can be a long and complicated process, but new blood tests are giving doctors a simpler way to look for biological signs of the disease. Dr. Nathaniel Chin, a UW Health Alzheimer’s specialist, said the tests can detect proteins associated with Alzheimer’s and give doctors more certainty about what may be causing a patient’s memory symptoms. Read more SEPTEMBER 2026 New App Provides Resources To Caregivers of Neurodegenerative Patients on the Central Coast A new app is getting the attention of local caregivers for patients of neurodegenerative diseases, which can help lead “from care to cure.” The Peter Cohen Foundation introduced an app recently called EverythingALS . “Named after Peter, my husband,” says Indu Navar, EverythingALS founder and app developer. “We have over 24 pharma companies who have partnered with us, about 15 clinics and institutions have partnered with us, and I work with about 7000 ALS families from 60 countries.” Read more AUGUST 2026 Russell Andrews ‘Went Numb’ After ALS Diagnosis, but Says ‘Lending My Voice Is the Least I Can Do’ (Exclusive) For Russell Andrews, being diagnosed with amyotrophic lateral sclerosis (ALS) was something he never saw coming. So, when the 64-year-old actor — best known for his roles in Straight Outta Compton and Better Call Saul — started experiencing symptoms, he didn’t think much of it. “I would feel twitches in my arms. I would feel like I was having pinched nerves consistently in my neck,” he tells PEOPLE. “But my walking was fine, my balance was fine.” Read more AUGUST 2026 Researchers turn to AI to decipher a devastating neurological condition For individuals with amyotrophic lateral sclerosis (ALS), the diagnostic journey is typically a harrowing and expensive year-plus ordeal involving at least three healthcare professionals. ALS, a fatal condition with few options for treatment, slowly robs patients of their ability to move and communicate. Diagnosing the condition can be extremely difficult, according to the ALS Association, a nonprofit group that supports ALS research. Read more JULY 2026 Chris Johnson’s ALS diagnosis sparks Ice Bucket Challenge revival, but expert says awareness alone won’t move the needle Chris Johnson’s ALS diagnosis sent shockwaves through the NFL and the Nashville community, and the outpouring of support has reintroduced the Ice Bucket Challenge to a new generation. But 12 years after the original viral sensation raised millions for medical advancement, the question remains: why is ALS research still so far behind? Read more JULY 2026 Everything ALS founder provides insight on Chris Johnson diagnosis At the end of June, former Tennessee Titans running back Chris Johnson revealed that he has been diagnosed with Amyotrophic Lateral Sclerosis (ALS) at the age of 40. ALS is a neurodegenerative disease with no cure. ALS impacts the nerves in the brain and spinal cord that affect motor skills. The nerves that give signals to the muscles to contract and move become diseased and die off, resulting in an inability to use those muscles. This affects physical movement in the arms and legs, the ability to speak, and even the ability to breathe. Eventually, the disease is fatal. Read more JUNE 2026 Anthropic Launches Claude Science, Illumina's Spatial Insights Tool, Wellcome Sanger Institute, Google DeepMind AI Consortium Hartwig Medical Foundation and Ultima Genomics expand their strategic collaboration; Thermo Fisher launches its Invitrogen E-Gel Power Snap Lite Electrophoresis System; the Pistoia Alliance announces the next phase of its Identification of Medicinal Products Ontology; and more. Read more JUNE 2026 Why Trust Is Clinical Trials' Next Big Breakthrough Clinical trials face major delays, costing sponsors $800,000 per day in lost sales, as 80% fail to meet enrollment targets. Experts link this to a lack of trust rooted in past unethical practices and concerns about data extraction. EverythingALS and Citizen Health pioneer patient-centric models to rebuild trust. EverythingALS, a nonprofit founded by Indu Navar, empowers ALS patients as collaborators via AI trial-matching and biomarker development. Citizen Health, venture-backed and co-founded by Nasha Fitter, focuses on rare diseases and achieves high data-sharing consent by treating patients as partners. Both show trust boosts engagement, improves quality, accelerates research, saves millions in drug development and positions trust as infrastructure. Read more JUNE 2026 Advanced care planning push, skipped checkups and a new Alzheimer's resource A federal proposal on end-of-life planning, why young adults are skipping checkups, a new Alzheimer's tool and heat safety — today's health headlines. CLEVELAND — The Trump administration is pressing hospitals and Medicare patients to make health care decisions before they become incapacitated. A new proposal would require hospitals to report end-of-life decisions starting in 2028, or risk losing payments by 2030. Read more JUNE 2026 New tool helps Alzheimer's families find clinical trials RICHMOND, Va. — A new tool aims to help families caring for a loved one with Alzheimer's disease by making it easier to find treatments and programs. The Alzheimer's Disease Registry Initiative, known as ADRI, is a virtual research platform that connects people with Alzheimer's or dementia and their caregivers to researchers. The goal is to match patients with clinical trials to accelerate breakthroughs in Alzheimer's treatment. Read more JUNE 2026 Seattle's Allen Institute drives $400M push for breakthroughs in neurological disease treatments: HealthLink SEATTLE — A multi-million dollar initiative led by the Allen Institute in Seattle aims to propel new treatments and therapies for some today's most confounding neurological diseases. Neurodegenerative diseases affect an estimated 57 million people worldwide, according to estimates from the Allen Institute. Read more JUNE 2026 New funding towards ALS research; fishermen and oil companies continue battle over rights to drowned land Earlier this month, the organizations EverythingALS and Vision 2030 announced a partnership with the Allen Institute to accelerate research into the progression of amyotrophic lateral sclerosis, also known as Lou Gehrig’s disease or ALS. The disease is a progressive neurodegenerative condition where patients lose the ability to walk, use their hands, talk and eventually breathe. But the new investment will be geared towards finding using AI-powered technology to look for a cure at the cellular level. Read more JUNE 2026 EverythingALS and Vision 2030 Invest in Allen Institute Initiative to Accelerate ALS Research SAN FRANCISCO--(BUSINESS WIRE )--Lou Gehrig Day — EverythingALS, a nonprofit dedicated to accelerating research, technology, and patient access for amyotrophic lateral sclerosis (ALS), and Vision 2030 are partnering with the Allen Institute to accelerate research into ALS disease progression and to identify new targets that could form the basis for novel medicines to treat the disease. This ALS-focused research will be supported by EverythingALS and Vision 2030’s $1M initial investment in the newly launched Allen Institute’s Brain Health Accelerator. The Allen Institute has committed $200M to the Brain Health Accelerator, a research initiative to study neurodegenerative diseases. Read more MAY 2026 Husband's ALS battle inspires new app During ALS Awareness Month, EverythingALS founder Indu Navar is turning personal loss into a mission to transform the way ALS is understood, managed, and treated. After losing her husband Peter to ALS, Indu used her background in technology to create EverythingALS, a platform using artificial intelligence and data to support patients and caregivers, connect people to clinical trials, and help track changes in speech, breathing, and movement. By bringing together patients, researchers, clinicians, and technology, EverythingALS is working to accelerate research, provide better answers, and ultimately help change the future of ALS care. Read more MAY 2026 Using AI to Transform ALS Research and Patient Care Indu Navar, founder and CEO of EverythingALS, discusses how artificial intelligence and remote digital tools are changing the way ALS is studied and monitored. Drawing from her personal experience losing her husband, Peter Cohen, to ALS, she explains how EverythingALS enables people to participate in research from home while helping researchers better understand disease progression. The interview highlights the potential of speech, movement, and other digital data to accelerate clinical trials and the development of new treatments for ALS. MAY 2026 How One Caregiver Is Rethinking ALS, Alzheimer's & Healthcare with Indu Navar This week on Mind What Matters, Elizabeth Humphreys and Nikki DeLoach sit down with entrepreneur, technologist, and healthcare innovator Indu Navar for one of the most eye-opening conversations the podcast has had to date. After losing her husband Peter to ALS, Indu found herself confronting a healthcare system that felt outdated, disconnected, and devastatingly slow. Instead of walking away from that experience, she decided to challenge the system itself. Read more MAY 2026 New AI matchmaker pairs ALS patients with clinical trials in seconds EverythingALS has launched a new online tool called SAVA AI that uses artificial intelligence to instantly match people with amyotrophic lateral sclerosis (ALS) to clinical trials. The platform is available for free through the EverythingALS website or as a mobile app, providing patients with a secure way to find research opportunities they may be eligible for in real time. Read more MAY 2026 HHS Proposes to Restructure Biomedical Research With AI Research breakthroughs tackling complex diseases and chronic illnesses can take years. The U.S. Department of Health and Human Services is hoping to speed that up ten-fold with artificial intelligence-enabled ecosystem of shared research and experimental procedures. The Advanced Research Projects Agency for Health, a unit of HHS, is spearheading a five-year Intelligent Generator of Research grant program with the stated intent of disrupting a centuries-old status quo of research spearheaded by individual labs. Read more APRIL 2026 EverythingALS Launches AI called SAVA AI to Match Patients with Clinical Trials SEATTLE--(BUSINESS WIRE )--EverythingALS, the patient-focused nonprofit leveraging technology and data science to accelerate care and research for ALS, today announced the launch of SAVA, an AI-powered clinical trial matching tool that connects ALS patients with clinical trials they may qualify for. Read more APRIL 2026 Denham Springs man uses his ALS journey to help others navigate the disease BATON ROUGE, La. (WAFB) - This week is Patient Access Week, a time to recognize the people who make sure patients get the help they need when they need it. Joe Redmond has been living with ALS for more than a decade, far outlasting the average survival window of two to four years after a diagnosis. Now, he is using his own experience to light the path for others. Read more MARCH 2026 Congress Approves Record $315 Million for ALS Research Amid New Treatment Efforts Indu Navar is quoted on EverythingALS's open-data platform, its nearly two dozen pharma consortium partners, and the importance of patient-industry collaboration in removing barriers to clinical trial participation. The article also highlights EverythingALS's expert-led discussions and efforts to establish speech metrics as FDA-approved clinical endpoints. Read more FEBRUARY 2026 Why Every Caregiver Needs a One-Page Emergency Plan Part of being a caregiver is to expect the unexpected and to create calm in moments of chaos. That pressure can be immense, so finding ways to lessen it can go a long way. In honor of National Caregivers Day, we asked experts about the best ways to do this. One way is to create a one-page emergency plan, a cheat sheet of all the details, routines and practices necessary to -prevent delay and indecision during emergencies. Read more FEBRUARY 2026 From Tragedy to Innovation: Patient-Led Data Systems and ALS w/ Indu Navar A conversation with Indu Navar We have to care to cure! Indu Navar is the founder of EverythingALS and a leading voice in patient-driven ALS research. After losing her husband to ALS following a long and exhausting diagnostic process, Indu turned her background in technology and data systems toward fixing what she saw as a broken approach to ALS care and research. Read more FEBRUARY 2026 Should You Share Your Health Info With an AI Chatbot? Indu Navar, founder of EverythingALS, weighs in on the risks and benefits of sharing personal health data with AI tools. She argues that patient data is the highest currency available for fighting rare diseases like ALS, and that the potential to accelerate a cure should outweigh privacy concerns — while still recommending basic safety precautions. Read more FEBRUARY 2026 ALS Advances Unite Patients and Pharma on Novel Targets, Biomarker Breakthroughs Indu Navar, CEO and founder of EverythingALS, joins BioSpace's Denatured podcast alongside the Chief Medical Officer of VectorY Therapeutics. The episode covers how patient-pharma collaborations are accelerating clinical trials, the latest advances in ALS biology, and the development of biomarker-driven endpoints. Read more FEBRUARY 2026 Historic ALS Investment Signals New Treatment Momentum Coverage of Congress approving a record $315 million in federal ALS research funding for 2026. Indu Navar is quoted on EverythingALS's pharma consortia, the organization's push for FDA approval of speech metrics as clinical trial outcomes, and its expansion of the expert talks series. Read more FEBRUARY 2026 EverythingALS Advances a New Clinical Research Model for ALS Trials A deep dive into how EverythingALS is modernizing ALS clinical trials with a speech-based digital biomarker awaiting FDA review. The machine learning algorithm, trained on data from over 1,200 participants including the HEALEY ALS Platform Trial at Mass General, matched speech pathologist assessments 96% of the time — and requires only one minute of recorded audio, no clinic visit needed. Read more FEBRUARY 2026 Rare Disease Day Read more Wisconsin Live Desk talks with the founder of EverythingALS ahead of rare disease day. JANUARY 2026 EverythingALS Taps 'Power in the Crowd' to Revamp Research Norms After less than three years of collecting voice samples, the Peter Cohen Foundation / EverythingALS awaits FDA approval of its AI algorithm as a secondary biomarker for tracking ALS progression. Indu Navar discusses how the listener-effort prediction model — the first-ever objective, scalable digital biomarker for any neurological disease — will be deployed in clinical trials as early as Q1 2026, across its consortium of 22 pharma partners. Read more JANUARY 2026 EverythingALS Taps 'Power in the Crowd' to Revamp Research Norms After less than three years of collecting voice samples, the Peter Cohen Foundation / EverythingALS awaits FDA approval of its AI algorithm as a secondary biomarker for tracking ALS progression. Indu Navar discusses how the listener-effort prediction model — the first-ever objective, scalable digital biomarker for any neurological disease — will be deployed in clinical trials as early as Q1 2026, across its consortium of 22 pharma partners. Read more NOVEMBER 2025 Q&A: Caregivers 'the Invisible Backbone' of the Neurodegenerative Disease Journey In recognition of National Family Caregivers Month, Healio interviews Indu Navar about her personal caregiving experience with her husband Peter, the founding of EverythingALS, and how the organization supports caregivers through community groups, education, and participation in remote digital research studies — turning lived experience into contributions to ALS biomarker development. Read more OCTOBER/NOVEMBER 2025 AI Offers New Hope for ALS Patients Seeking Clinical Trial Matches Indu Navar, CEO and founder of EverythingALS, discusses how AI and machine learning are being used to match ALS patients with clinical trials. The piece highlights EverythingALS's role in connecting patients to research opportunities and the potential of technology to accelerate treatment development for those living with the disease. Read more OCTOBER 2025 SAVA AI: Transforming How Patients Find Clinical Trials SAVA AI is an intelligent trial-matching platform that connects patients to the right clinical trials in seconds rather than weeks. Built by EverythingALS, the system combines human insight with advanced large-language-model (LLM) technology developed in partnership with Amazon Web Services. It interprets a person’s natural questions such as “Are there any ALS trials recruiting in Texas?” and delivers personalized, plain-language results drawn from verified, real-time sources like ClinicalTrials.gov . Read more SEPTEMBER 2025 Air Pollution’s Link To Amyotrophic Lateral Sclerosis (ALS) Air pollution from fossil fuels is the main contributor to climate change. The damage caused by air pollution doesn’t stop there; it also contributes to human diseases, suffering, and premature deaths. Indu Navar, an expert researcher, caregiver, and nonprofit founder , answered some questions for us about air pollution exposure and amyotrophic lateral sclerosis (ALS) . She is one of the founders of Everything ALS . Read more SEPTEMBER 2025 3 American Business Women Who Are Making A Difference In The World September 22 is American Business Women’s Day when we celebrate the achievements of the many successful women entrepreneurs and business leaders who are thriving amid the challenges of our ever-changing political and economic environment. Read more SEPTEMBER 2025 Invisible battles: The fights we don’t see until it’s too late High blood pressure, often referred to as the “silent killer,” is one of the most common yet ignored threats to health, affecting nearly 50% of adults in the U.S. Lacking symptoms, it can escalate into a hypertensive crisis triggering stroke, heart attack and kidney damage. The leading expert and chair of the latest American Heart Association guidelines breaks down what the numbers mean, why so many people remain undiagnosed and how small changes in lifestyle can save lives. Read more AUGUST 2025 Confidence Through Health Indu Navar, CEO of EverythingALS.org, provides us insight into the challenges and benefits of merging technology advancements with the healthcare system. In just a few short years, Indu has brought together multiple players in the neurological care area to improve the speed and capacity for patient care. Read more JULY 2025 Research Moves Slowly. Rare Diseases Don’t—So Patients Aren’t Waiting When Casey McPherson became a father, his purpose became clear. He needed to raise his daughter, Rose, to be loving, courageous, healthy and strong. He needed to protect her. Read more JULY 2025 It was already difficult enough for patients and caregivers dealing with severe illness. Indu Navar set up Everything ALS to help people with that process. Now things are about to get more difficult. Indu gives advice on this MM as to her organization and how it can help navigate the ever changing healthcare landscape. Read more MAY 2025 10 Things You Should Never Say to a Caregiver Avoid these platitudes, and learn what to say instead. Read more MAY 2025 KBOO's Lexus Ponce interviews nurse practitioner Martha Beach about how people with serious medical conditions can prepare in the face of more frequent emergencies like wildfires. Read more APRIL 2025 Bay Area app uses AI to help people with early detection of ALS symptoms A former tech executive who lost her husband to amyotrophic lateral sclerosis, ALS, hopes her app will help people with the early detection of ALS symptoms. Read more APRIL 2025 The Ice Bucket Challenge Is Back: Why Some Are Criticizing the 'Rebranding' of the Viral Trend 11 Years Later Students from the University of South Carolina started a recent campaign using the ice bucket challenge to raise mental health awareness Read more APRIL 2025 Everything ALS AI app helps connect thousands to clinical trials Read more MARCH 2025 I started a nonprofit to fight ALS after my husband's death. Here's how tech and AI can help us find a cure. Indu Navar has spent her career in tech, building and investing in organizations in Silicon Valley. She founded the Peter Cohen Foundation and EverythingALS after her husband died of ALS. Cohen had a long tech career, too. He built Amazon Mechanical Turk and AWS at Amazon. Read more MARCH 2025 App connects people with ALS, caregivers to supportive tools, guidance EverythingALS Pathfinders program offers one-on-one support with people diagnosed with ALS MELBOURNE, Fla. – Every 90 minutes, someone gets diagnosed with ALS. And every 90 minutes, someone dies from the disease. There’s no cure and the statistics are discouraging, but there’s a mobile app that’s creating hope for people living with ALS and their caregivers. Read more FEBRUARY 2025 Denham Springs man diagnosed with ALS helping to connect community DENHAM SPRINGS, La. (Louisiana First ) — Joe Redmond had a successful career as a radio and music executive in Louisiana and Tennessee for 40 years. Over time, he started having trouble with his voice and speaking. “I was slurring and often asked to repeat things so I knew something was wrong,” he said. Redmond saw many doctors over five years. Finally, he was diagnosed with Amyotrophic lateral sclerosis (ALS), or Lou Gehrig’s disease. This is a deadly neurodegenerative disorder that impacts motor neurons in the brain and spinal cord. Read more FEBRUARY 2025 Weekends with Larry Marino Podcast Read more JANUARY 2025 Former music exec on losing voice to ALS – and finding hope in community; rise in Islamophobia after Bourbon Street attack A diagnosis of amyotrophic lateral sclerosis, or ALS, is difficult for anyone to hear. But that was especially the case for Joe Redmond, a music executive from Denham Springs who spent his career in radio. While he is losing his voice, Joe has been determined to take advantage of all the opportunities he has, including working with the Team Gleason organization, and a new caregiving program called Pathfinders. Read more DECEMBER 2024 Minnetonka woman helping connect ALS community through app "Pathfinders" MINNETONKA, Minn. — A Minnetonka woman is helping connect the ALS community through an app. On Jan. 5, 2022, Faith's son, Scott, was diagnosed with ALS. ALS is a fatal neurological disease that affects nerve cells in the brain and spinal cord. Scott was 50 years old at the time of his diagnosis. He was a marathon runner and avid cyclist. Read more SEPTEMBER 2024 EverythingALS Launches App for ALS Community New version of the app will connect people with ALS while collecting data to support research. EverythingALS, a technology- and data-focused nonprofit, has launched an app to support people living with amyotrophic lateral sclerosis (ALS), their families and caregivers, researchers, and health-care professionals. Read more SEPTEMBER 2024 EverythingALS launches new app version for broader ALS community Patients and caregivers can access resources, contribute to ALS research EverythingALS has launched a new version of its mobile app that now includes community support, artificial intelligence-powered chat assistance, and enhanced research opportunities to better serve people with amyotrophic lateral sclerosis (ALS) and their caregivers. The app, which was previously designed only for people taking part in observational studies, has been expanded to also include patients and caregivers from the broader ALS community, allowing them to access vital information and resources, and to contribute to ALS research. “We invite everyone in the ALS community, from newly diagnosed individuals to long-term patients and caregivers, to explore the new features and benefits of this comprehensive app,” the nonprofit EverythingALS said in its press release . Read more DECEMBER 2024 EverythingALS and Compass UOL partner to advance artificial intelligence and computational biology by training and supporting 2,000 Top Talent to Cure ALS at Amazon web services(AWS) re:Invent 2024 in support from AWS LAS VEGAS, Dec. 4, 2024 /PRNewswire/ --A partnership between Compass UOL, an AI transformation services company, and non-profit EverythingALS is using artificial intelligence to address Amyotrophic Lateral Sclerosis (ALS), one of the most intractable puzzles in medicine. EverythingALS and Compass UOL officially launched their partnership on December 4 at 4:00 PM PT at the annual AWS re:Invent conference at the AWS for Healthcare and Life Sciences booth within the AWS for Industries Pavilion. Read more JUNE 2024 Could Artificial Intelligence hold the key to a cure for ALS? Researchers say yes CLEVELAND — ALS is a deadly disease that slowly attacks the nervous system. Currently, there is no cure, but some researchers believe artificial intelligence could hold the key to eradicating the disease. Good Morning Cleveland anchor Tiffany Tarpley spoke with the founder of EverythingALS, Indu Navar, about an app that uses AI to see how early ALS can be detected. Navar helped create the app after she lost her husband to ALS. She's encouraging people of all ages and backgrounds to download the app to help advance ALS research. Read more MAY 2024 Indu Navar: ALS Awareness Month Read more MAY 2024 St. Petersburg couple participate in speech study for earlier ALS diagnosis ST. PETERSBURG, Fla. — A patient-focused nonprofit organization is using artificial intelligence to help analyze audio and video recordings of patients with ALS and those without the neurological disorder, to advance diagnosis and prognosis of the disease. Read more MAY 2024 EverythingALS CEO Indu Navar and Chairman Bill Nuti talk ALS awareness month with Jim Cramer Read more MARCH 2024 EverythingALS launches AI platform to accelerate ALS research EverythingALS has introduced a platform aimed at advancing amyotrophic lateral sclerosis (ALS) research using artificial intelligence (AI) and machine learning — with the ultimate goal of eradicating the disease and restoring lost motor function to those with ALS and other neurodegenerative disorders. Read more MARCH 2024 EverythingALS Launches the Vision 2030 AI Hub : Charting the Path to an ALS Cure and Advancing Neurodegenerative Disease Research Vision 2030 will utilize advanced technologies and an innovative operating model for research and drug development Read more AUGUST 2023 New $400K grant aims to help ID digital diagnostic markers in ALS A new two-year, $400,000 grant will support studies — by EverythingALS and the Sean M. Healey and AMG Center for ALS at Massachusetts General Hospital (MGH) — aimed at identifying early digital diagnostic markers in amyotrophic lateral sclerosis (ALS). Read more AUGUST 2023 Effort to gather data on A.L.S. BINGHAMTON, NY – (WIVT/WBGH ) On the eve of the annual Walk to Defeat ALS, an effort is underway to bring modern innovation to find ways to better diagnose, treat and ultimately cure the fatal disease. Read more JULY 2023 Daily AI Roundup: Biggest Machine Learning, Robotic And Automation Updates 13th July 2023 This is our AI Daily Roundup . We are covering the top updates from around the world. The updates will feature state-of-the-art capabilities in artificial intelligence (AI) , Machine Learning , Robotic Process Automation, Fintech, and human-system interactions. We cover the role of AI Daily Roundup and its application in various industries and daily lives. Read more JUNE 2023 AI could provide breakthrough for early diagnosis of rare diseases For people living with rare diseases, one of the major challenges is being able to receive a rapid and accurate diagnosis. Often the process takes years, but Ben Hargreaves finds that there is a new wave of research utilising AI that could change this. Read more JUNE 2023 Could AI help diagnose diseases like ALS more quickly? BOULDER, Colo. (KDVR) — Michael Robinson was diagnosed with amyotrophic lateral sclerosis, or ALS, almost eight years ago when he was just 45 years old. “I was late for a meeting and went to go run and couldn’t get my right leg to move, and being a physician and knowing what I know, my immediate thought was I think I have ALS,” the Boulder resident said. Read more JUNE 2023 EverythingALS: Searching for a Cure with AI EverythingALS, a patient-focused non-profit, is currently conducting the world's largest AI-powered ALS study. John Howell is joined by Indu Navar, Founder of EverythingALS, to discuss the details of the study and history behind the non-profit. The study is still taking participants, both those who have ALS and those who don't. For more information, visit everythingals.org. Read more JUNE 2023 Non-profit Conducts Studies to Help with ALS "The way I look at it, as technology is here today. We can make an impact to people with ALS today. So, what we are doing is we're looking at these progression markers and applying this to clinical trials that's happening today. So, we work with about 11 pharma companies that partnered with us on this initiative," Founder and CEO of EverythingALS Indu Navar said. Read more JUNE 2023 Everything ALS works to help doctors and families diagnose the disease faster While reflecting on the process that her family endured while her husband battled the disease, Navar says, "There is something called diagnosis fatigue. And it really creates a lot of very, very deep, deep sorrow and grief just going through the diagnosis because it is, I say, it's death by a thousand cuts." Read more JUNE 2023 Tech entrepreneur aims to use artificial intelligence to speed up diagnoses of ALS DETROIT LAKES — Using artificial intelligence and machine learning, a tech entrepreneur is going after the fatal disease of ALS – also known as Lou Gehrig's Disease. Read more JUNE 2023 Bringing Technology to ALS CARE Indu Navar, founder of EverythingALS, joins Amy & JJ. And, just in time for the Fargo walk. Read more APRIL 2023 "EverythingALS" joins Harvard, MIT and IBM for unique research EverythingALS founder Indu Navar joined Kyla Grogen to discuss the unique research they are conducting with Harvard, MIT, and IBM. Watch the clip to learn how recording your voice for 20 minutes a week could be the key to finding a quicker way to diagnose and treat ALS. Read more APRIL 2024 Listen Up: Emerging Vocal Biomarker Could Aid ALS Drug Development It’s been a disappointing spring for the amyotrophic lateral sclerosis community, with the Phase II failure of Sanofi and Denali Therapeutics’ candidate and Amylyx’s decision to pull Relyvrio from the market . But drugmakers are hopeful that the development and validation of novel biomarkers for the disease, including neurofilament, genetic markers and, more recently, speech, can help improve patient care and expedite the development of effective treatments. Read more MARCH 2024 Deciphering the cellular mechanisms behind ALS At MIT, Fraenkel works in the Department of Biological Engineering and co-directs the Computational Systems Biology graduate program. For the study of ALS, he and his collaborators at Massachusetts General Hospital (MGH), including neurologist and neuroscientist Merit Cudkowicz, were recently awarded $1.25 million each from the nonprofit EverythingALS organization. The strategy behind the gift, Fraenkel says, is to encourage MIT and MGH to increase their collaboration, eventually enlisting other organizations as well, to form a hub for ALS research “to break down barriers in the field and really focus on the core problems.” Read more MARCH 2024 A new way to detect ALS in patients ALS is a crippling disease that affects the nervous system. There is a new and easier way to detect ALS. ALS also known as Lou Gehrig’s disease, affects the nervous system by weakening muscles and ultimately paralyzes the patient. Indu Navar is the CEO and Founder of Everything ALS, she says there is a new effort to help ALS patients by using AI machine learning. Read more MARCH 2024 Citizen-Driven Research Aids Development Of Digital Biomarkers For ALS March 20, 2024 | When it comes to research on amyotrophic lateral sclerosis (ALS), every stakeholder—most especially patients—knows time is of the essence. From diagnosis to death, life expectancy from the debilitating neuromuscular disease can be two years or less. “The time people give us is currency,” says Indu Navar, founder of the nonprofit Peter Cohen Foundation operating as EverythingALS. Read more JANUARY 2024 Citizen-Driven Research Aids Development Of Digital Biomarkers For ALS When it comes to research on amyotrophic lateral sclerosis (ALS), every stakeholder—most especially patients—knows time is of the essence. From diagnosis to death, life expectancy from the debilitating neuromuscular disease can be two years or less. “The time people give us is currency,” says Indu Navar, founder of the nonprofit Peter Cohen Foundation operating as EverythingALS. Read more JANUARY 2024 Governor Hochul proposes historic $25m budget for ALS research in New York A groundbreaking moment in the search for a cure for ALS. Governor Hochul is looking to set aside a historic amount of money for ALS research in New York. She made the announcement in her budget address last week, but in this week's Wellness Wakeup, you'll see for the governor and many others, it's personal. Read more DECEMBER 2023 10 unexpected ways life changes when you become a family caregiver Some family caregivers go into it knowing that caring for a loved one is their fate, while others are unexpectedly thrust into it. But whether it’s expected or not, the family caregiving journey is rarely predictable, says Jody Gastfriend , a licensed clinical social worker, author and senior care consultant. Read more DECEMBER 2023 Slowing ALS with Speech: Study leverages IBM’s AI, creates digital biomarkers EverythingALS is working with clinical research stakeholders from IBM Research, Massachusetts Institute of Technology, and Harvard University in a longitudinal study focused on early disease detection based on patterns noted in audiovisual sessions. Read more OCTOBER 2023 Former tech executive leads nonprofit to help those with ALS Moving from tech entrepreneurship to caregiving was never a step Indu Navar expected to make, but this leap of faith turned out to be transformative. Today, she is making use of both skill sets as the CEO and founder of EverythingALS , a nonprofit patient-led advocacy group focused on creating digital biomarkers for early detection of ALS. Read more SEPTEMBER 2023 EverythingALS Announces Student Fellow Scholarship Awards and Expanded Student Ambassador Program aims to accelerate ALS Research SEATTLE, Sept. 27, 2023 (GLOBE NEWSWIRE) -- EverythingALS, a citizen science research organization dedicated to developing cure for ALS, announced today the Student Fellow Scholarship Awards and the expansion and continued enrollment of student Ambassadors program. Both programs are core pillars of the EverythingALS Care to Cure™ impact model. Read more SEPTEMBER 2023 Local ALS Association Chapter’s ‘Walk to Defeat ALS 2023’ held in Salem SALEM, Va. (WFXR ) — On Sept. 16, different ALS Association Chapters across the nation hosted their annual Walk to Defeat ALS. Our local chapter in Virginia was no different. The event was to raise funds for amyotrophic lateral sclerosis or Lou Gehrig’s disease. It’s a rare progressive neurological disorder that affects nerve cells in the brain and spinal cord resulting in weakened muscles. Currently, it’s a terminal diagnosis, meaning it has no cure. Read more AUGUST 2023 New $400,000 Grant Supports EverythingALS.org and Mass General Hospital (MGH) to Develop NeuroLens, a Digital Diagnostics technology initiative for early detection of Amyotrophic Lateral Sclerosis (ALS) SEATTLE--(BUSINESS WIRE )--EverythingALS today announced it has received $400,000 from ALS Finding a Cure® and The ALS Association to support studies for the identification of early digital diagnostic markers of ALS. Read more AUGUST 2023 Buffalo's ALS ambassador raising awareness ahead of weekend walk ORCHARD PARK, N.Y. (WKBW) — It is a disease that robs people of their ability to walk, talk, swallow and eventually breathe. ALS, often called Lou Gehrig's Disease most commonly afflicts people between the ages of 40 and 70. As many as 30,000 Americans have the disease at any given time. This Saturday, Buffalo will be hosting the Western New York Will Walk to Defeat ALS , at Delaware Park. Read more JULY 2023 Merging as EverythingALS, 2 nonprofits seek to better treatment “We firmly believe that the proliferation of non-profit organizations in this field leads to duplication of efforts, wasting precious time, money, and most importantly, lives,” Bill Nuti, CureALS’ founder and CEO and now chairman of the board of directors for Everything ALS, said in a joint press release . Read more JULY 2023 EverythingALS and CureALS Join Forces to Discover a Cure for ALS “They reflect our commitment to advancing research, improving diagnosis and therapies, leveraging data for analysis and technology integration, and ensuring comprehensive support for people living with ALS and FTD.” Read more JULY 2023 California tech company using artificial intelligence in ALS studies BOULDER, Colo. — More than 5,000 Americans are diagnosed with amyotrophic lateral sclerosis (ALS) each year, and roughly 600 people are here in Colorado, according to the Rocky Mountain chapter of the ALS Association. Read more JUNE 2023 Groundbreaking Nonprofit, CureALS Founded and Launched by Former NCR Chairman and CEO Bill Nuti to Eradicate ALS NEW YORK--(BUSINESS WIRE )--CureALS, a pioneering nonprofit organization dedicated to eliminating ALS (Amyotrophic Lateral Sclerosis) and other complex neurodegenerative diseases such as Alzheimer’s, Parkinson’s, and Frontotemporal Dementia, has officially launched today. Read more APRIL 2023 How AI and Facial Recognition Could Spot Stroke and Other Diseases Researchers are training computer algorithms in efforts to quickly identify ailments and speed treatment. Patients at Johns Hopkins Hospital who are suspected of having a stroke might get an unusual request from physicians: Can we film your face ? The doctors’ goal is to identify stroke patients by facial characteristics instead of waiting for brain scans or blood tests, helping speed both treatment and recovery. Read more APRIL 2023 Non-profit behind world's largest AI-powered ALS study ST. PETERSBURG, Fla. — ALS non-profit EverythingALS is using artificial intelligence and other technologies to help find a way to diagnose ALS and other neurological diseases faster and find a cure. It’s partnering with healthcare companies in the effort and conducting speech research to spot and track early signs of ALS. Read more APRIL 2023 Project CommUNITY Women Breaking Barriers: Indu Navar, Founder of Everything ALS "I made a promise to him that I will keep fighting for him and the disease,” Navar said. “And we need to prevent from other people going through what we went through. I want to keep them alive through this work. And I really feel it was such a terrible experience for us that I really don't wish this on anybody" Read more APRIL 2023 How AI CAN LOOK INTO YOUR EYES AND DIAGNOSE A DEVASTATING BRAIN DISEASE “The eyes are the windows to the soul.” It’s an ancient saying, and it illustrates what we know intuitively to be true – you can understand so much about a person by looking them deep in the eye. But how? And can we use this fact to understand disease? Read more MARCH 2023 STUDY SEEKS TO IMPROVE ALS DIAGNOSES WITH AI Speech recognition patterns can give clues to neurological conditions A study is underway to determine AI’s suitability for diagnosing the neurological disease ALS. The study is using AI-powered virtual assistants to detect potential signs of ALS in a participant’s speech patterns and facial gestures. Read more FEBRUARY 2023 LOCAL RESIDENT REVEALS HIS ALS JOURNEY Learn about the ALS journey of local resident Tommy Culpepper and find out you can support him! - KNWA & FOX24 - Northwest Arkansas & River Valley News + The ALS Association Arkansas Chapter Read more FEBRUARY 2023 What Dr. Chatbot ordereD Your doctor could be a robot sooner than you think. The pandemic and its toll on the health care sector spurred interest in the role artificial intelligence can play in easing burdens and improving efficiency, particularly via chatbots to tackle routine tasks like scheduling appointments and billing issues. But evidence is building that suggests chatbots are already pretty good at giving health advice. Read more JANUARY 2023 Montgomery County man with ALS part of study that aims to find root cause of disease "When a man died, he was said to have gone west," repeated 59-year-old Todd Kelly into a computer. He isn't reading a best-selling novel, but reciting speech to help treat and cure ALS. "The problem with ALS, unlike many other diseases, is they can't find a biomarker. The biomarkers, what you can see, is affected by a treatment," he described. Read more JANUARY 2022 Getting Vocal In December of 2016, Valerie Geerer was doing her normal lunchtime walk with work colleagues when a friend noticed something off about her gait. “I remember she said, ‘Is there something the matter with your foot?’” the fifty-nine-year-old Stamford resident recalls. “I told her I felt fine. A month later I was tripping myself. It was ironic. Six months earlier, my husband Michael and I were climbing mountains in Utah. And suddenly I couldn’t walk without stumbling.” Read more DECEMBER 2022 ALS genetic carrier finds the “path to higher ground” in clinical research ALS genetic carrier finds value in EverythingALS study leveraging digital biomarkers as a means to create tools for early detection of ALS and potentially other neurological diseasese. Read more DECEMBER 2022 New way to detect ALS; early diagnosis critical for treatment LAS VEGAS (KLAS) — Every 90 minutes, someone gets diagnosed with amyotrophic lateral sclerosis, or ALS. It’s a progressive neurodegenerative disease that affects nerve cells in the brain and spinal cord and there is no cure. Read more NOVEMBER 2022 Woman's Husband's Health Journey Inspires Everything ALS NBC10’s Erin Coleman speaks to Everything ALS founder Indu Navar about her husband’s own ALS diagnosis and how the group is working to better ALS research. You can help the fight through Everything ALS or at the 2022 Walk to Defeat ALS. Read more NOVEMBER 2022 Walk to Defeat ALS happening in North Las Vegas Indu Navar, founder of EverythingALS, joined us to talk about how your participation helps raise funds and awareness. WATCH HERE NOVEMBER 2022 Non-profit conducts study to diagnose ALS quicker LANSING, Mich. (WLNS) — In the 150 years since ALS was discovered there is still no cure or single test to diagnose the disease. The demand for more answers is what drove one woman to start up her own non-profit. EverythingALS began its research in 2021 and now they’re working toward diagnosing the disease faster. “I really want to help people who are going through this disease,” said Indu Navar, Founder of EverythingALS. The study analyzes data when it comes to physiological changes and the progression of the disease. Navar says she wants to shift the focus to the brain, something she believes isn’t understood well enough. READ MORE SEPTEMBER 2022 Q&A With Indu Navar, founder of Everything ALS Indu Navar, founder of Everything ALS, speaks with Pharm Exec about how she lost her husband to the disease and how she's trying to improve the way its diagnosed. Indu Navar Diagnosing ALS is a difficult process for patients experiencing symptoms. After the death of her husband, tech entrepreneur Indu Navar founded Everything ALS, and organization she hopes will refine and improve the way ALS and other neurological conditions are diagnosed. READ MORE OCTOBER 2022 New technology helping ALS patients in Louisiana BATON ROUGE, La. (BRPROUD) — ALS, often called Lou Gehrig’s disease, is a progressive motor neuron disease that gradually robs people of their ability to walk, talk, swallow, and eventually breathe. Indu Navar, the founder of EverythingALS, said, “ALS has no known cause or cure and so patients suffer for years not knowing what is wrong and have to go through rigorous testing and a process of elimination to finally get diagnosed. If they are diagnosed, there are no treatments. Life expectancy is two to five years.” READ MORE SEPTEMBER 2022 EverythingALS Joins Forces with Aural Analytics, FeetMe, ZEPHYRx and Others for a First-Of-Its-Kind ALS Research Study SAN FRANCISCO (PRWEB) SEPTEMBER 19, 2022 EverythingALS, a patient-focused non-profit that brings together people living with ALS, caregivers, physicians, researchers, and pharmaceutical companies to collaborate on an open innovation platform using cutting-edge technologies and data science to improve progression measurements for neurological disease like Amyotrophic Lateral Sclerosis (ALS), has initiated a new study, The Radcliff Study, with partners in the quest to find a diagnosis, treatment, and cure for ALS... READ MORE AUGUST 2022 Groundbreaking research involving artificial intelligence could diagnose ALS patients sooner Five thousand people in the U.S. are diagnosed with a neurological disease called ALS every year. Medical experts say it typically takes an average of two years to diagnose, but new research will likely make that timetable a lot shorter. In 2019, Mark Weston and his wife, Kathleen, had their retirement all planned out. "We were all set up for a sail off into the sunset and have a really fun retirement," Weston said. "We had, we bought a house on the coast of Maine several months earlier." A week before the big move, he got a life-changing diagnosis. READ MORE AUGUST 2022 NeuroSense Joins EverythingALS Open Innovation Consortium; Set to Enroll US and EU Patients in Phase IIb Study NeuroSense's support will aid EverythingALS with ground-breaking patient research in a joint effort to develop treatments LOS ALTOS, Calif. and CAMBRIDGE, Mass., Aug. 2, 2022 /PRNewswire/ -- EverythingALS , a patient-focused non-profit that brings together patients, caregivers, physicians, researchers, and pharmaceutical companies using technological innovations and data science to support efforts to improve care for those living with a neurological disease like Amyotrophic Lateral Sclerosis (ALS), today announced NeuroSense Therapeutics Ltd. (NASDAQ: NRSN ) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, as a new collaborator in the effort to identify treatments and a cure for ALS. READ MORE AUGUST 2022 ‘Death by 1,000 cuts:’ How emerging tech could change the journey for ALS patients EverythingALS aims to speed drug development through improved diagnostics. in 2016, Indu Navar’s husband, Peter Cohen, experienced the first symptom of what turned out to be amyotrophic lateral sclerosis (ALS), a progressive degenerative disease commonly known as Lou Gehrig’s disease. EverythingALS founder Indu Navar Permission granted by EverythingALS/Indu Navar “His foot was just acting weird,” says Navar, who founded the California nonprofit EverythingALS two years ago. “We didn’t know where to go, so we went to a chiropractor,” she says. READ MORE JULY 2022 Healthbeat: New ALS research driven by patient-focused non-profit SCRANTON, LACKAWANNA COUNTY— New research is underway to better understand and treat ALS, a difficult disease to diagnose with no known cure. ALS patient Paul Miller of Scranton is one of the participants. The progressive neurodegenerative disease ALS affects as many as 30,000 Americans. There is no known cure despite efforts to better understand it and treat it. ALS is a puzzling disease for certain with so much needing to be learned about it. READ MORE TOMMY EDWARD CULPEPPER,Jr MOVIE CONNOISSEUR JULY 2022 Bentonville man works to help diagnose ALS sooner A Bentonville man is dedicating his life to advocating for people with ALS and trying to help diagnose the disease sooner. “I’m a movie connoisseur,” said Tommy Edward Culpepper, Jr. “I love movies.” For Culpepper, movies have always been his saving grace. Even when he was a kid growing up in St. Louis, Missouri. “I grew up in the Peabody Projects and the home environment wasn’t the greatest,” he said. “Star Wars, Blade Runner, Highlander. Movies like that are excellent getaways for me.” Until he found himself in a nightmare that started in the doctor’s office... READ MORE JULY 2022 These 2 Surprising Traits May Predict ALS, New Research Says How ALS researchers are using an intriguing tool to learn keys of this disease that has at times taken years to diagnose. Plus, one woman's story of why she agreed to participate in this research Amyotrophic lateral sclerosis (sometimes called Lou Gherig’s disease, or ALS ) affects around 15,000 Americans, with about 5,000 receiving a new diagnosis each year, according to the Centers for Disease Control and Prevention. READ MORE JUNE 2022 Continue that momentum from the ALS Ice Bucket Challenge by getting involved in a unique study - New Day NW Researchers want every American to start recording their voice daily. They believe this data could be used to eventually develop cures for ALS. #newdaynw READ MORE MAY 2022 Patients giving voice to ALS research Back in 2014, millions of people poured icy water over their heads to spread ALS awareness and support research for the devastating neurodegenerative disease. Now tech developers want to hear your voices. Brian Andre has been living with ALS for six years. “On average they only give you 2 to 5 years of life after diagnosis and some progress very quickly,” he said. “I’m really in a very small percentage of patients who see little or no progression. … My weakness is in my left side, left leg and arm. So it throws my gait off.” READ MORE INDU NAVAR, CEO - EVERYTHINGALS MAY 2022 Live At 9: Researchers Collecting Audio and Video to Help ALS Detection Remember the summer Americans took time to dump buckets of ice water on their heads to help fight the deadly disease ALS? This summer, there’s a more comfortable way to help researchers learn about ALS and other neurological disorders. Researchers want people to record their voices and upload them for study. READ MORE Austen Eadie-Friedmann before his diagnosis of amyotrophic lateral sclerosis or ALS MAY 2022 A Connecticut man is battling a fatal disease with ‘enormous courage’. Love and his work with an ALS group give him ‘purpose Three years ago Austen Eadie-Friedmann, 38, had a dynamic career in the pharmaceutical/biotech field working for a Fortune 500 company and living in exciting places such as New York City, Boston and Europe, with his husband, William DeGregorio. The couple, now together for 18 years and married for five, loved their life traveling the world, sharing a passion for art. Then the devastating diagnosis arrived... READ MORE INDU NAVAR, CEO - EVERYTHINGALS MAY 2022 How high tech shoes could help doctors better understand ALS MOUNTAIN VIEW, Calif. - There is no cure for ALS, the progressive neurodegenerative disease that affects nerve cells in the brain and spinal cord, but a Silicon Valley nonprofit is hoping to change that. Starting Tuesday, EverythingALS , a Silicon Valley nonprofit and advocacy group, is starting its second research study involving ALS patients, using shoes with high-tech censors to track and study their movements. The study is open to 100 participants in the early stages of ALS, and is still accepting new participants.... READ MORE MAY 2022 Tech Tuesday: Using AI to fight ALS LANSING, Mich. (WLNS) — One non-profit organization is using technological innovations and data science to support those grappling with amyotrophic lateral sclerosis, otherwise known as ALS. EverythingALS was started by Indu Navar. READ MORE INDU NAVAR, CEO - EVERYTHINGALS MAY 2022 Bringing Awareness To ALS And Those Who Suffer From It In this podcast, we are joined by Indu Navar. Indu Navar is the CEO of Everything ALS, a company that prioritizes bringing awareness to Amyotrophic Lateral Sclerosis (ALS) and those who suffer from it. ALS is a neurological condition that affects the victim's motor neurons. This causes muscle atrophy all across the body, which can eventually cause suffocation and even death. LISTEN NOW APR 2022 Be The Good with Kate Cherichello Be the Good with Kate podcast- Kate Cherichello scheduled a taped interview with Indu for Wednesday, March 9th at 3:30pm EST to discuss EverythingALS and the research study. Episode went live on April 29th. LISTEN NOW FEB 28, 2022 MITSUBISHI TANABE PHARMA JOINS EVERYTHINGALS CONSORTIUM TO HELP ACCELERATE BIOMARKER DISCOVERY FOR NEUROLOGICAL DISEASES (San Francisco, CA)-- Today, EverythingALS.org (EALS), a patient-centric, citizen-based California nonprofit accelerating the discovery of digital biomarkers for neurological diseases such as amyotrophic lateral sclerosis (ALS), announced that Mitsubishi Tanabe Pharma Holdings America, Inc. READ MORE FEB 12, 2022 San Francisco based nonprofit launches new ALS research SAN FRANCISCO (KCBS SF) — A San Francisco-based nonprofit is recruiting average people to take part in ALS research. KCBS Radio’s Keith Menconi explains. READ MORE DEC 2021 ALS, Lou Gehrig’s Disease, takes many lives, Everything ALS is doing Deb Fabricatore lost her younger brother to ALS in 2014, and became involved in ALS advocacy. Indu Navar lost her husband in 2019 and immediately stepped up into action by building a nonprofit devoted to honoring her husband. READ MORE Bay Area Nonprofit Seeks 300 Volunteers in ALS Speech Study SAN FRANCISCO (CBS SF) — A Bay Area nonprofit dedicated to advancing research on an incurable — and fatal — disease of the nervous system is looking for 300 more people by the end of this month to participate in the largest-ever research project on the illness. READ MORE NOV 21, 2021 EverythingALS said it needs more than 300 volunteers for its study to combat amyotrophic lateral sclerosis, more commonly known as Lou Gehrig’s disease, an incurable, degenerative illness. READ MORE NOV 21, 2021 Bay Area non-profit looking for volunteers in Lou Gehrig diseases study OCT 2021 EverythingALS Launches “Stories and Innovation in ALS” Podcast October 21, 2021 (Silicon Valley, CA) – For an inside look at how ALS impacts patients and their caregivers as well as the innovations that researchers and clinicians are coming up with to find biomarkers, treatments, and cures for this life-threatening disease, start listening to the EverythingALS podcast , “Stories and Innovation in ALS.” EverythingALS (EALS) was founded in 2020 to help discover biomarkers – which are nonexistent -- and document the progression of ALS by launching the world’s largest speech study with more than 600 participants. READ MORE APRIL 2021 Accelerating Rare Disease Research TEDxSantaCatalinaSchool In this moving, TEDx talk, Indu Navar tells how she lost her husband, Peter Cohen, to ALS and what she is doing to bring together patients, families, researchers and people everywhere to change the way that rare diseases are looked at. WATCH VIDEO Digital Health InfoCast: Machine Learning for a Cause Canada has been an early leader in the AI space and there is no shortage of activity flourishing across the country. Today, we welcome Fanny Sie from Roche Canada and Indu Navar of Everything ALS to talk about machine learning and the End ALS Kaggle Challenge . LISTEN JULY 30, 2021 Indu Navar, CEO and Founder of EverythingALS, explores the roles of Artificial Intelligence, Machine Learning, and Brain Computer Interface in the search for a cure for ALS. She will also share innovative research studies on ALS detection, how Pharma can work with and support ALS patient advocates, and her key leadership lessons for digital health entrepreneurs and innovators. WATCH VIDEO JUNE 25, 2021 Impetus Digital PODCAST JULY 2021 New project to better identify and treat ALS uses AI and data sharing Through the AI CoE, Roche has collaborated with EverythingALS , AnswerALS, the Ontario Brain Institutes and ALS Canada to launch an open data science competition called the End ALS Challenge. READ MORE READ MORE Mar 29, 2021 THE STORY OF MODALITY.AI: HEALTHTECH AWARD WINNER Suendermann-Oeft states that one of the most significant achievements for them has been collaborating with the non-profit organization EverythingALS , as well as MIT, Harvard, and IBM to scale the number of Modality platform users to over 100 within three months for a study focusing on the early detection and improved prognostic accuracy of ALS ... "Jody O'Donnell introduced me to the founders of every Everything ALS , brother and sister, Murgesh Navar and Indu Navar, and Indu lost her husband to ALS a few years ago. Really, we just kind of hit it off from the get-go. Tremendous pair, both kind of serial entrepreneurs; they started multiple companies in the Bay Area and they just brought a passion and energy, a desire to do things quickly and challenge the status quo ... READ MORE April 30, 2021 interview with Katie Pecora for Patients Rising The Roche Canada Artificial Intelligence Centre of Excellence (AI CoE) is excited to collaborate with Answer ALS and EverythingALS to launch an initiative called the End ALS Challenge , with the support of ALS Society of Canada , Ontario Brain Institute (OBI) and NetraMark Corp . The goal is to surface insights through an open data competition.. READ MORE Mar 29, 2021 EndALS Kaggle Challenge to TACKEL ALS EverythingALS Selected to Present at the American Academy of Neurology Virtual Annual Meeting EverythingALS, a California nonprofit dedicated to bringing technological innovations and data science to support people with ALS, has been selected to ... READ MORE April 16, 2021 READ MORE Mar 25, 2021 Roche Canada AI Centre and EverythingALS to tackle ALS The Roche Canada Artificial Intelligence Centre of Excellence (AI CoE) is excited to collaborate with Answer ALS and EverythingALS to launch an initiative called the End ALS Challenge, with the support of ALS Society of Canada, Ontario Brain Institute (OBI) and NetraMark Corp... Roche Canada Artificial Intelligence Centre and EverythingALS opens digital competition to tackle ALS EverythingALS, a California nonprofit dedicated to bringing technological innovations and data science to support people with ALS, has been selected to ... READ MORE Mar 18, 2021

EVERYTHING ALS Pathfinders Everything ALS Pathfinders' vision is to empower individuals affected by ALS and their families. Our threefold mission focuses on: Our main priority is to provide support for individuals with ALS, from offering care to seeking a cure. As an Everything ALS Pathfinder, we wholeheartedly welcome you into our community, a place where you will never have to feel isolated. This is a community where you belong, where your voice is heard, and your experiences are valued. Let's come together and provide unwavering support to help each other Live a fulfilling life despite the difficulties we may face with ALS. 1. Physical Empowerment: We are dedicated to finding practical solutions and resources to alleviate the physical challenges associated with ALS, aiming to improve the quality of life for patients as their conditions evolve. 2. Mental Resilience: We're here to support you at all times. Our goal is to improve the mental well-being of people with ALS, caregivers, and their families by providing ongoing support and fostering a sense of community. You are not alone in this journey. 3. Spiritual Support: By addressing spiritual concerns, we aim to provide a comprehensive approach to healing, ensuring individuals find solace and meaning amid the challenges they face. My name is Willard Blackwell . I was diagnosed with ALS in May of 2022. I had fallen while playing pickleball, which prompted the doctors to investigate my symptoms. As a professional singer and musician leading the Gator Nation Band, I have encountered daily challenges due to the loss of full use of my hands or legs. I no longer perform with my band but recently sang with friends. I still try to do the things I love as long as they don't worsen my symptoms. I have learned about conserving energy, and I try not to overexert myself so I can keep moving forward. I find joy in music and comedies – anything that brings a smile to my face. This experience with ALS has taught me a lot about maintaining a positive attitude while battling this terrible disease. Initially, I was reluctant to ask for help. My friend, Kathleen, noticed my hesitation and called in my soul tribe because she knew I needed more assistance. I understand that seeking help can be difficult, but it can also be incredibly rewarding. We don't have to go through this alone. It's much better to have support to help you navigate your way. If you feel that I can support you on your journey, please connect with me on Fireside Chats. My name is McFinn Lovere . My experience of reversing my ALS put me on the path to being of service to others with this devastating disease. At my weakest point I was only able to move two fingers and my head. I know what 24-hour daycare means. I have experienced the feelings you take on from isolation. I had one caregiver who was excellent. I had another caretaker who looked at it as a job, not compassionate service. It is so important for your mental stability to have someone caring for you who understands the stress ALS creates for pALS and their families. I hope my and my family's experiences will help relieve some of the Stress ALS brings into your life. Your Everything ALS Pathfinder, McFinn, is reaching out; reach back. mcfinn@everythingals.org My Name is Faith Oremland . My son, Scott, was diagnosed with ALS on January 5, 2022. It was the worst day of my life…until he died on March 24, 2026. That is and always will be the worst day of my life! Before he died, I spent much of my time volunteering in the ALS community. I wanted to help everyone diagnosed with ALS and support their families because it is a frightening journey to try and handle alone. Now I want to help all the parents who, like me, have been devastated by the loss of their child. I am living the grief and I want to share what I have learned on this sad journey. I have resources and stories to share that may help you. Most importantly, I have an ear for listening – whether you want to scream, cry, rant or even whisper, I offer you a non-judgmental approach to grief. Losing a child is unimaginable until it happens to you. Where do you turn for someone to understand what you are going through? I understand and I am here for you. Being an Everything ALS Pathfinder gives me the opportunity to help others on our ALS journey. You are not alone! It's about sharing our stories, listening to each other, providing helpful information, and being there with compassion and love. So long as we remember them, they will never die. You can reach me anytime at faith@everythingals.org My name is Monica Martinez , and I live in Texas. At 48, I was diagnosed with Bulbar Onset ALS. In late 2019, I noticed trouble enunciating words, which soon turned into slurred speech. As a police officer, my voice was crucial. One day, after speaking on the radio, a fellow officer texted me, asking if I had been drinking because I sounded drunk. This prompted me to seek medical advice. After years of seeing various doctors and undergoing speech therapy, in March 2023, my neurologist gave me devastating news: "Monica, you will never be able to carry your firearm again." I was bewildered. "Monica, you have Bulbar Onset ALS. I'm so sorry. You should get your affairs in order." The diagnosis of ALS was heartbreaking, but giving up my career was even harder. At 49, I was forced into early retirement after 24 years of service. Since my diagnosis, I found solace in the ALS community, realizing I was not alone. This new family provided support, and I reciprocated. Together, we are stronger. Welcome to Pathfinders! We are here to support, guide, and walk with you on this journey. You are not alone! WE GOT THIS! TOGETHER WE ARE BETTER THAN ALS! I can be reached at monica@everythingals.org My name is Ivonne Vaughn. On April 13, 2024, I was at a lovely church garden party. I tried to step up on a platform with my right leg, it was too weak to support me. I stepped down and stepped up with my left leg. On January 16, 2025, after four MRIs, two X-Rays, one muscle biopsy and three Nerve Conduction Studies (NCS) and Electromyography (EMG) I was diagnosed with limb onset ALS. The Doctor said, “you have ALS,” I said I know I have A Loving Savior. He smiled and said no Amyotrophic Lateral Sclerosis. On the 2.5-hour drive back to our home my husband told me he was 99% certain it was ALS months earlier. He knew about ALS; I had much to learn. I threw myself into getting educated and learning all I could about ALS, available ALS resources/organizations and how to live and accept the incremental changes I was experiencing. I did this by attending a plethora of ALS groups and webinars. In ALS support groups, I see I am not alone and learn about living everyday with ALS. My goal is to help and encourage those with ALS (pALS), those caring for ALS loved ones (cALS) and to share the HOPE I have in my ALS journey. We all need good listeners in our lives. As a Pathfinder, I am here to listen, support, and encourage you. "It is during our darkest moments that we must focus to see the light." - Aristotle "Try to be a rainbow in someone's cloud." - Maya Angelou I can be reached at ivonne@everythingals.org Hi, I’m Chris OBryan . I’ve been living with a rare, slower-progressing form of familial ALS since 2014. The name of my diagnosis has changed over time, but what hasn’t changed is learning how to live with it one day at a time. My mom also had ALS, and I walked with her through her journey. At first, I tried to prepare for my own progression by comparing it to what I saw with her. Over time — especially through support groups — I came to understand something important: no two ALS journeys are the same. Knowing this might be part of my future gave me the chance to prepare physically, mentally, and emotionally. We made some good decisions, and like most things in life, there are also things I would do differently. That’s part of the learning. There are positive days and there are heavy days. That’s real. What I’ve learned is that no one should have to navigate those days alone. I’m here to listen, to talk, and to check in. Sometimes just knowing someone understands makes all the difference. Walking beside you — because none of us should face ALS alone. I can be reached at chris@everythingals.org Hi, my name is Tim Fulham . I am from New Orleans, LA and attended school there. After college, I taught high school biology for 8 years but eventually transitioned to a career in pharmaceutical & medical device sales, sales leadership and eventually sales training. Over the years, my work gave me the opportunity to live in New Orleans, Connecticut, New Hampshire, North Carolina, Athens, Greece and London, England. 30+ years later I spent another year back in the high school classroom this time teaching biomedical science before my health forced me into retirement. I have two adult sons, one daughter-in-law and one toddling grandson. I enjoyed great health my entire life, until I was first diagnosed with PLS in March of 2024. After seeing a neuromuscular specialist, my diagnosis was changed to ALS in January of 2025. Becoming a pathfinder has given me the opportunity to share my journey in a way that can help others that have recently been diagnosed. Every day, I am thankful to wake up and engage in a busy, love filled life focused on what I can still do, not what I’m losing the ability to do. I hope that my experiences traveling along this road can help you with your journey. I can be reached at tim@everythingals.org Hi, my name is Peggy Merrill. My journey with Motor Neuron Disease began with difficulties speaking, and a hypersensitivity in my throat. As a yoga teacher and studio owner this was particularly challenging since I relied on my voice to share my love of all things yoga and meditation. Eventually I had to close my studio, although I had hundreds of hours of recorded practices from the Covid lockdowns. ElevenLabs was able to use audio from them to create a custom voice clone for me, which I am using to create new practices to share within the ALS/PLS/MND community, for pALS and cALS alike. I would love to assist you with your communication challenges and, as an ambassador for ElevenLabs, I can facilitate this process for you. I’m also happy to be a sounding board, and hold space for you and your caregiver to find some peace in all of this chaos. I can be reached at peggy@everythingals.org Hi, my name is Terry Small. My wife and I were married for more than 30 years and raised two sons together. In February of 2026, the love of my life was diagnosed with ALS and was, sadly, a very fast progressor. During her journey, I had the privilege of being not only her husband, but also her caregiver and advocate. She passed away in August. My wife was a dietitian, and after her diagnosis, she brought all of her professional knowledge and determination to fighting the disease. She explored nutrition closely and tried everything she reasonably could from a nutritional standpoint in hopes of slowing its progression and maintaining her strength for as long as possible. That became an important part of our ALS experience. Our time with ALS was far too short, but it taught me more than I ever expected to learn about caregiving, navigating rapid changes, advocating for someone you love, making difficult decisions, and trying to remain a husband when ALS suddenly makes you a caregiver as well. As a male caregiver, I understand that men don't always find it easy to talk about the fear, exhaustion, helplessness, love, and grief that can come with caring for a spouse with ALS. I certainly didn't have all the answers, but I learned a great deal along the way. I became a Pathfinder because I want to use what I learned to help others facing this disease. If you are caring for a spouse or loved one with ALS—especially someone experiencing rapid progression—or have questions about nutrition, caregiving, advocacy, or simply how to navigate the day-to-day realities of ALS, I am here to listen, share my experience, and talk openly about what this road can be like. I can be reached at terry@everythingals.org My name is John Hudacek . The day I received my diagnosis, I knew this could be the end or a new beginning. After spending the first three months being scared, I realized that the difference was in my mind and my attitude. So, I decided to look at this chapter of my life differently. Early on I saw that many of us pALS are looking for that ray of light breaking through the drizzling overcast. If you look hard enough, you will find it. I hope to share my life experience to help others find courage and resilience and develop the skills to help us cope while others find that cure. As a veteran, I can assist other vets find the resources that make a difference in this journey. I was diagnosed in November 2021 with a limb-onset, non-dominant arm. Slow progressing, just now starting to weaken my other arm. Now is the time to discover the hidden strength in each of us. I am honored to hold your hand on this journey. You can contact me at johnhudacek@everythingals.org My name is Kathleen McCallum , and for the past two years, I have been helping my friend Willard, who was diagnosed with ALS in 2022. I asked him if he wanted to do a documentary to help him navigate his ALS in a creative way and bring hope. Our Journey of Hope documented the positive steps we took to help Willard’s symptoms, extend his time, and detox his body in hopes of reversing his ALS symptoms. Prior to helping Willard, I fought for my mother when she had breast cancer and, later, level 4 stomach cancer. At the end of her life, she also had Lewy Body Dementia. My dad had Alzheimer’s disease, and we participated in many Alzheimer’s fundraisers as well. I have studied alternative healing since the 1980s, and I am a certified microbiome nutritional coach. My goal is to bring more hope to those suffering from this horrendous ALS disease and to bring more awareness about ALS to the world. There is hope, and if I can help provide it for you, please contact me at kathleen@everythingals.org My name is Shawn Penno. I think my years of work in the field and advocating for workers will translate nicely into helping pALS with their journey. Please reach out if you need someone to 'vent' to, help with problems, or just someone to talk to alleviate the isolation. I live in BC, Canada, and have been a care aide for 25 years, 2 in long-term care and the rest in the Community. I was diagnosed in September '23 with limb onset ALS after 16 months of 'investigating,' with a diagnosis of carpal tunnel, thoracic outlet syndrome, and such. The devastation of hearing THAT Dx—we were hoping for anything but that—really made me soul-search. Do I want to Drop everything and make a bucket list, or…I decided that my work is what really fulfills me; the gratitude I get from my clients is priceless. Work gives me the focus to stay positive and live in the moment. Something I teach in my class is we want to "enable our clients, not disable them.” This has taken on a whole new meaning now that I'm the one becoming disabled! I WANT to do what I can while I still can! I even built my own wheelchair ramp right after my Dx while still having the arm strength to do it! I can be reached at shawn@everythingals.org My name is Anthony (Tony) Martin Varela . My better half is named Cheri and we live in Huntington Beach, California. I have two children and two grandchildren with one on the way!! I am a retired Firefighter who worked for the City of Los Angeles. I worked 35 years before Retirement. I love outdoor activities and try to get out and enjoy the fresh air as often as I can. I was diagnosed with ALS in April of 2023. After two years of wondering why I was losing weight and strength, a paramedic friend told me to see a neurologist. After doing so, I received the bad news. I keep a positive outlook as much as I can, but staying busy seems to keep my mind off of it and works the best. I am looking forward to helping in any way I can. I can be reached at tony@everythingals.org My name is Cathy Cummins , like most pALS, I’ve lived an exciting and fulfilling life. And, I’m not done yet. Diagnosed with PLS in 2005, then ALS in 2008, I began a healing journey. In 2004, with left leg symptoms, I needed crutches; in 2005, a chair; and by 2008, a power chair. As a chiropractor, professor, and elite athlete, my life changed dramatically, and I felt lost. In 2009, I passed out on stage while singing with my barbershop quartet. Now, I have swallowing and autonomic issues. This journey is not easy. When I was diagnosed, my team rallied and created a plan that included a physical, chemical, and spiritual approach to healing. I’ve learned so much about myself along the way. I feel like having ALS has offered me a path to discover what life is really about. For me, it's been about balancing my energy, learning to adapt. This wasn’t possible for me to do alone. I believe we are on this journey for a reason, and we are stronger together. If you would like me to share your Journey. Reach out, and I will be a Pathfinder with you. I can be reached at cathy@everythingals.org Hi, my name is Wilbert Greenfield . I am 54 years of age living in Washington DC. Living with ALS has taught me resilience and the importance of cherishing every moment. I navigate daily tasks with creativity and adaptability, finding joy in small victories and milestones. I am passionate about raising awareness for ALS, advocating for research funding, assistive technologies, and supporting fellow ALS warriors and their families. Through sharing my story and experiences, I strive to inspire hope and promote understanding of this complex disease. My faith anchors me. When my body failed, I learned to rely on something greater. Surrendering to God’s will gave me a new freedom. My physical limitations stripped distractions, leaving me with a profound connection to Jesus. ALS taught me faith—trusting in His promises despite uncertainty. I find strength and peace in knowing my worth isn’t defined by my abilities, but by my identity in Christ. God’s plan is perfect, and His love is abundant. My body may decline, but my spirit soars, supported by God’s unconditional love. I can be reached at will@everythingals.org Hi, my name is Lynn Brielmaier . I am an electronics engineer with ALS who is completely paralyzed. Last year, I designed and built a fast, custom AAC eye-gaze computer that costs about half as much as a standard offering. I have worked in the oil industry, computer manufacturing, the alarm industry, and marine propulsion. I have been shocked by 28kV from the backside coil of a color cathode-ray tube and was involved in a 480-volt arc flash incident that resulted in second-degree burns to my hands. Currently, I am a Person with Lived Experience (PWLE) advisor to the NIH, FDA, and the just-unfurling ALL ALS, the largest Natural History Study (NHS) ever undertaken in ALS. I serve on two neuroethics committees, providing industry guidance on Brain-Computer Interfaces and consulting with two BCI firms. I can be reached at lynn@everythingals.org Hi, my name is Joe Redmond. These days, I live a purpose-driven life! I do what I can…WHILE I CAN! If I can make your journey any easier, or if you have any questions, let me help you find answers. My hope is to be the resource you need. I spent 15 years in radio and 25 years in the Music Industry (in Nashville). Through the years, I’ve worked in Finance and Real Estate and owned a bakery! Currently, I live in Baton Rouge, LA. That was what I DID…it wasn’t WHO I AM! I was diagnosed with ALS in 2012…thankfully, it’s a very slow-progressing form. When ALS took my speaking (I slur!), my whole world changed, and I lost my career. For a guy who’s always made his living talking…this is a difficult pill to swallow. But I am more than just my diagnosis! My skill set can STILL be put to good use! Even though MY speech is failing, I try to give ALS Patients a voice! I can be reached at joe@everythingals.org . Pathfinders Emeritus I’m Michael Montemayor , and I have a wife and three kids. We live in Washington State. I graduated from Washington State University in 2003 with a business degree. I was diagnosed with ALS in July 2023 . A lot has changed for me and my family since my diagnosis. I struggle to do some of the everyday simple tasks, but there are still a lot of things I can still do. What keeps me going is my trust in God, knowing He has a plan for me and that He is in control, which gives me peace. I also have lots of help and support from family and friends. My plan is to keep fighting against ALS and not let it control my life. I have met lots of other ALS patients who have been a blessing to me, and I hope to be able to help others with ALS as well. God Bless!! My name is Doug Hill. I am 47 years old and a father of three daughters, ages 16, 14 and 12. I am a Cornell Chemical Engineer graduate, class of ’99, and have been working full time at a specialty chemical company for 26 years now. My wife is a middle school Spanish teacher. I was diagnosed with bulbar onset ALS in January of 2024. I love playing and watching sports – from football, baseball, basketball, tennis and golf to downhill skiing (my main passion!). As a family, we also enjoy small venue music concerts with artists that really connect with the audience. Since my diagnosis, I have needed to adapt continuously during my journey. It’s like a puzzle always needing a solution! There is one thing that doesn’t and will never change – my fight, my grit, my determination and my unwavering hope. ALS doesn’t define me; it has redefined me. In fact, it makes me stronger, as a Pathfinder, I am an active participant and advocate in the ALS community, and I would love to connect with you to share what I’ve found and how it has helped me in this journey.